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Abstract
Cryptogenic fibrosing alveolitis (CFA) is a chronic, progressive and usually fatal
lung disorder of unknown aetiology, with a survival curve worse than for many
cancers. As patients present in the later stages of this disease with no known natural
history, elucidating the pathogenesis of CFA has proven to be very difficult. Thus,
experimental animal models are essential in this process, providing much insight into
the temporal, cellular and molecular mechanisms behind CFA. The work presented
in this thesis is based on a modified murine model of fluorescein isothiocyanate
(FITC)-induced pulmonary fibrosis.
The acute phase of the disease was characterised by FITC deposition surrounding the
large and smaller airways and blood vessels, and in the alveolar walls, with a
granulocytic infiltrate that was replaced over a week by a chronic mononuclear
infiltrate. In the chronic phase, after a second dose of FITC, FITC deposition was
often accompanied by thickening of the alveolar walls, deposition of fibrous tissue,
and occasional B lymphocyte aggregates, all of which were found adjacent to areas
of normal lung tissue. Immunohistochemical staining for cell surface proteins
suggested that dendritic cells (DCs) may play a role in antigen presentation to
lymphocytes in the aggregates, and thus may be the basis for a local humoral
immune reaction. A system for scoring the lung fibrosis demonstrated higher levels
of fibrosis in areas of FITC deposition compared to FITC-free areas. Moreover, the
severity of fibrosis increased with time. Measurement of bronchoalveolar lavage
(BAL) cytokine levels suggested that this model may resemble a Th2-like immune
response, warranting further investigation.
Both DCs and alveolar macrophages (AMs) were isolated from FITC-treated and
PBS control mice. FITC DCs in the chronic stages of the disease were less efficient
T cell stimulators than PBS DCs, and may polarise T cells towards a Th2-type
response in vitro by inducing the production of IL-13. BAL AMs were poorer T cell
stimulators than DCs, consistent with published reports, although they were more
efficient at T cell stimulation than those from control mice, and may also contribute
towards a Th2 polarisation in the later stages of fibrosis.
Preliminary studies into the in vitro effect of FITC on lung epithelial cell lines
suggest that alveolar epithelial cells (AECs) may be more susceptible to damage by
FITC than bronchiolar epithelial cells.
The pathogenesis of CFA is poorly understood, and appropriate therapy relies on the
correct understanding of the nature of the lung's response to injury. The FITC-
induced model of pulmonary fibrosis characterised in this thesis, once optimised, will
enable further study of fibrosis that develops through the inflammatory route. The
data resulting from the evaluation of this model have provided insight into new
directions for study that could ultimately lead to the development of novel and





"Felix qui potuit rerum cognoscere causas "
(Lucky is he who can understand the causes ofthings)
Virgil 70-19 BC: Georgics
1.1 Alveolar Structure of the Lung
The normal adult lung contains 300 x 106 alveoli, which are grape-like structures that
branch off terminal bronchioles [1] (Figure 1.1). The alveolar surface of the lung is
covered primarily by two distinct types of epithelial cells in an almost balanced
numerical proportion. Alveolar type I cells cover approximately 90% of the alveolar
surface. They are thin, squamous epithelial cells that cover the pulmonary
capillaries, and are required for effective gas exchange. Type II cells are cuboidal in
shape and are found at junctions of alveolar septa and along the alveolar surfaces
surrounding intrapulmonary vascular and airway structures. This places type II cells
in close proximity to endothelial cells, AMs, fibroblasts and other interstitial cells,
and implicates their immediate involvement in any processes that occur at the
alveolar level [2], Type II AECs have five known primary functions; first, they
secret surfactant; second, they function as ion pumps and move fluid from the
alveolar spaces into the subjacent interstitial spaces; third, as these cells represent the
stem cell population for alveolar epithelium and can regenerate type I epithelium,
they are responsible for repair following alveolar injury; fourth, type II cells control
alveolar inflammation by secreting anti-inflammatory cytokines and antioxidants;
and finally, they play a role in the metabolism of xenobiotics [3],
6
Figure 1.1 High power view of a normal alveolus. The cut surface
demonstrates the type I (EP1) and type II (EP2) epithelial cells, endothelial cells (EN),
basement membrane (M), red blood cells (RBC) in the capillaries (CAP), fibroblasts (F), and
connective tissue (C). Inflammatory cells are not shown. Figure taken from Crystal et al. [1]
with permission. Copyright © 1984 Massachusetts Medical Society.
1.2 Lung Response to Injury
In most organs, tissue injury is followed by cycles of the normal physiologic
response of inflammation and repair. Inflammation leads to matrix stimulation with
mesenchymal cell proliferation and altered phenotype that stops the injury and
provides temporary repair, and is often in the form of localised and transient scar
formation. When the insult or injury is minimal, this is followed by matrix
mobilisation, or fibrolysis and apoptosis of the repair cells, with eventual restoration
of normal structure and function [4,5], However, when injury is repetitive or larger
in magnitude, the repair process is exaggerated and usually widespread, known as
remodelling, and frequently results in scarring or fibrosis [4,6].
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In the lung, shortly after injury the alveolar surface becomes denuded, followed by
type II pneumocyte proliferation resulting in alveolar re-epithelialisation and the
eventual return of the organ to normal function [2], In chronic tissue injury however,
many of the control mechanisms, which normally have a protective effect, are
bypassed. A continuous cycle of repair distorts ECM deposition, proliferation of
mesenchymal cells, and alteration of normal lung structure that effectively impairs















and Connective Tissue Synthesis
Alveolar
Exudate
Figure 1.2 Early events in the pathogenesis of lung fibrosis. Figure
taken from Crouch [8] with permission. Copyright © 1990 the American Physiological
Society.
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1.3 Cryptogenic Fibrosing Alveolitis
CFA, also known as idiopathic pulmonary fibrosis (IPF) in North America, is a
chronic, diffuse, patchy, irreversible fibroproliferative lung disease of unknown
aetiology, for which existing treatments are of limited benefit [5,9-12], It is
characterised pathologically by abnormal proliferation of lung mesenchymal cells,
accumulation of excessive amounts of ECM proteins, and extensive lung
parenchymal remodelling with accompanying evidence of injury and debatably,
inflammation [13-15],
1.3.1 Classification
The interstitial lung diseases refer to a group of many acute and chronic lung
disorders with variable degrees of pulmonary inflammation and fibrosis. CFA, now
recognised as a distinct clinical disorder, is a subset of the interstitial lung diseases
and is one of a family of idiopathic interstitial pneumonias [11,16] (Figure 1.3).
Hamman and Rich [17] first described a series of patients who developed what is
today considered a variant of CFA. These patients had what the investigators called
an "interstitial fibrosis" of unknown cause. It was later called Hamman-Rich
disease and was applied to most cases of pulmonary fibrosis at that time. That term
is now reserved for acute interstitial pneumonia (AIP). Scadding [18] first
introduced the term "fibrosing alveolitis" to define progressive lung disease that was
characterised by two histological features present in varying combinations. These
were thickening of the alveolar walls, which first appeared cellular but showed an
early, and strong, tendency towards fibrosis, and the presence of large alveolar
mononuclear cells in the alveolar spaces.
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Figure 1.3 Relationships among usual interstitial pneumonia,
idiopathic interstitial pneumonias in general, clinically diagnosed
cryptogenic fibrosing alveolitis (CFA), and interstitial lung diseases.
Usual interstitial pneumonia is the most common histologic pattern in cases previously
defined as CFA. Figure adapted from Ryu et al. [19]
In 1975, Liebow [20] critically examined the pathologic features of the interstitial
pneumonias and divided them into five groups based on specific histologic criteria
(Table 1.1). These were usual interstitial pneumonia (UfP), desquamative interstitial
pneumonia (DIP), bronchiolitis obliterans with interstitial pneumonia (BIP),
lymphoid interstitial pneumonia (LIP), and giant cell interstitial pneumonia (GIP).
Other investigators studying these same diseases suggested combining these groups
into a single entity, but there was no consensus on the various terms proposed:
diffuse interstitial fibrosis, CFA, IPF, classical interstitial pneumonitis-fibrosis, and
diffuse fibrosing alveolitis [21-24],
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Original Classification of Idiopathic Interstitial Pneumonias
Usual Interstitial Pneumonia (UIP)
Desquamative Interstitial Pneumonia (DIP)
Bronchiolitis Obliterans with Interstitial Pneumonia (BIP)
Lymphoid Interstitial Pneumonia (LIP)
Giant Cell Interstitial Pneumonia (GIP)
Table 1.1 Liebow classification of interstitial pneumonia. Data taken
from Liebow [20],
In 1998, Katzenstein and Myers [10] suggested a revised classification scheme of
four histologically distinct forms of idiopathic interstitial pneumonia that comprised
the morphologic spectrum traditionally included under the designation CFA. This
scheme maintained the UIP and DIP classifications from Liebow, and included AIP
(previously Hamman-Rich syndrome) and nonspecific interstitial pneumonia (NSIP),
as well as a more limited disorder resembling DIP, respiratory bronchiolitis
interstitial lung disease (RBILD). LIP and GIP were excluded because they are not
idiopathic, as well as BIP as pathologically it is a predominantly intraluminal rather
than interstitial abnormality. These proposals by Katzenstein and Myers have
evolved into the current classification system agreed upon in an international
consensus statement jointly issued by the American Thoracic Society and the
European Respiratory Society [11] (Table 1.2). This consensus statement thus
defined CFA, "...as a specific form of chronic fibrosing interstitial pneumonia
limited to the lung and associated with the histologic appearance of usual interstitial
pneumonia (UIP) on surgical.. .lung biopsy. The etiology is unknown." Although
recent data now suggest that some patients with CFA may also show a pattern of
NSfP [25,26], UIP is considered to be the predominant histological pattern equating
with CFA [27], and for the purposes of this thesis, the term CFA will refer to
idiopathic interstitial pneumonia with a pattern ofUIP.
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Revised Classification of Idiopathic Interstitial Pneumonias
Usual Interstitial Pneumonia (UIP)
Desquamative Interstitial Pneumonia (DIP)
Respiratory Bronchiolitis-associated Interstitial Lung Disease
(RBILD)
Acute Interstitial Pneumonia (AIP)
Nonspecific Interstitial Pneumonia (NSIP)
Idiopathic Bronchiolitis Obliterans Organizing Pneumonia
(Idiopathic BOOP or Cryptogenic Organizing Pneumonia)
Lymphoid Interstitial Pneumonia (LIP)
Table 1.2 Current classification of idiopathic interstitial pneumonias.
Data taken from American Thoracic Society [11],
1.3.2 Epidemiology of CFA
There are few data available regarding the epidemiology of CFA. Estimates vary
and can depend on the location of the sample population, or other factors such as
racial and ethnic predictors, however, the data that do exist suggest that CFA is
among the most common of the chronic interstitial lung diseases and may account for
a majority of new interstitial lung disease cases [28].
1.3.2.1 Incidence, Prevalence and Mortality
The exact incidence, prevalence and mortality of CFA are not known, although all
have been shown to increase with age [29-32]. Patients usually present between the
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ages of 50 to 70 years, with two thirds of these patients over the age of 60 at the time
ofpresentation, with a mean age at diagnosis of 66 years [22,23,33,34],
The incidence of CFA has been estimated at 10.7 cases per 100 000 per year for
males, and 7.4 cases per 100 000 per year for females [30], although the criteria that
provided the basis for these data are not precisely defined. This same population-
based study, which focused on all interstitial lung diseases in the population of
Bernalillo county, New Mexico revealed a prevalence of 20.2 cases per 100 000 for
males and 13.2 cases per 100 000 for females with CFA [30]. In individuals over the
age of 75 years, the prevalence exceeded 175 per 100 000. Mortality data estimate a
50 to 70% death rate at five years after diagnosis of CFA [11,25,35], Flowever, it is
thought that mortality associated with CFA is likely to be grossly under-reported, and
that epidemiologic data cannot define the high death rate of this chronic disease [12].
1.3.2.2 Genetic Predisposition
It is still unclear whether CFA has a single mechanism of pathogenesis or in fact has
numerous causes. CFA appears to cluster in families in up to 3% of cases,
suggesting the participation of genetic factors [36-38], Providing additional
compelling evidence for a genetic link is familial CFA, which is identical to the non-
familial form of the disease, except that it has been shown to follow a pattern of
autosomal dominant inheritance with variable penetrance [38-40],
Indeed, in the series of events leading to pulmonary fibrosis there are many points at
which abnormal expression of any number of genes could potentially predispose to
the development of pulmonary fibrosis by altering the immunological response to
injury, or by modulating collagen metabolism in the lung. Bitterman and Crystal
[41] hypothesised in 1980 that insult to the lungs of genetically susceptible
individuals may result in CFA as they are unable to control immunologic or
inflammatory processes, possibly because the genetic abnormalities could cause
increased synthesis ofmatrix proteins or profibrotic mediators [37].
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Pulmonary fibrosis similar to CFA is also frequently observed in autoimmune
diseases, including rheumatoid arthritis and systemic sclerosis [42,43], Humans
often show a marked variation in responses to profibrotic agents even at similar
levels of exposure, which may also suggest a predisposition to fibrosis [37], Certain
inbred stains of mice show profound differences in their susceptibility to profibrotic
agents, and transgenic animals that either lack or overexpress genes involved in the
expression of cytokines can develop lung fibrosis [44,45], Moreover,
polymorphisms have been observed in interleukin-1 receptor antagonist (IL-lra),
tumour necrosis factor-a (TNF-a), and major histocompatibility complex (MHC)
loci [46,47],
However, there has been no systematic assessment made of CFA heritability and
despite all the suggestions of such, there is as yet no clear evidence of a genetic basis
for CFA [12,48],
1.3.2.3 Potential Risk Factors
Potential environmental risk factors have been examined in the investigation of the
pathogenesis of CFA, with cigarette smoking being the most prevalent [49], Up to
75% of index patients with CFA have been reported to be current or former smokers,
and many of the inflammatory features of CFA are more strongly linked to smoking
status than to the underlying lung disease [16], Cigarette smoking is thought to alter
pulmonary immune function, reduce clearance of inhaled agents, and increase
respiratory epithelial permeability; it may also cause respiratory bronchiolitis, an
entity histologically similar to DIP that may, in turn, lead to fibrosis [50], However,
it is still unclear whether CFA patients who are nonsmokers have a better prognosis
than smokers, as conflicting findings have been reported in different series [51],
Several viruses, particularly those of the herpesvirus family, have been implicated in
the pathogenesis of CFA, however, there is no clear evidence that convincingly
points to a viral cause [52-56], Other risk factors, such as environmental exposure to
14
dust [29], commonly prescribed drugs [57,58], gastroaesophageal reflux [59], and
exposure to solvents [60] have been suggested. However, the studies which attempt
to define these factors have often examined unconfirmed, or solely clinically
diagnosed, cases ofCFA [48,61].
1.3.3 Pathogenesis of CFA
It has been suggested that CFA is the consequence of sequential acute lung injury
that results in irreversible damage to the alveolar surface of the lung; more
specifically, it would appear that the ability of type II alveolar cells to restore
damaged type I cells is seriously affected [2,16,62], Supporting histological
evidence in the lungs of CFA patients shows cuboidal-shaped hyperplastic type II
cells, large reactive elongated epithelial cells which may represent transitional cells
among type II and type 1 pneumocytes, microscopic areas of epithelial cell
denudation, and areas of honeycomb lesions lined with bronchiolar epithelium [2],
1.3.3.1 The Inflammation Debate
Pulmonary fibrosis has been traditionally viewed as a consequence of chronic
inflammation that injures the lung, modulates fibrogenesis, and leads to the end-stage
fibrotic scar [10]. However this interpretation has been questioned in recent years
because several of the key concepts that formed the basis for this hypothesis are
deemed by some to be no longer valid [5,7,16,48,63,64],
The evidence to support the claim that inflammation does not play a major role in
CFA pathogenesis is four-fold [48], Firstly, inflammation is not a prominent
histopathologic finding in UIP, but is usually mild, occurs mainly in areas of
collagen deposition or honeycomb change, and rarely involves otherwise unaltered
alveolar septa [10]. Moreover, foci of proliferating fibroblasts are more prominent
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than evidence of inflammation in the lung tissue [65]. Secondly, there is some
evidence, primarily from transgenic animal models, that inflammation is not required
for the development of a fibrotic response. Adamson et al. [66] were able to induce
a lung fibrotic response in a blood-free environment suggesting that epithelial injury
does not require co-existing ongoing inflammation to stimulate the development of
fibrosis; Sime et al. [67] showed that overexpression of a replication-deficient
adenovirus expressing only active, rather than latent, transforming growth factor-P 1
(TGF-pi) induced fibroblast proliferation and progressive ECM accumulation; silica
instillation in IL-10-deficient mice induced greater lung inflammation but less
fibrosis than wild-type mice [68]. Thirdly, most markers of inflammation fail to
correlate with stage or outcome in CFA [48]. Finally, anti-inflammatory therapy
does not improve disease outcome [69-71]. For these reasons, recent attention has
focused on the ECM and molecules that normally regulate its homeostasis [15].
The new hypothesis suggests that unknown insults provoke multiple microscopic
foci, or microenvironments, of epithelial damage and stimulation (Figure 1.4).
Following the normal physiologic inflammatory response the altered mesenchymal
cell phenotype, rather than being removed by fibrolysis and apoptosis, is retained by
avoiding apoptosis. Matrix production persists and fibrolysis is reduced, while
activated AECs continue to release factors inducing further fibroblast migration and
proliferation and changes in cell phenotype. In the microenvironment of the lesion,
myofibroblasts can induce epithelial cell apoptosis and basement membrane
disruption, thus contributing to abnormal re-epithelialisation. Other areas outside
these microenvironments remain normal in structure and environment. The final
result is a patchy, aberrant remodelling of the lung parenchyma [4-7,64],
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Figure 1.4 Original and new hypotheses for the pathogenesis of
cryptogenic fibrosing alveolitis. Traditionally, CFA has been viewed as a result of
self-perpetuating chronic inflammation that causes progressive parenchymal fibrosis. Newer
theories suggest that CFA is the result of the wound-healing response to sequential lung
injury. In both cases, several interacting factors could modify the fibrotic response: genetic
background of the patient, the predominant inflammatory phenotype (Th1 or Th2), and
environmental inflammatory triggers, such as cigarette smoking, viral infection, and
respirable toxins. Figure adapted from Gross and Hunninghake [16].
This new hypothesis, however, is not without its faults. In a recent pro/con editorial
on this subject, Streiter [5] raised some interesting points. Most importantly, Streiter
suggested that UIP represents the end result of a continuous, untreated process that
starts as NSIP and progresses in stages of disease. This is based on findings of
interlobar and intralobar variability of idiopathic interstitial pneumonia, and the
coexistence of chronic inflammation and fibrosis in a prospective study of patients
with idiopathic interstitial pneumonia [26],
The arguments that clinical measurements of inflammation fail to correlate with UIP
stage or outcome, and that conventional anti-inflammatory therapy is ineffective
[48], imply that UIP is a unique disease rather than the end stage of a process.
Streiter states that the evidence, however, supports UP as being a manifestation of
prolonged chronic inflammation and evolving fibrosis, progressing in stages from
NSIP, to NSIP with fibrosis, and finally, to UIP [26], Anti-
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inflammatory/immunosuppressive agents in fact demonstrate efficacy in the
treatment of NSIP, which represents the early stage of the process; the presence of
pulmonary fibrosis itself is more related to the progression of the process making
such treatments understandably less efficacious and dependent on the stage of
disease of the patient.
Streiter also points to evidence showing that the ratio of T helper Type 1 (Thl):T
helper Type 2 (Th2) cytokine expression polarises chronic inflammation [72,73], and
suggests that a switch from an initial Thl response to a Th2-dominated response
could be induced by repeated and/or persistent episodes of injury, promoting
dysregulated repair with chronic inflammation, fibrogenesis, and finally end-stage
fibrosis. The importance of the Thl/Th2 response in pulmonary fibrosis is discussed
in the next section.
Streiter's arguments are also supported by Majumdar et al. [74], who found evidence
of a chronic inflammatory cell profile in a quantitative study of lung biopsies, and du
Bois and Wells [51], who state that the histological appearances of advanced lung
disease, in the form of "honeycomb" or "end-stage" lung, may be identical in any
number of diffuse lung diseases as the lung has only limited responses to injury. It is
earlier in disease, they suggest, that individual processes may be distinctive for the
nature of the initiating factors and subsequent pathological response, whether this be
immunological, inflammatory, or even fibrogenetic.
Thus, the original "inflammatory route" hypothesis suggests that an initial insult or
injury to the lung leads to an influx of first acute, then chronic, inflammatory cells
(Figure 1.3). The continuing presence of these cells maintains both immunological
and inflammatory responses, and therefore is responsible for the progressive disease.
In CFA, the number and activation levels of fibroblasts are increased, and as the
disease progresses, the interstitial deposition of collagen and other connective tissue
matrix proteins interferes with lung function [51,75-77],
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The debate regarding the involvement, or lack, of inflammation in the pathogenesis
of CFA continues, and indeed is beneficial as it provides potential new therapeutic
targets. Perhaps the most insightful comment, however, has been made by Gauldie
et al. [7], who state that "...inflammation appears necessary but not sufficient to
explain the pathophysiology of fibrosis. This would appear more consistent with the
suspected natural history of [CFA]."
While the pathogenesis of this disease is highly complex and still poorly understood,
many factors, such as cytokines, growth factors, chemokines, and regulators of
apoptosis have been implicated in its progression [15],
1.3.3.2 Th2 Cytokine Hypothesis of Fibrosis
Naive T lymphocytes differentiate into distinct effector cells depending on the
cytokine milieu they encounter during activation, and it is the heterogeneity of the
responding CD4+ T cell populations that is at least partially responsible for the type
of immune response that develops in response to a foreign antigen [78]. Thl and
Th2 polarised inflammation represent two contrasting and mutually antagonistic
responses of an organism to an immunogenic insult, in that individual cytokines are
able to further stimulate and polarise the prevailing response [6,79], Expression of
these cytokine patterns is classically associated with generation of cell mediated
(Thl) and humoral (Th2) immunity, however they are also likely involved in the
repair processes that follow acute injury and the subsequent inflammation [6].
A simplified overview of the Thl/Th2 paradigm in the lung suggests that the Thl
response, characterised by cytokines including interferon-y (IFN-y), IL-2, IL-12, and
IL-18, may be considered a favourable protective response, and is thought to
promote repair with restoration of normal tissue architecture; in contrast the Th2
response, characterised by cytokines including IL-4, IL-5, IL-10, and IL-13, and
monocyte chemoattractant protein-1 (MCP-1), may favour excessive fibroblast
activation, proliferation, and ultimately the deposition of ECM protein and
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fibrogenesis [6]. Indeed, in murine models of lung disease, animals whose response
to tissue injury is predominantly of the Th2 type are more prone to pulmonary
fibrosis after lung injury than those with a predominantly Thl response [80],
Thus, the fact that Thl and Th2 cytokines are expressed by many cells and have
different functions suggests the potential importance of an imbalance in expression
dictating different immunopathologic responses [81,82], and has led to the
hypothesis that fibrosis occurs when such an imbalance exists between the Thl and
Th2 cytokines, shifting in a Th2 (type 2) direction [6,83] (Figure 1.5).
Injury and Inflammation
Fibroblast/myofibroblast accumulation




Figure 1.5 The basic premise of the Th2 cytokine hypothesis of the
progression of CFA pathogenesis. If, after injury and inflammation, the prevailing
cytokine response is shifted in the direction of the type 2 response, fibrosis can develop in
the lung. The mechanism(s) by which Th2 inflammation generates tissue fibrosis is still
poorly understood. Figure adapted from Sime and O'Reilly [6].
Data supporting the concept that fibrosis occurs when the cytokine balance shifts in
favour of the Th2 response originate from both in vitro and in vivo studies. The
inflammatory response in CFA is thought to closely resemble a Th2-type immune
response. As in asthma, a classic Th2-mediated inflammatory disease, there are
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eosinophils, mast cells, and increased amounts of the Th2 cytokines IL-4 and IL-13
[80,84-86]. Apart from lymphocytes, mast cells, macrophages, monocytes, epithelial
cells, and activated fibroblasts have all been shown to produce significant levels of
IL-4, IL-10, and IL-13 when appropriately stimulated [87,88] (Table 1.3).






Table 1.3 Non-T lymphocytes cell populations that can synthesise
type 2 cytokines. Data taken from Lukacs et al. [89]
There is substantial evidence from both in vitro and in vivo animal studies
demonstrating the importance of Th2 cytokines in activating fibroblasts and inducing
their proliferation, and the resulting collagen production and deposition. For
example, in a model of chronic Aspergillus fumigatus, the depletion of IL-13 (but not
IL-4) had a beneficial effect on goblet-cell hyperplasia, mucus production, and
subepithelial fibrosis [90], while the pulmonary overexpression of IL-13 in the
airways of mice has been shown to cause a mononuclear and eosinophilic
inflammatory response, mucus cell metaplasia, and airway fibrosis [79], and to
induce tissue fibrosis by selectively stimulating and activating TGF-fll [91]. In the
bleomycin-induced model of pulmonary fibrosis, IL-5 and MCP-1 RNA have been
reported to be increased, and neutralisation of these cytokines resulted in decreased
inflammatory cell recruitment and pulmonary fibrosis [92-94], Gene expression of
IL-4 is also increased in this model [95], and IFN-y-inducible protein-10 has been
shown to inhibit bleomycin-induced pulmonary fibrosis [96]. Silica-induced fibrosis
was significantly attenuated in an IL-10 knockout mouse [68], and finally, IL-12 has
been shown to attenuate bleomycin-induced pulmonary fibrosis, most likely due to a
concomitant increase in intrapulmonary IFN-y [97].
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Animal studies have thus provided much insight into a role for Th2 cytokines in the
mediation of pulmonary fibrosis, but recent human studies have confirmed this
profile in CFA. Hancock et al. [85] detected IL-13 protein in the BAL fluid in the
majority of patients with CFA tested but in none of the control subjects, and the
proportion of BAL purified AMs expressing IL-13 mRNA was increased in CFA
patients. MCP-1 mRNA is strongly expressed in lung epithelial cells from patients
with CFA, but not in cells from non-CFA patients [98], while MCP-1 levels are
increased in the BAL fluid from CFA patients [99].
Perhaps most significantly, the presence of the Th2 cytokine IL-4 has been shown to
predominate over the expression of IFN-y in CFA patients [100,101]. Belperio et al.
[102] speculate that this pattern of cytokine expression may suggest a potential role
for the humoral response in CFA pathogenesis, or more likely, the inability of IFN-y
to tilt the balance away from a Th2-dependent profibrotic environment. This finding
by Wallace et al. [100,101] was confirmed in a separate study, where it was also
noted that Th2 cytokines were increased in CFA patients relative to systemic
sclerosis patients [74]. The importance of this finding is noted [6] in that systemic
sclerosis patients have lower levels of Th2 cytokines, as well as increased numbers
of cells expressing Thl cytokines, compared to CFA patients. As this is coupled
with a less aggressive disease, it suggests the cause is a more favourable balance
between the profibrotic Type 2 and antifibrotic Type 1 responses [6], Further
substantiation is found in the recent suggestion that IFN-y treatment of CFA patients
who failed to respond to glucocorticoids may be beneficial [103],
It must be mentioned, however, that in CFA one only sees end-stage disease, and
therefore it must be with caution that the Thl/Th2 balance is emphasised. The early
events in humans that result in disease are unknown, and while we can extrapolate
from animal models, they too have their problems. Animal models of pulmonary
fibrosis will be discussed further on.
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1.3.3.3 Autoimmunity in CFA Pathogenesis
There are several factors that together, provide compelling evidence for an
immunological pathogenesis for CFA. In patients with CFA, there have been reports
of increased numbers of neutrophils, eosinophils, CD4+ and B lymphocytes, and
plasma cells [104,105], while stimulation of polyclonal B lymphocytes results in
increased peripheral blood immunoglobulin concentration [106]. Increased B cell
numbers have been associated with a poorer prognosis in CFA, and BAL fluid from
CFA patients has increased B cell growth factor activity [107] and immunoglobulin
[104] as compared to normal subjects. There are also immune complexes present in
the blood, BAL fluid and tissue of CFA patients [108-112]. Non-organ-specific
circulating autoantibodies have been found in approximately 40% of CFA patients
[113], and include antinuclear and rheumatoid factor antibodies, anti-DNA
topoisomerase II antibodies, and anti-cytokeratin 8 and 18 antibodies [111,112,114-
118],
The variable expression of autoantibodies has led to the suggestion that they
represent a non-specific consequence of lung inflammation and injury, and may not
even be a primary cause of tissue damage, but rather augment the inflammatory
response [106], However, specific immunohistochemical data have shown the
presence of circulating IgG autoantibodies to hyperplastic type II epithelial cells, and
to a type II epithelial cell-derived cell line, in patients with CFA, which indicates an
endogenous and lung-specific autoantigen and suggests a site where immunological
injury could occur in CFA [119,120], Wallace et al. [120] also noted that the
distribution of the putative autoantigen in the lung tissue appeared to correlate with
that described for immune complexes [121], This group subsequently found that
antibody raised against the autoantigen they had described induced increased
secretion of profibrotic cytokine TGF-P, and tenascin, an ECM protein, in the type II
epithelial cell line A549, and that decreased A549 cell numbers appeared to be a
cytostatic effect [122,123]. Interestingly, they suggested that in vivo, the
autoantibody could delay the re-epithelialisation of the damaged alveoli after lung
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injury, which would provide a mechanism for promoting fibrosis by dysregulation of
fibroblast activity [66,122,124],
Hapten immune pulmonary interstitial fibrosis is mediated by an immune response
against hapten-modified self antigen, and with its abnormal regulation of
inflammation in the lung and unresolved fibrosis, is a useful animal model for
studying the autoimmune process in pulmonary fibrosis [125], Work on this model
has shown that the infiltration of immune inflammatory cells that contribute to the
fibrogenic process is dependent on alteration of the suppressive phenotype of the
resident AMs [126], Investigation of the mechanisms that might restore the
immunosuppressive phenotype of the AMs in the lung could lead to novel therapies
for patients with autoimmune-regulated CFA. Furthermore, the participation of
CD40/CD40 ligand (CD40L) interactions, which have been identified as important in
lung injury models of pulmonary fibrosis mediated by oxygen or radiation [127,128],
and more recently directly implicated in human CFA [6], were required to elicit the
secondary immune responses that lead to pulmonary fibrosis in this model [129],
Finally, an interesting study by Kaneko et al. [130] recently demonstrated that the
costimulatory molecules CD80 (B7.1) and CD86 (B7.2) were expressed without
class II MHC molecules in AECs in lung tissue from CFA patients. They suggest
that the dysregulation of these molecules in AECs may lead to the activation of
autoreactive T cells, which might then contribute to CFA pathogenesis.
Although the pathogenesis of CFA remains elusive, the participation of the humoral
immune response cannot be discounted. Further investigation is warranted to
identify the exact role of the autoantigen specificities identified in sera from CFA
patients. Questions remaining to be answered involve determining whether the
autoantibodies represent evidence of ongoing injury or if they are initiating the
injurious process, and if their presence is amplifying a cycle of inflammation and
fibrogenesis that is already established [106].
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1.4 Antigen Presenting Cells (APCs) in the Lung
Regardless of the role that inflammation may or may not play in CFA pathogenesis,
there is certainly an immune response occurring in the lungs of CFA patients. As
any T cell response depends upon activation by an APC, a role for these cells is
indicated. There are many cells in the lung that could potentially act as APCs:
epithelial cells, fibroblasts, endothelial cells, neutrophils, T and B lymphocytes,
AMs, and DCs. The minor players in terms of antigen presentation are T cells,
epithelial cells, fibroblasts and endothelial cells, which have inducible MFIC
molecules [131,132],
B lymphocytes are present in normal human lung tissue, but lymphoid aggregates
containing B cells are scarce in the mucosa and are less well organised than in
bronchus-associated lymphoid tissues described in other species [131]. B cells
constitutively express MHC class II molecules, and play an important role in
initiating immune responses [133]. They utilise antigen-specific membrane
immunoglobulin and pinocytosis to effectively internalise antigen [134], although
they have not been documented to migrate from tissues into draining lymph nodes
bearing antigen as do DCs.
Thus, the vast majority of antigen presentation in the lung is the responsibility of the
AMs, which police the alveolar surfaces in the deep lung, and the "professional"
APCs, the DCs, which form a contiguous network within, and directly below, the
airway epithelium and throughout the alveolar interstitium [135]. The airways and
alveoli constitute a large surface that is continuously exposed to antigen. AMs are
likely the first cells to encounter invading particles in the lung, and can release anti¬
inflammatory cytokines or inflammatory mediators. If the epithelial surfaces are
disrupted, however, a local network of DCs is ready to take up antigens and migrate
towards the lymph nodes to trigger T cells in the central immune response [135].
This review will focus on DCs and AMs. The isolation of lung APCs is discussed in
Chapter 5.
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1.4.1 DCs in the Lung
DCs originate from progenitors found in the bone marrow and, after circulating in
the blood, migrate to all lymphoid organs and most nonlymphoid organs, including
heart, liver, kidney, skin, gut and lung [136,137]. Upon arrival, DCs are in an
immature state characterised by high antigen uptake capacity and low surface
expression of MHC class II and T cell costimulatory molecules CD80 and CD86.
[138]. In the tissues, DCs constantly sample their environment for antigen. Once in
contact with antigen, and in the presence of "danger" signals [139], DCs begin to
mature; antigen uptake and processing capacity decrease while MHC class II and T
cell co-stimulatory molecules are upregulated on the surface of the cell.
In the murine lung, DCs form an extensive network in the airway epithelium,
alveolar septae and in connective tissue surrounding pulmonary veins and airway
vessels, from which they can sample the environment for antigen [140-143], DCs
are thought to have a high turnover rate at mucosal surfaces, where they are in
constant contact with inhaled particles or organisms [144]; Holt et al. [145] have
estimated a three day turnover for epithelial DCs in the rat, and this rapid rate is
consistent with a surveillance or "sentinel" role for these cells. After antigen uptake
in the airways, DCs migrate to the paracortical T cell zone in the draining lymph
nodes of the lung, where they come into contact, and interact, with nai've T cells
[146],
Under inflammatory conditions, immature DCs are thought to be recruited by
inflammatory chemokines such as macrophage inflammatory protein (MlP-la),
MEP-3a, MCP 1-4, and TNF-a [147,148], Maturation at the site of injury can be
induced by the release of oxygen radicals, heat shock proteins, and changes in the
balance between suppressive [IL-10, prostaglandin E2 (PGE2), nitric oxide (NO)] and
inflammatory mediators [TNF-a, granulocyte-macrophage colony stimulating factor
(GM-CSF), IL-1) [149]. Critically, DCs that have recognised and taken up foreign
antigen must migrate to the draining lymph nodes, against chemotactic gradients that
attract immature DCs into the inflammatory site. To achieve this, maturing DCs
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produce inflammatory chemokines leading to ligand-induced downregulation of C-C
chemokine receptor 1 (CCR1), 5, and 6, and upregulation of others [150], The
nonmigratory DCs situated around lung venules and within the alveolar wall,
therefore, are responsible for presentation and amplification of effector T cell
reactions during the effector and/or memory response.
1.4.1.1 Phenotypic Heterogeneity of Lung DCs
A phenotypically diverse population of DCs appears to exist in the lung [151]. Two
distinct populations of DCs, lymphoid and myeloid, have been described in the
murine spleen [152,153], however lung DCs do not completely correspond to either
of these strict designations [154], A number of groups have phenotyped DCs
isolated from lung tissue with varying results, often reporting more than one distinct
population, and depending on variables such as whether freshly isolated or cultured
cells were phenotyped, or the method of isolation. Murine lung DCs utilise multiple
accessory molecules to transmit activation signals to counter receptors on T cells,
including CDlla, CD40, CD80 and CD86, and intercellular adhesion molecule-1
(ICAM-1) [154], and these markers, along with many others including CDllb, a
marker of myeloid lineage [152] and possibly maturation [153], CD8a, a lymphoid-
related marker [152], DEC-205, a lectin-like receptor shown to be involved in
antigen processing by DCs [138,155], F4/80, a myeloid marker, and Fc receptor
(FcR) [142], are used to identify and characterise murine lung DCs. A recurrent
problem, however, is the lack of specific DC markers. Therefore, combinations of
MHC class II and the integrin CD1 lc expression intensity are predominantly used as
murine lung DC markers [156], again with variable results.
For example, Lipscomb and colleagues [154,155,157] showed that DCs isolated from
the lungs of mice existed in two populations, differentiated on the basis of high and
moderate MHC class II expression. They examined both populations for expression
of accessory molecules on freshly isolated and cultured DCs. The majority of freshly
isolated DCs expressed moderate levels of MHC class II and ICAM-1, and low
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levels of CD80, CD86, CD40, and CDlla, all of which increased after culture.
Expression of MHC class II on DCs seemed to coincide with the expression of
several accessory molecules, with those expressing high levels of MHC class II
having greater expression of CD80, CD86, CD40, CDlla, and ICAM-1 than DCs
with moderate class II levels. Accessory molecule expression also increased after
culture on class II high-expressing DCs. The majority of fresh DCs expressed
moderate levels of CD lib that didn't change after culture, but those DCs with the
highest levels of class II MHC also expressed the highest levels ofCD1 lb.
Vermaelen et al. [138] selected only CDllc+/low autofluorescence cells, and found
the majority expressed MHC class II, although intensity was not reported.
Interestingly, after an overnight adherence step without the addition of cytokines,
they did not find any expression of CD8a, F4/80, CD80, CD86, or CD40. They
suggested that this may be the result of the overnight adherence step. Moderate to
high levels of expression were found for DEC-205, ICAM-1, CD1 la, and CD1 lb.
Gonzalez-Juarrero and Orme [158] phenotypically identified three distinct lung DC
populations after overnight culture in GM-CSF, based on cell surface expression of
CDllc and MHC class II antigens analysed by flow cytometry. The first population
was comprised of small cells [forward scatter (FSC)low, side scatter (SSC)low] that
stained MHC class IIIow, CDllclow. The second population consisted of large cells
with low granularity (FSCmod, SSC,0W) that stained MHC class IIhigh, CDllclow. The
third population was made up of larger and more granular cells (FSChlgh, SSChlgh)
that stained MHC class IIlow, CDllch'gh. Most of the cells exhibited what is
considered an immature phenotype (CDllcmid t0 hlgh and MHC class Hlow) [159,160],
A small number of more mature cells (MHC class IIhlgh) [161] was also seen, as
described by Lipscomb and colleagues (above) [157], and elsewhere [145], After
seven day expansion in GM-CSF, these lung DCs were MHC class IIlow and
CD1 lclow"hlgh. They were negative for CD8a, expressed low levels of F4/80, high
levels ofCDlla, CD lib, and ICAM-1. In addition, most cells expressed CD80, but
only a small percentage expressed CD40 or CD86.
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Finally, Gong et al. [151] examined rat lung and found that airway epithelial DCs
constitute a distinct subset of pulmonary DCs. Airway DCs did not express ICAM-1
and only showed low expression of MFIC class II. Greater than 50% of these cells
displayed FcR. In contrast, the majority of parenchymal DCs were ICAM-1 positive,
while less than 5% expressed FcRs, and all were intensely positive for MHC class II
expression. Functionally, they also showed that the airway DCs were more effective
stimulators of antigen-induced T cell proliferation than parenchymal DCs, while the
latter were superior in stimulating proliferation of allogeneic T cells. Therefore, both
groups were found to be heterogeneous, and the authors suggest that this reflects the
continuous turnover that these cells undergo in the lung.
These studies show the considerable phenotypical and functional heterogeneity that
exists in DCs, and reflect their different levels of maturity and function [145,151].
The capacity of DCs for antigen uptake and processing is highly dependent on the










Immunity Innate immunity Specific immunity
Phagocytosis ++++ +++ +
TNF-a, IL-1 production ++++ +++ ±
T cell activation + ++ ++++
Cell surface expression
MHC class I ++ +++ ++++
MHC class II ++++ +++ ++++
Costimulatory molecules
CD40 ± + +++
CD80 ± + +++
CD86 ± + +++
Table 1.4 Phenotype and function of murine alveolar macrophages
and dendritic cells. Table adapted from Nicod et al. [131].
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1.4.1.2 Immunoregulatory Functions of Lung DCs
The mechanisms by which lung DCs activate the immune response, and how the
cytokines produced by DCs themselves and their microenvironment could promote
the development of deviant responses in the lung, have not yet been elucidated, and
remain important questions to be answered [162],
DCs are unique in their capacity to induce primary immune responses, although this
function is closely related to their maturational state. Consistent with the high
antigenic load at these sites, respiratory and intestinal mucosal DCs are functionally
specialised for antigen uptake [163], However resident tissue DCs are
predominantly functionally immature in terms of nai've T cell activation in order to
prevent the initiation of potentially damaging immune responses, and generally do
not acquire this capacity until they have left the tissue site and migrated to peripheral
lymph nodes [136]. Precocious or unregulated in situ maturation of respiratory tract
DC functional activity may lead to excessive T cell activation within the airway
mucosa and to damaging local pathology in response to continuous environmental
antigen exposure, a scenario that has been proposed for the aetiology of chronic
asthma [164], Studies correspondingly indicate that the majority of murine
respiratory tract DCs express low levels of surface MHC class II, and produce IL-10
but minimal IL-12 - an immature phenotype that favours Th2 cell differentiation
[165,166], although as discussed above, there is clearly a degree of heterogeneity.
These DCs, which are predominantly of myeloid origin, are alternatively termed
DC2s and preferentially stimulate Th2 cell development [167], In contrast, mature
DC1 cells isolated from peripheral lymphoid organs, express CD8a and stimulate the
generation of Thl cells through the production of IL-12 [166]. It should be noted
that this concept was originally described for human DCs, in which there is a reversal
of the murine system: DC Is are monocyte-derived cells and, therefore, of myeloid
origin, whereas DC2s express T cell markers and are probably of lymphoid origin
[168],
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This evidence suggests two separate DC lineages, however Kalinski et al. [169]
showed that subset-independent DCs can give rise to either a Thl or a Th2 response,
and demonstrated the importance of the microenvironment during maturation,
suggesting that the ability of DCs to induce a particular type of Th response is
predetermined in the tissues by the character of the local inflammatory response that
induces the final DC maturation. Most likely, the solution will fall between the two
theories, although there is not yet a final conclusion on this subject.
Thl/Th2 differentiation may also be influenced by the interactions of costimulatory
molecules on APCs with their ligands on CD4+ T cells. Studies in other organs have
shown the importance of CD40-CD40L and CD80/CD86-CTLA-4/CD28 interactions
in Th2 generation [170], Furthermore, the cytokines present in the
microenvironment, IL-4/IL-10/IL-13 vs. IL-12, play a decisive role in orchestrating
the differentiation along the Thl or Th2 lineage [171], and in vitro and in vivo data
suggest that IL-12 production by DCs can also be modulated by microenvironmental
tissue factors, as well as pharmacological agents. PGE2 [169,172], p2-agonists [173],
histamine [174], and NO [175] have all been identified as inhibitors of IL-12
production and thus favouring Th2 differentiation. Taken together, these findings
support the theory that induction of either Thl or Th2 differentiation depends on both
the DC maturation state and on the influence of environmental factors [176] (Figure
1.6).
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Figure 1.6 DC regulation of Th cell differentiation. Differentiation along the
Th1 or Th2 pathway is triggered by stimulation with the antigen-MHC complex presented by
the appropriate APC. The mature DC1, which may represent a separate lineage or share
the same precursor as the immature DC, produces IL-12 that drives Th1 differentiation. The
immature DC2, in contrast, does not produce IL-12, thus possibly providing a permissive
environment for Th2 differentiation. Figure adapted from Sinigaglia and D'Ambrosio [176],
Presentation of antigen by DCs is not by itself sufficient to activate T cells. The
potent capacity of DCs to activate immunologically naive T cells is related to both
their high constitutive expression of MHC class II and T cell costimulatory
molecules, such as CD40, CD80, and CD86. Deficiency or absence of expression of
these molecules reduces the APC function of DCs, and may render them potentially
tolerogenic, and thus the T cells become unresponsive or fail to proliferate [177].
Recent studies suggest that in vitro-generated myeloid murine DCs with an
"appropriate" surface phenotype (immature DC2s or "costimulatory molecule
deficient") or CD8a' lymphoid DCls can subvert allogeneic T cell responses [178].
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1.4.2 AMs in the Lung
Although ultimately macrophages derive from common haematopoietic precursors,
they differ considerably in various tissues with respect to morphology, secretory
products, surface phenotype and function [179]. In particular AMs, which comprise,
by number, approximately 85% of free cells in the alveoli [144], are a distinctive cell
type in a unique environment where they function to phagocytose and neutralise a
large daily burden of foreign organisms and particles that reach the distal airways
[180]. Clearance of these particles must be accomplished without excessive
inflammation that could compromise gas exchange, suggesting that AMs are
specialised phagocytes [179], Indeed, AMs have been shown to differ from other
macrophage populations in terms antigen-presenting capacity [181]; the better AMs
are at phagocytosis, the poorer their antigen presenting capacity, and they are known
to suppress T cell proliferation in the lung [144,182,183],
AMs reside within the airways at all levels of the respiratory tract, in the lamina
propria, the interstitium, the alveolar regions and pleura, and within pleural spaces
[184], They are normally isolated from lungs by BAL [185], and this method is
discussed further in Chapter 5.
1.4.2.1 Phenotype ofAMs in the Lung
Pulmonary macrophages are both phenotypically and functionally diverse [184]
(Table 1.4). Within subpopulations, AMs differ in expression of MHC class II, Fc
and complement receptors, phagocytic capacity, cytokine production, and responses
to chemotactic stimuli, and attempts to characterise them can exploit many of these
factors [186-188], Phenotypically, the majority of AMs have been shown to express
high levels of cell surface CD 11 a, CD 11c, and F4/80, with variable expression
reported for MHC class II, CDllb, CD40, and other markers [131,179,184,189,190],
and very little, if any, expression of accessory molecules such as CD80 and CD86
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[191]. In some pathological states such as sarcoidosis, however, AMs express high
levels of CD86 and CD40 [192], and this is despite their apparent end-stage
differentiation state. In fact, similar changes have been found when murine AMs
have been exposed to bleomycin [193],
1.4.2.2 Functions ofAMs in the Lung
It is well established that resting AMs help to create an immunosuppressive
environment in which the initiation of immune responses and the activation of
antigen-specific T cells in the lung are limited [194]. Suppressed pulmonary immune
responses, however, can be overcome by exposure to infectious agents or foreign
antigens [195], and the suppressive activity of AMs specifically, can be inhibited by
exposure to GM-CSF [196],
AMs phagocytose and neutralise foreign organisms and particles that reach distal
airways, and produce oxygen radicals, cytokines, lysozyme, complement and many
other substances. However, when AMs are exposed to bacterial products such as
lipopolysaccharides, they release higher levels of cytokines such as TNF-a compared
to peripheral monocytes, which release higher levels of IL-10 compared to AMs
[197]. This demonstrates the higher inflammatory properties of AMs that may
theoretically influence the phenotype and maturation stage of DCs in their vicinity.
Nicod et al. [131] propose that AMs could influence neighbouring DC activation,
and Thl/Th2 differentiation could be influenced when memory T cells migrate to the
vicinity of interstitial DCs, while macrophages release either IL-10 or IL-12.
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1.5 Animal Models of Pulmonary Fibrosis
Animal models are useful and necessary tools for investigating the factors involved
in the pathogenesis and progression of pulmonary fibrosis. The majority of the
animal models of pulmonary fibrosis have been produced in rodents, although
rabbits, pigs, and primates have been used to a limited extent. Many rodent models,
each with its own distinguishing features, have been produced, but this discussion
will focus on the well-accepted models of silica-, ionising radiation-, and bleomycin-
induced pulmonary fibrosis, as well as the FITC-induced model.
1.5.1 Silica-induced Model of Pulmonary Fibrosis
Silicosis is the fibrotic lung disease caused by the inhalation of damaging amounts of
respirable free crystalline silica [198]. It is a progressive disease characterised by the
persistence of pulmonary interstitial inflammation leading to increased proliferation
of fibroblasts and exaggerated production of collagen [199,200]. Several cell types,
including predominantly AMs, but also fibroblasts and epithelial and endothelial
cells, play a central role in the inappropriate inflammatory lung response and in the
development of silicosis by releasing a variety of mediators such as proinflammatory
cytokines (e.g. TNF-a, IL-1, IFN-y [201]) and factors that promote mesenchymal
cell growth [68].
Although the mechanisms involved in the initiation of pulmonary inflammation and
lung disease in silicosis are still under investigation [202], this model of has provided
valuable insight into the complex role of the Th2 response in the development of
pulmonary fibrosis. While increased Type 2 activity has been reported in the mouse
silicosis model [203], the same group also found that the Type 2 cytokine IL-10
mediated different types of lung responses depending on the type of inflammatory
cells involved, and suggested that when looking at human data, the stage of the
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pulmonary disease needs to be carefully taken into account to interpret changes in
IL-10 levels [68],
Similarly, while IL-9, a T cell-derived cytokine active on both T and B lymphocytes,
has been shown to reduce the lung fibrotic response to silica and was accompanied
by an expansion of lymphocytes in the lung as well as a reduction of the Th2
response to silica [204], production of IFN-y, a Thl cytokine, was also increased by
lymphocytes in a mouse model of silicosis [205],
1.5.2 Radiation-induced Model of Pulmonary Fibrosis
The lung is particularly sensitive to cell injury induced by irradiation [206].
Relatively high and repeated doses of radiation often lead to pulmonary fibrosis,
while continued doses of radiation produce continued pulmonary injury [207],
Endothelial cells have been identified as the predominant sites of cell injury induced
by irradiation, and delayed repair following severe injury to the endothelium may
cause an extended period of surface denudation with concomitant loss of fibroblastic
control, resulting in cell proliferation and collagen deposition; it has been postulated
that prolonged disruption of the normal endothelium-fibroblast control system is the
crucial event in radiation-induced pulmonary fibrosis [206]. However, this is also
accompanied by pulmonary oedema, death of type I alveolar cells, hyperproliferation
of type II cells, and pneumonitis [207].
Radiation-induced pulmonary fibrosis has provided additional evidence of a role for
the Th2 response. Both protein and gene expression of the prototypical Type 2
cytokine IL-4 have been reported in AMs [208] and CD4+ T cells [209] in a rat
model of the disease. Moreover, the finding that inbred strains ofmice differ in their
propensity to develop lung fibrosis after exposure to radiation [210] provides a useful
model to identify genetic factors influencing this trait. Studies of the time course to
develop lung damage in mice support the theory that there are strain differences in
susceptibility [211], and research into this area could provide the basis for
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determining similar events in the human form of the disease as there are currently no
assays, either genetic based or otherwise, available to determine individual
susceptibility to radiation-induced lung damage.
1.5.3 Bleomycin-induced Model of Pulmonary Fibrosis
Bleomycin is a cytotoxic agent used effectively in the treatment of various types of
human cancer as it does not induce major myelosuppression or immunosuppression,
however it soon became apparent that bleomycin exhibits a dose-dependent
pulmonary toxicity and induces pulmonary fibrosis [58,212], This toxic effect of
bleomycin has been utilised advantageously in a number of experimental approaches
to pulmonary fibrosis in animal models. The bleomycin model is the most used
experimental model of pulmonary fibrosis, and is a paradigm of the inflammatory
route [64],
Pulmonary toxicity due to bleomycin probably has multiple mechanisms, including
direct tissue toxicity of the drug and indirect toxicity through amplification of
pulmonary inflammation, which work both in sequence and simultaneously [58,213].
Bleomycin administration in rodents results in a dose-, route-, and strain-dependent
pulmonary inflammatory response that is characterised by increased leukocyte
accumulation, fibroblast proliferation, and lung collagen content [213-216], During
the initial stages of lung injury, bleomycin binds to DNA and iron which induces free
radical formation, resulting in lung lipid peroxidation and injury [213,216,217],
Typically, intratracheal instillation of bleomycin causes a type I pneumocyte necrosis
up to one day post-challenge, followed by acute alveolitis on day two or three, and an
intense interstitial inflammation after 4-12 days [218-220], In addition, initiation of
fibroblast proliferation and synthesis of ECM occurs 4-14 days post-challenge, and a
two-fold elevation in collagen content is found three weeks post-challenge
[214,215,219], Fibrosis is seen within the interstitium and the alveoli, leading to
end-stage diffuse pulmonary fibrosis [214,219], Thickening of the alveolar septa and
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loss of lung elasticity result from these pathologic changes in pulmonary
architecture, and lead to significant morbidity in the animal. As these features are
similar to those seen in the lungs of humans with CFA, the rodent pulmonary
inflammatory response to intratracheal bleomycin instillation is thought to constitute
a representative model of human CFA [221,222],
However, the bleomycin model has recently been criticised as not resembling the
human CFA [223]. A recent long-term study using bleomycin-induced lung injury in
rats found that in the late chronic stages the model did not behave as a restrictive
syndrome, nor was the histologic pattern compatible with the particular histologic
pattern of UIP, which defines CFA in humans [223], In addition, they noted that a
number of animal studies have shown a reduction in histologic and biochemical
markers of fibrosis in the bleomycin model with the use of anti-inflammatory and
antifibrotic agents [224-227], whereas in humans CFA generally does not respond to
treatment with these agents [10]. Additional problems with the bleomycin model are
discussed in Chapter 3.
Although the features of bleomycin-induced lung injury are well established, the
pathogenesis of its subsequent progression and evolution has not yet been determined
[228,229]. Thus, many factors have been investigated which are relevant to the
study of CFA pathogenesis.
TGF-P is thought to be one of the most important factors in pulmonary fibrosis, and
production of this cytokine has been widely demonstrated in bleomycin-induced
pulmonary fibrosis in mononuclear cells, fibroblasts, eosinophils, bronchial epithelial
cells, and endothelial cells [230-232], although activated AMs are considered the
predominant source [233-235].
TNF-a production has been reported to be increased [220,230] and also unchanged
[236] in mice administered bleomycin, and the importance of C-C chemokines and
their receptors [219,222,237], are coming to the forefront in bleomycin-induced
pulmonary fibrosis research, as is the role of adhesion molecules [238,239]. The
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administration of IL-12 leads to increased IFN-y production and a decrease in
pulmonary fibrosis in mice administered bleomycin, suggesting that a Thl cytokine
profile is beneficial in attenuating the fibrotic response [97].
As with radiation-induced pulmonary fibrosis, there are strain differences in
sensitivity to bleomycin-induced fibrosis, with BALB/c mice considered to be a
"resistant" strain [240,241]. Interestingly, Gur et al. [242] demonstrated only a mild
and delayed increase in IFN-y secretion in bleomycin-treated BALB/c mice, in
contrast to C57BL/6 mice. Subsequently, this group showed that treatment with
cyclosporin A, a potent immunosuppressive agent, augments the development of
bleomycin-induced lung fibrosis in BALB/c mice, and that this was associated with
increased secretion of IFN-y [229], Thus they suggest that the resistance of BALB/c
mice to bleomycin-induced pulmonary fibrosis may be mediated in part by the
prevalence of a Th2 response, and a decreased Thl response, in this strain.
1.5.4 FITC-induced Model of Pulmonary Fibrosis
In 1995, Roberts et al. [243] described a novel model of pulmonary fibrosis induced
in mice and rats by a single, surgical intratracheal instillation of the fluorescent
haptenic antigen FITC. The FITC remained in the interstitium associated with the
connective tissue for up to five months, at which time there was patchy pulmonary
fibrosis. A chronic mononuclear interstitial infiltrate, dominated by T lymphocytes,
was localised to areas of FITC deposition, and serum antibodies against FITC were
demonstrated.
Further characterisation of this model [244] confirmed these findings in both
BALB/c and C57BL/6 mice, and demonstrated quantifiable increases in lung
collagen content. They also found that the development of fibrosis was independent
of T cell-specific immunity, although they only evaluated the model in the short term
(day 21). CCR2 knockout mice were subsequently shown to be protected from
39
fibrosis in the FITC model, suggesting that CCR2 activation leads to the generation
of a variety of mediators involved in the fibrotic process [62,245], The FITC-
induced model ofpulmonary fibrosis is discussed further in Chapter 3.
1.6 Lung Cytokines in Pulmonary Fibrosis
The development of lung fibrosis, and therefore CFA, appears to be associated with
the in situ release of a broad range of cytokines that act as critical mediators of cell
function and cell-cell communication by influencing many physiological cell
properties, including proliferation, differentiation, and activation of other
immunocompetent cells, chemotaxis, and connective tissue metabolism including
increased synthesis ofECM proteins [83,246],
Numerous cytokines have been implicated in the progression of CFA, including IFN-
y, TGF-P, TNF-a, GM-CSF, the interleukins IL-1, IL-4, IL-8, IL-10, and IL-13, and
C-C chemokines MCP-1 and MTP-la, which will be discussed here.
1.6.1 IFN-y
IFN-y, the "classic" Thl cytokine, is a 20kDa cytokine produced mainly by
lymphocytes and macrophages, which plays a central role in the cellular immune
response. Several potential anti-fibrotic actions have been reported for IFN-y. These
include inhibition of fibroblast proliferation and collagen synthesis and deposition,
promotion of fibroblast apoptosis, and inhibition of the production and action of the
fibrogenic cytokine TGF-P [247-254], IFN-y also attenuates bleomycin-induced
lung fibrosis when administered to mice [255,256], and has been shown to
downregulate TGF-P 1 and procollagen I and III gene expression in this model [251],
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Studies of lung tissue and blood from patients with CFA have found absolute and
relative deficits in IFN-y as compared with the Th2 cytokines [74,251,257],
suggesting, as discussed previously, that a cytokine imbalance plays a role in CFA
pathogenesis. Indeed, the increase in IL-4 and IL-5 expression in CFA appears to be
concomitant with a reduction in IFN-y expression [74,100,101]. Diminished IFN-y
reported in patients with CFA was also coupled with the observation that those
patients with the lowest plasma levels of IFN-y had the most marked deterioration in
lung function on follow up, therefore, low IFN-y levels could enhance collagen
accumulation [250]. Interestingly, IFN-y production has been demonstrated in the
type II epithelial cells from patients with extrinsic allergic alveolitis and sarcoidosis,
in which there is less frequent progressive fibrosis and a response to
immunosuppressive therapy, but it was not expressed in CFA patients [100,101].
Recently, the potential importance of IFN-y as a therapeutic immunomodulator was
demonstrated in trials of IFN-y administration to CFA patients undertaken in an
attempt to switch the inflammatory response to a more protective Thl-type
phenotype [103]. Lung function in these patients was significantly improved under
IFN-y and glucocorticoid treatment. Although this was a preliminary study, if
confirmed it would represent a striking breakthrough in the treatment of CFA.
Despite the abundant evidence for an antifibrotic effect for IFN-y, however, there are
also reports of potentially profibrotic actions. Recently, Chen et al. [258]
demonstrated the presence of elevated IFN-y levels in the BAL of susceptible mice
administered intratracheal bleomycin, and a reduced inflammatory response, and
lower weight loss and mortality in IFN-y knockout mice, suggesting that the
inflammatory response to intratracheal bleomycin exposure is amplified by the local
expression of IFN-y in the lung. They suggest that IFN-y may modulate the
inflammatory and fibrotic response to bleomycin through its ability to enhance
production of other proinflammatory mediators, such as TNF-a, and warn that the
potential for toxicity related to enhancing proinflammatory processes should be
realised in the clinical use of IFN-y in pulmonary fibrotic disorders.
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1.6.2 TGF-p
TGF-P is a pleiotropic cytokine that exists in five isoforms, three of which are
expressed in mammals (TGF-P 1, -P2, -P3) and these and their receptors are
ubiquitously expressed in normal tissue and most cell lines [259], Regulation of
activity, however, is based on whether or not TGF-P is biologically active or latent.
The latent form of the molecule is biologically inert, and signaling through TGF-p
receptors requires exposure of the active site of the ligand, either through
conformational change or through cleavage of the latency-associated peptide
[260,261], Regulation of the activity of the latent complexes is one of the principal
pathways for regulating TGF-p effects, and the various mechanisms provide
potentially useful therapeutic targets [12]. TGF-p 1 is produced by T cells,
monocytes/macrophages, platelets, fibroblasts and epithelial cells, and has emerged
as a key cytokine in tissue repair and fibrosis, having important effects on both
immune and structural cells [6,262,263],
TGF-P 1 is chemotactic for fibroblasts, induces the synthesis and deposition ofmatrix
proteins and glycoproteins through increased mRNA transcription and stability, and
inhibits collagen degradation via inhibition of collagenase production and increased
production of metalloproteinase inhibitors [262,264-266], TGF-P 1 exerts a growth-
inhibitory effect on various cells, including AECs, suggesting that it is critical in the
regulation of AEC growth [267], However in vitro, bioactive TGF-P 1 can be
released from its latent form after damage to an epithelial cell monolayer and
upregulation of activating molecules, and increases the speed of epithelial repair
[261],
Both animal and human studies have provided much insight into the role(s) TGF-P 1
may play in CFA pathogenesis, although the exact mechanisms of its actions have
not been fully elucidated. In vitro, bleomycin has been shown to induce TGF-P 1
mRNA expression and protein synthesis in endothelial cells and fibroblasts
[268,269], while differential TGF-P 1 gene expression, predominantly localised to
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macrophages, has been demonstrated in murine bleomycin-induced lung fibrosis
[235]. TGF-pl gene expression and protein synthesis increase in several
experimental models of pulmonary fibrosis [270,271]. However, evidence to
implicate TGF-P 1 as a direct effector of fibrogenic pathology came from the
transient overexpression of active TGF-pi by adenoviral gene transfer, which was
shown to induce a severe, irreversible fibrotic reaction in the lungs, accompanied by
extensive destruction of normal lung architecture and collagen deposition [67,272],
Moreover, neutralisation of TGF-pi using antibodies significantly reduced
experimental lung and kidney fibrosis [273,274],
Human studies have also generally supported a role for TGF-pi in fibrogenesis,
although there are conflicting reports. Local augmented tissue expression in
epithelial cells and mRNA in AMs from lung biopsy specimens, and elevated TGF-
pi levels in BAL fluid and plasma, have all been reported in patients with CFA [275-
281], In early disease with minimal fibrosis, enhanced TGF-pi expression was
found primarily in AMs, but in advanced honeycomb fibrotic lesions typical of a UIP
phenotype, TGF-pi overexpression was localised to hyperplastic type II AECs [276],
However, decreased TGF-pl production by AMs and normal BAL levels have also
been reported [282],
Of all cytokines investigated to date, the TGF-P family has the most potent
stimulatory effect on ECM deposition [263,283,284], Gene expression and protein
production are increased in the lungs of patients with pulmonary fibrosis [275-281],
and inhibitors of TGF-P function attenuate fibrosis in animal models of the disease
[273,274], Coker and Laurent [285] have proposed that these three criteria be
satisfied before anticytokine therapy is indicated, and as all three are fulfilled by
TGF-P 1, it makes an attractive therapeutic target. Indeed, pirfenidone, which
inhibits TGF-P 1-mediated collagen synthesis and fibroblast mitogenesis in vitro and
TGF-P 1 gene expression in vivo, appears to slow progression of CFA when
administered to patients [286],
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1.6.3 TNF-a
TNF-a is an important proinflammatory cytokine that is produced by different cell
types in the lung, including activated monocytes and macrophages, neutrophils, and
T cells, and when released in large amounts systemically, promotes neutrophil
activation and adhesion to endothelial cells, with a local cytotoxicity leading to an
increased capillary permeability with fluid leakage and shock [287,288]. However, a
modest but persistent production of TNF-a may lead to chronic inflammation with
fever, anaemia, bone resorption and wasting [289],
A role for TNF-a in the pathogenesis of CFA has been suggested through various in
vitro and in vivo studies, although understanding of its precise role is still poor.
TNF-a promotes fibroblast proliferation and collagen synthesis in vitro [220,277],
although inhibitory effects on collagen gene expression have also been reported
[290], TNF-a mRNA expression is elevated in rodent bleomycin-induced lung
fibrosis [220,230], and soluble TNF-a receptors reduce lung fibrosis in murine
models [291], Mice overexpressing TNF-a develop CFA-like fibrosis characterised
by an increased expression of TNF-a by type II AECs [292], There is also evidence
that inhibition of early TNF-a expression with either anti-TNF-a antibodies or TNF-
a antagonists inhibits fibrogenesis [220,291]. However, TNF-a upregulation has
been documented in other inflammatory and immune lung pathologies in which
normal lung repair processes occur without fibrosis [288,293], and Sime et al. [293]
suggest that TNF-a may then act indirectly through upregulation of other fibrogenic
molecules in fibrotic diseases such as CFA. As such, there is evidence that TGF-pi
upregulation occurs in some pathologies in which TNF-a is associated with the
fibrosis but not in those where TNF-a expression leads to normal resolution
[230,277,294], Furthermore, Sime et al. [293] demonstrated that in normal adult rat
lung, transient overexpression of TNF-a resulted in intense but transient
inflammation and patchy interstitial fibrosis associated with secondary upregulation
of TGF-pi and induction of pulmonary myofibroblasts. In contrast, however, it is
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also worth noting that high concentrations of TGF-P have been shown to moderately
reduce TNF-a production by AMs [295].
In human CFA, compared with cells from normal lungs, TNF-a immunoreactivity is
increased in hyperplastic type II cells [296], In patients with CFA or asbestosis,
BAL fluid-derived macrophages release increased amounts of TNF-a compared with
controls [297], while AMs from patients with fibrosing alveolitis have also been
shown to secrete more TNF-a than patients with nonfibrotic disease and normal
individuals [298]. TNF-a, therefore, also fits the criteria proposed by Coker and
Laurent [285] for determining suitability for anticytokine therapy, and indeed,
promising results have been obtained by treating CFA patients with the same drug,
pirfenidone, discussed above, which also has anti-TNF-a properties [286],
1.6.4 GM-CSF
GM-CSF regulates the proliferation and differentiation of cells in the granulocyte-
macrophage lineage, and also has potent effects on the function of mature
hemopoietic cells [299]. The lung is a rich source of GM-CSF, and studies in the
context of pulmonary fibrosis indicate that GM-CSF may play an important but
complex role in healing in the lung, likely determined by quantity, location and
kinetics of expression [300],
Overexpression of murine GM-CSF induced by adenovirally-mediated gene transfer
in the rat resulted in pulmonary fibrosis [301,302], and transgenic overexpression of
GM-CSF in the lung under control of the surfactant protein C promoter results in
enhanced lung growth and alveolar type II cell hyperplasia [303]. However
neutralisation of GM-CSF, associated with a decreased number of macrophages in
the alveolar space, in bleomycin-treated rats worsens pulmonary fibrosis, indicating
that appropriate concentrations of this cytokine favour normal healing [300],
Similarly, Piguet et al. [304] found that administration of GM-CSF reduced
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deposition of hydroxyproline, a measure of the lung collagen content, in response to
bleomycin in mice. Christensen et al. [300] were also able to show that GM-CSF
mRNA expression was diminished after intratracheal administration of bleomycin in
rats before the development of pulmonary fibrosis, and that isolated type II cells
from these animals demonstrated decreased expression of GM-CSF mRNA in
response to in vitro stimulation with lipopolysaccharide. These data, they suggest,
provide strong evidence that a defect in AEC expression of GM-CSF can play an
important role in determining progression to fibrosis after lung injury, as GM-CSF
has a protective role in bleomycin-induced pulmonary fibrosis [300]. Further
support for a protective role for GM-CSF was shown by this group [305] in that mice
with a targeted deletion of the GM-CSF gene had significantly enhanced fibrogenesis
after bleomycin administration, and they indicated a possible mechanism for this
effect could be impaired production of the potent antifibrotic eicosanoid, PGE2.
1.6.5 IL-1
IL-1 has multiple roles, with effects on inflammation, the immune system and
various cell functions [287], Of the constituents of the IL-1 family, IL-1 [3 is the
more prominent in propagation of the inflammatory process [306], IL-1 p is present
in chronically inflamed tissues and in tissues undergoing fibrogenesis, with
accumulation of myofibroblasts and matrix deposition [230,307-309]. Inhibition of
IL-ip at the initiation of animal models of fibrosis has been shown to attenuate the
disease [310], Finally, the transient overexpression of IL-1 p in the epithelial cells of
rodent lung using adenoviral gene transfer induces acute inflammation with alveolar
tissue destruction resulting in progressive interstitial fibrosis, and this long-term
effect coincides with sustained induction of TGF-P [306].
Interestingly, while normal BAL IL-1 levels have been observed in patients with
CFA, concentrations of IL-lra, which competes with IL-1 for its receptors and
counteracts the proinflammatory functions of IL-1, are increased [311]. AMs from
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patients with CFA also produce higher levels of IL-lra in vitro than do those from
healthy controls [312], IL-lra has been localised to hyperplastic type II cells,
fibroblasts [311], and AMs [312], The balance between IL-1 and IL-lra is seen as a
crucial ratio in destructive inflammatory disease [313].
There is also evidence for a protective role of exogenous IL-lra in a number of
animal models of acute lung injury. Targeted overexpression of IL-lra to distal
airway epithelium has been shown to give partial protection from IL-l|3-induced
airway inflammation and injury [314], and exogenous administration of IL-lra can
partially reverse changes of pulmonary fibrosis in bleomycin-induced fibrosis in
mice [310],
1.6.6 IL-4
IL-4 is the prototypic Th2 cytokine produced by macrophages and Th2 cells, and
while it is known to have anti-inflammatory effects, it can also promote fibroblast
chemotaxis and proliferation, collagen gene expression, and collagen synthesis [315-
317], Notably, in other inflammatory interstitial lung diseases such as sarcoidosis
and hypersensitivity pneumonitis, type II pneumocytes express both IL-4 and IFN-y,
but only profibrotic IL-4 appears to be detectable in the lungs of CFA patients [100],
However, there are conflicting reports about a role for IL-4 in CFA. Neutralising
antibodies to IL-4 have been shown to prevent dermal collagen deposition in murine
scleroderma [318], but IL-4 also modulates the expression of proinflammatory
cytokines such as IL-1 and TNF-a, which are both involved in bleomycin-induced
pulmonary fibrosis [242], In addition, bleomycin-induced pulmonary fibrosis is not
altered in either IL-4-overexpressing or -knockout mice [319].
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1.6.7 IL-8
IL-8 is a chemotactic and activating factor leading to neutrophil migration and the
release of their granule content, and while AMs are thought to be the major source of
IL-8 in the lower respiratory tract in humans, many other cell types, including
endothelial and epithelial cells, monocytes, fibroblasts and neutrophils, are capable
of IL-8 synthesis and release [320]. In CFA, IL-8 is increased in the BAL fluid
[99,321], and IL-8 mRNA is increased in AMs [322,323], suggesting a positive
correlation between IL-8-specific mRNA in AMs and percentage of neutrophils in
the BAL from patients with CFA.
There is some speculation that the intensity of IL-8 expression may be related to
prognosis or disease activity in CFA, based on work showing less intense IL-8
expression in patients with fibrosing alveolitis associated with systemic sclerosis
compared to patients with CFA, who have a worse prognosis [321]. Ziegenhagen et
al. [320] confirmed this hypothesis by demonstrating that the degree of neutrophilic
alveolitis in CFA is associated with increased serum levels of IL-8, and that serum
IL-8 levels correlated significantly with impairment of lung function parameters.
These findings may prove useful in the serological assessment of disease activity in
CFA patients.
1.6.8 IL-10
IL-10 is produced by Th2 cells, B cells, monocytes, macrophages and keratinocytes,
and has an anti-inflammatory and protective role in different pathologies [83]. IL-10
acts to reduce the synthesis of proinflammatory cytokines, including IL-1, IL-6, IL-8
and TNF-a and GM-CSF by monocytes/macrophages and neutrophils [83]. In
addition, IL-10 can reduce macrophage free radical release and NO synthesis, and
IFN-y synthesis by T cells, as well as inducing apoptosis of activated neutrophils [4],
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The role of IL-10 in fibrosis is unclear. IL-10 has been shown to have anti¬
inflammatory effects in vivo in a collagen-induced arthritic model [324], It has
reduced the production of Th2 cytokines and eosinophilia in allergic mice, however
it also augmented airway reactivity [325], In a silica-induced model of pulmonary
fibrosis, IL-10 was shown to be anti-inflammatory, but also to exert pro-fibrotic
activity [68], Finally, IL-10 gene transfer into mouse lungs was shown to inhibit the
development of pulmonary fibrosis by intratracheal bleomycin administration,
partially through the reduction of TNF-a expression [326], This study also found
that constitutive and TGF-)3-stimulated type I collagen mRNA expression was
significantly reduced in vitro by IL-10, although IL-10 did not affect proliferation
induced by platelet-derived growth factor (PDGF).
1.6.9 IL-13
IL-13 is a pleiotropic protein that is produced in large quantities by appropriately
stimulated CD4+ Th2 cells, as well as by B cell lymphomas, keratinocytes, mast cells
and basophils [327]. IL-13 and IL-4 have overlapping effector profiles as their
receptor complexes share the signal transducing IL-4E chain [327], but there are a
number of important functional differences between IL-4 and IL-13. Most
importantly, IL-4 directly induces both human and murine T cell proliferation and
differentiation while IL-13 probably mediates its effects on T cells indirectly [328],
IL-13 can induce B cell proliferation, immunoglobulin production in primary
immune cells, and acts as a chemoattractant for monocytes [329], It can also inhibit
the production of inflammatory cytokines by both macrophages and monocytes
[330], It is worth noting that, unlike IL-4, IL-13 is produced by DCs isolated from
tonsillar germinal centres [331], and may contribute to DC regulatory functions of B
cell proliferation and differentiation [327]. This suggests that IL-13 may play a role
in maintaining the B cell aggregates often found in biopsies from patients with CFA.
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IL-13 has emerged as a key component of Th2-mediated immunity, as it is known to
contribute to the pathogenesis of asthma and other pulmonary diseases via its ability
to generate myofibroblast proliferation and ECM deposition, mucus metaplasia,
eosinophilic inflammation, and airway hyperresponsiveness [79,91,332-335], IL-13
transgenic mice show that chronic expression of this cytokine manifests significant
degrees of subepithelial and moderate amounts of adventitial fibrosis [79], and
causes type II alveolar hypertrophy and surfactant lipid and protein accumulation in
the setting of pulmonary fibrosis [336], Interestingly, overexpression of IL-13 but
not IL-4 in mouse lungs results in an overall increase in lung collagen content [91],
The potential for IL-13 to play a significant role in the pathogenesis of CFA is
growing, as elevated mRNA levels have been found in BAL-derived AMs from
patients with pulmonary fibrosis [85], and is discussed in more detail in Chapter 6.
1.6.10 C-C Chemokines: MCP-1 & MIP-1a
C-C chemokines are a family of chemotactic cytokines known to modulate cytokine
production, adhesion molecule expression and mononuclear cell proliferation
[222,337], MCP-1 and MlP-la are members of this supergene family, and because
of their chemotactic activity and ability to activate mononuclear phagocytes, they
have been implicated in the pathogenesis of pulmonary fibrosis. Eosinophils,
macrophages, vascular smooth muscle cells, epithelial cells and myofibroblasts are
the major cellular sources of MCP-1 in fibrotic lungs at different stages of disease
[94,98,338], while macrophages appear to be the major source ofMlP-la [94,219],
Time-dependent upregulation of lung MCP-1 and MlP-la mRNA expression has
been shown in rodent bleomycin-induced pulmonary fibrosis, with peak expression
preceding or overlapping the active fibrotic response [338],
Passive immunisation of bleomycin-challenged mice with anti-MIP-la antibodies
has been shown to reduce total lung inflammatory cell content by 35%, and to inhibit
the fibrotic reaction [219,339], It has also been postulated that TNF-a could
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stimulate MlP-la in vivo, as MlP-la protein expression is decreased by 80% in
bleomycin-challenged mice treated with soluble TNF receptor at two days post-
challenge, which corresponds to the first MIP-la expression peak [340]. In this
same study mice treated later, at the second MlP-la peak, demonstrate a modest
35% reduction in MlP-la.
MCP-1 has been shown to increase type I procollagen synthesis in vitro [341].
MCP-1 antigens can also be detected in the BAL fluid from mice with bleomycin-
induced pulmonary fibrosis [99]. MCP-1 signalling via the CCR2 receptor results in
the generation of profibrotic signals in the FITC-induced model of pulmonary
fibrosis, and mice deficient for CCR2 are protected from the fibrotic response
induced by FITC [62], MCP-1 has been implicated in the imbalance of Thl/Th2
regulation associated with pulmonary fibrosis. Neutralisation of MCP-1 in a Th2-
type model of fibrosis has been associated with significantly reduced IL-4 and IL-5
generation, but treatment with MCP-1 neutralising antibody in a Thl-type model had
no effect on cytokine production or inflammatory lesion size [342]. In addition, T
cell activation in the presence of MCP-1 enhances IL-4 generation [343], and
similarly, MCP-1 has been shown to directly contribute to the production of IL-4 by
antigen-activated T cells in a variety of cell-to-cell interactions [344,345].
1.7 Lung Cells in Fibrosis
Alveolar epithelial and/or capillary cell injury occurs early in the sequence of events
leading to pulmonary fibrosis, and promotes recruitment of circulating immune cells
into the lung. These effector cells, including neutrophils, eosinophils, and
lymphocytes, as well as resident lung cells such as AMs, alveolar epithelial and
endothelial cells and fibroblasts, can then release a variety of factors that can
influence the progression of CFA [83].
Although the various cell populations can closely interact in the pathogenesis of lung
fibrosis, their involvement in lung injury and fibrogenesis will be discussed
independently.
1.7.1 Neutrophils
Inevitably, the sequence of tissue injury is accompanied by a local inflammation
predominantly comprised, within hours, of neutrophils. Neutrophils amplify the
disruption of the tissue mainly by the release of oxidants, proteases and elastases that
injure the local cells and extracellular components, thereby facilitating the
development of pulmonary fibrosis [346], and while there can be little question of
their key role in the initial injury to the lung, their role in the fibrogenic process is
much less clear. Indeed, depletion of neutrophils from the lungs of rats [347] or
hamsters [348] by administration of antineutrophil serum prior to intratracheal
bleomycin gives rise to an increase in lung collagen content and in collagen synthesis
rates.
However, neutrophils are considered to be major effector cells in CFA [349].
Pulmonary compartmentalisation of neutrophils (and eosinophils) may occur in
chronic lung inflammation associated with CFA [323], with neutrophils representing
up to 20% of BAL fluid cells [50], The damaged cells and loss of normal pulmonary
architecture that are histopathologically associated with CFA are also reminiscent of
the kinds of derangements expected from extracellular degranulation of neutrophils
[350], Indeed, the BAL fluid of CFA patients shows markedly increased levels of
enzymes released by neutrophils, including myeloperoxidase and collagenase, and
neutrophils from these patients have been shown to release increased amounts of
preformed proteins and toxic oxygen radicals, which may cause the parenchymal cell
cytotoxicity [351,352], Neutrophil elastase has also been implicated in bleomycin-
induced pulmonary fibrosis [353]. Furthermore, reactive oxygen metabolites
released by neutrophils have been shown to directly alter type II AEC function and
induce cytotoxicity [354], There are also immune complexes present in the blood,
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BAL fluid and tissue of CFA patients [108-112], and their interaction with
neutrophils has been shown to induce neutrophil activation, resulting in further lytic
enzyme and oxygen radical release [355].
Finally, activated neutrophils are also a source of cytokines, such as IL-1, IL-8, and
TNF-a, which further heighten the ongoing inflammatory response, and can
contribute to the progression of the fibrotic process [356].
1.7.2 Eosinophils
The accumulation of eosinophils in both alveolar spaces and the parenchyma has
been noted in CFA [357]. Increased numbers of these cells are usually found in the
BAL of CFA patients [358], and raised concentrations of the granular eosinophil
cationic protein have also been detected [359].
Two lines of evidence have suggested the importance of eosinophils in pulmonary
fibrosis. First, these cells are now known to be a key source of cytokines with
known inflammatory and fibrosis-promoting activities, including TGF-pi, IL-5, GM-
CSF, IL-8, MlP-la and TNF-a [360], The recruitment of eosinophils to the lung for
activation and participation in the pathogenesis of lung fibrosis in the bleomycin-
induced model of pulmonary fibrosis appears to be in response to a significant
increase in lung IL-5 mRNA and protein expression [93]. Of specific importance is
the finding that eosinophils are the primary source of TGF-pi and MCP-1, both
pro fibrotic cytokines, in bleomycin-induced pulmonary fibrosis [94,232],
Eosinophils have also been found to localise to areas undergoing active fibrosis, and
at these sites they were activated and expressing such fibrosis-promoting cytokines
as TGF-pi [232], Secondly, the presence of eosinophils in lungs of patients with
pulmonary fibrosis correlates with worst prognosis or resistance to therapy [358,361 -
363]. Thus there is compelling evidence to suggest that eosinophils may play an
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important role in pulmonary fibrosis via their ability to elaborate the cytokines
capable of driving the fibrogenic response.
1.7.3 Lymphocytes
T cells, through their unique capacity for primary antigen recognition, may play a
larger role than originally considered in fibrosis. There have been conflicting
reports, however, on the necessity for T cells in the fibrotic response. For example,
one group reported that athymic nude mice, which are T cell deficient, were no
different from normal mice in the induction of fibrosis by bleomycin [364], Another
group, however, showed lower cellular infiltration, fibroblast proliferation, collagen
synthesis, and connective tissue accumulation after intratracheal bleomycin in nude
mice compared to euthymic controls [215]. However, Th2 cells can modulate the
proliferation and biosynthetic capacity of fibroblasts [365], largely because of their
ability to generate IL-4, which recognizes specific receptors expressed by fibroblasts
[317], and to stimulate them to proliferate and to undergo directed movement toward
inflammatory stimuli [366].
T cells are therefore believed to influence fibrogenesis indirectly, through the release
of a wide repertoire of cytokines, such as IL-1, IL-4, IL-5, IL-10, IL-13, and TNF-a
[75], and as such play a role in the Th2-dominated environment of the fibrotic lung.
Of particular interest, T cells have been found to be the primary source of IL-5 in the
fibrotic lung [367], and upregulation of IL-5 mRNA and protein by T cells and
eosinophils at the site of active fibrosis have been shown in the bleomycin model
[93]. IL-5 plays a major role in the chemotaxis of eosinophils and release of toxic
mediators providing an additional role in the pathogenesis of lung injury and
inflammation. A role for T cells in bleomycin-induced and other models of
pulmonary fibrosis has been previously suggested [93], and may be mediated by T
cell-derived IL-5 in those lesions characterised by eosinophil infiltration. Indeed,
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this may be a mechanism by which neutralisation of TNF-a activity results in
abrogation of pulmonary fibrosis [360].
Interestingly, a ratio of CD4/CD8 > 1 in the BAL fluid from CFA patients has been
linked to a more benign course of disease [368], while another group showed that a
low CD4/CD8 ratio in the BAL fluid from patients with NSIP may indicate that the
alveolar structutre was not severely reconstructed by fibrosis [369],
B lymphocytes produce IgG, and IgG-containing immune complexes can be found in
patients with CFA [108-112], B cell aggregates have been demonstrated in the lungs
of patients with CFA [105,370,371], and have been associated with a local humoral
immune response [371], The involvement of these aggregates in CFA pathogenesis
is discussed in more detail in Chapter 4.
1.7.4 Lung DCs
The role of DCs in the pathogenesis of CFA has been largely overlooked, and will
perhaps remain so as the focus moves towards structural cells in the lung. However,
there is evidence to suggest that DCs have an integral role in the pathogenesis of this
disease. Certainly, as discussed, DCs play a critical role in Thl/Th2 regulation in the
lung, and as CFA has been shown to be a Th2-mediated disease, it suggests that DCs
may be mediators of this phenomenon in CFA. Indeed, immunohistochemical
analysis of murine lungs after bleomycin treatment showed increased staining of
highly positive MHC class II cells, also suggesting a role for DCs in fibrotic lungs
[237],
DCs may also be critical for the maintenance of chronic localised immune responses
in the lung, and much evidence comes from the study of chronic asthma. It has been
proposed that the presence of chronic inflammation and airway structural changes
leads to local maturation of DCs and to antigen presentation occurring in the airways
55
[372], and this could certainly apply to CFA as well. The cytokines TNF-a, GM-
CSF and IL-4 all have the potential to upregulate expression of DC costimulatory
molecules, and all are expressed in both asthmatic epithelium and CFA
[149,297,298,303], Increased numbers of mast cells are thought to be important in
asthmatic airways, as they express CD40L and produce cytokines that can activate
DCs and prolong their survival in tissues [373,374], Again, this could be applied to
CFA, as numerous reports have documented increased numbers and hyperplasia of
mast cells in pulmonary fibrosis [375-378], and specifically in fibrotic lesions [379],
as well as increased histamine levels [378], Finally, the process of airway
remodelling in both asthma and CFA leads to the deposition of ECM components,
such as collagens, fibronectin, and heparan sulphate, that have the capacity to
enhance DC differentiation and costimulatory function [380,381],
Although there is no direct evidence for a role for DCs in CFA pathogenesis, the
participation of this cell cannot be discounted, and warrants further investigation.
1.7.5 Alveolar Macrophages
The AM is the most prominent cell population obtained from the alveoli of
individuals with CFA [75,382], AMs are important regulators of the repair processes
that are initiated following lung injury, and have the capacity to either increase tissue
damage and fibrosis or to promote repair. The pathogenic potential of AMs comes
from their ability to release mediators that amplify inflammation by recruiting other
inflammatory cells such as mast cells, neutrophils, lymphocytes and other AMs
[337,382,383], to increase cell injury by the production of reactive oxygen and
nitrogen intermediates [354,384], or to increase the number and activity of
fibroblasts by the production of growth factors [385,386], AMs also have the
capacity to release many cytokines, some of which are involved in the processes
described above, including IL-1 [230], IL-8 [322], IL-13 [85], TGF-p [271], MlP-la
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[219], PDGF [385], and TNF-a [126,298], all ofwhich have been implicated in CFA
pathogenesis.
AMs, however, can also express molecules that inhibit fibrosis and promote repair in
the proper milieu. These include substances that promote the clearance of fibrin
matrix, such as urokinase [387,388], and downregulate inflammation, fibroblast
proliferation and collagen deposition, such as PGE2 or gelatinase B [248,389-392],
Therefore, the role of the AM in CFA pathogenesis is quite complex and requires
further investigation to determine what drives the AM to exert its pathogenic effects
rather than those promoting normal repair after injury.
1.7.6 Alveolar Epithelial Cells
AECs play a fundamental role in the resolution of inflammation. Following injury,
type II cells are required to rapidly proliferate and differentiate into type I AECs to
restore barrier integrity. Failure of type II AECs to carry out these tasks may
determine whether or not progression to fibrosis occurs [66], and it appears that this
process is seriously affected in CFA [2].
Type II AECs are an important source of enzymes, cytokines and growth factors,
many of them profibrotic, which are known to be important in CFA pathogenesis.
Most importantly perhaps, several studies have shown that in CFA, hyperplastic type
II cells constitute the main site of synthesis of TGF-pl and TNF-a
[276,277,296,393]. Interestingly, Khalil et al. [276,278] demonstrated that in early
fibrotic lungs (with inflammation and minimal fibrosis), TGF-pi was found mainly
in AMs, but in advanced fibrotic honeycomb lesions primarily seen in UIP, it was
mainly present in AECs. Other cytokines, besides TGF-P and TNF-a, whose
importance has been demonstrated in CFA have been found to be expressed by type
II cells, including PDGF [394,395], IL-4 [100], GM-CSF [300], and MCP-1 [98],
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The role of AECs as suppressors of fibroblast responses in the resolution of
inflammation, and their failure in the progression to fibrosis, is becoming a popular
focus for the investigation of CFA pathogenesis [48,396], Evidence for such a role
for type II cells comes from observations that in animal models of pulmonary
fibrosis, failure of AEC proliferation or differentiation is a major factor in fibrotic,
rather than reparative, responses to injury [66,397], and that AECs can inhibit
fibroblast proliferation in vitro [398,399], Two recent studies have elucidated some
of the mechanisms involved in the suppression of fibroblast proliferation,
demonstrating that the suppressive effects are regulated through MCP-1/CCR2
signalling, and mediated by PGE2 [400], which in turn is dependent on
cyclooxygenase-2 (prostaglandin synthase) [401],
1.7.7 Endothelial Cells
Injury to the epithelium and basement membranes appears to be necessary for the
fibrotic process to occur [402], however it is thought that endothelial cell injury is the
earliest lesion of bleomycin in pulmonary fibrosis [214,403], Endothelial cells are
able to secrete a variety of growth factors that theoretically have the potential to
stimulate fibroblasts [404], Stimulated endothelial cells can also produce
inflammatory mediators such as IL-8 and MCP-1, and endothelial adhesion
molecules are known to be reactive with counter-receptors expressed on leukocytes
[14]. Recently, endothelial ICAM-1 was shown to be essential for abnormal
leukocyte accumulation in capillaries and venules in bleomycin-induced pulmonary
fibrosis [239], Striking proliferation of endothelial cells may accompany the
development of pulmonary fibrosis [405,406] and the ability of these cells to
modulate fibrogenesis may merit further investigation [407],
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1.7.8 Lung Fibroblasts
Fibroblastic foci are early morphological changes associated with progression to
fibrosis, and occur in areas where the alveolar lining cells are destroyed and the
epithelial basement membrane is denuded. Following injury to the lung, fibroblasts
migrate to the area and are stimulated to secrete collagen and other matrix proteins.
They also release various proteases that can degrade and remodel these matrix
proteins. Dysregulation of this process can result in fibroblastic foci, followed by
abnormal remodelling of the ECM and subsequent destruction of the lung
architecture [64,396]
Fibroblasts from CFA patients show shifts in phenotype, from migratory, to
proliferative, to profibrotic leading to production of abundant ECM components in
the fibroblastic foci [64], Myofibroblasts isolated from the lungs of CFA patients
also show abnormal responses to, or release of, growth factors, other mediators and
ECM proteins, including enhanced collagen and TGF-[31, giving them a profibrotic
secretory phenotype [408]. Moreover, bleomycin-exposed lung fibroblasts secrete
increased amounts of TGF-pl protein as compared to normal lung fibroblasts [409],
The shifts in phenotype have been demonstrated in numerous studies on cell lines
established from human and animal fibrotic tissue [410], and from Rel-B knockout
mice with fibroblasts displaying sustained and persistent production of a wide array
of inflammatory chemokines thereby regulating the switch from an acute resolving to
a chronic persistent inflammation [411]. Most cells in the fibroblastic foci have been
shown to be myofibroblasts aligned in parallel to one another and therefore probably
contribute to active contraction and distorted architecture [412],
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases
(TIMPs) are involved in the degradation of ECM, and their normal activation
prompts clearance of the alveolar spaces after lung injury [48], Several studies have
shown profound changes in MMP and TIMP expression and localisation in CFA
lung tissue. In particular, TIMP-2 expression is predominantly localised to
myofibroblasts within the fibroblastic foci [413,414], suggesting enhanced
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progressive accumulation of fibrillar collagens, and perhaps increased fibroblast
survival as TIMP-2 is also able to induce proliferation [414], Additionally,
myofibroblasts from CFA patients synthesise the MMPs gelatinases A and B, which
degrade basement membrane molecules, contributing to the failure of orderly type I
cell repair and enhancing fibroblast/myofibroblast migration into the alveolar spaces
[414],
Lung fibroblasts from CFA patients have also been shown to have a defect in
cyclooxygenase-2 expression [389], and are unable to upregulate the TNF-a receptor
[415], compromising their ability to synthesise antifibrogenic PGE2, leading to their
deficient production of eicosanoid autocrine inhibitors of proliferation, and ECM
deposition [290]. In addition, fibroblasts and myofibroblasts from the lungs of CFA
patients induce AEC death in vitro [416], possibly through the synthesis of
angiotensin peptides [417], while in vivo, apoptotic AECs are detected primarily in
areas immediately adjacent to underlying foci ofmyofibroblasts [418].
1.8 Hypothesis and Aims of Project
The work described in this thesis was undertaken with the goal of providing new
insight into the pathogenesis of CFA. As such, these studies involved the
characterisation of the murine FITC-induced model of pulmonary fibrosis, and the
investigation of possible functional alterations in APCs from these lungs. As
structural cells in the lung are becoming an increasingly popular focus in the study of
CFA pathogenesis, preliminary studies were also conducted into the in vitro effects
ofFITC on lung epithelial cell lines.
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1.8.1 Hypothesis
The hypothesis of this project was that APCs are altered by, and contribute to, the
pathology of lung fibrosis, and that epithelial cell damage may have consequences
for APC function in terms of cytokine production.
1.8.2 Scientific Questions
• Chapters 3 & 4: What are the acute and long-term pathological effects
of FITC administration in mice, and how can they be measured
quantitatively? How are these effects reflected in terms of cellular content
and cytokine production in the BAL fluid?
• Chapter 5: What are the current methods in use for the isolation of lung
DCs and BAL AMs from murine lungs? What are the most appropriate
methods for use in this project? What are the phenotypes of the two isolated
cell populations?
• Chapter 6: Do DCs and BAL AMs from the lungs of FITC-treated mice
differ, from those of control mice, in their ability to induce antigen-specific T
cell proliferation? Is this reflected in production of Thl and Th2 cytokines?
• Chapter 7: What are the morphological effects of FITC treatment on the
two murine lung epithelial cell lines? How does FITC affect their viability?





Unless otherwise stated, all chemicals were obtained from Sigma Ltd (Poole, Dorset,
UK) or Fisher Scientific Ltd (Loughborough, Leicestershire, UK). All tissue culture
reagents and plastic ware were from Life Technologies Ltd (Paisley, Strathclyde,
UK). Recipes for solutions described are shown in Appendix 1.
2.1 Tissue Culture
Sterile technique was used for all cell preparation and culture.
2.1.1 CD4+ DO11.10 T Cell Purification
Using the MACS CD4 protocol (Miltenyi Bitoec GmbH, Bergisch Gladbach,
Germany), this method, with some minor changes, was used to isolate antigen-
specific CD4+ DOl 1.10 T cells from the spleens ofDO11.10 transgenic mice. These
cells express a T cell ap receptor specific for ovalbumin (OVA) peptide, amino acids
323-339 (OVA323-339), presented on I-Ad molecules [419]. The spleen and lymph
nodes were removed from the mouse and placed on the ground-glass ends between
two sterilised glass slides. The slides were continuously pressed together in a
circular motion until only the capsule of the spleen and lymph nodes remained. The
contents of the spleen and lymph nodes were washed with complete RPMI 1640 into
a petri dish. Complete RPMI was prepared by the addition of 10% foetal calf serum
(FCS) (Labtech International, Ringmer, East Sussex, UK), 2 mM L-glutamine, 100
U/ml penicillin/streptomycin, and 5xl0"5M P-2-mercaptoethanol. The isolate was
then pushed through a 40 pm cell strainer using a syringe plunger to obtain a single
cell suspension. The cells were washed twice in complete RPMI, layered on
LympholyteM (Cedarlane Laboratories Ltd, Hornby, ON, Canada) and spun to
remove red blood cells and cell debris. The cells were then washed twice and
counted. As per the MACS protocol, 100 pi of CD4 beads was used to stain 107
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cells. The cells were washed in MACS buffer, then a maximum of 107 cells were
added to one pre-wetted miniMACS MS column on a miniMACS separator
(Miltenyi Biotec). The CD4+ T cells adhered to the magnetic beads in the column,
and the cells were subsequently eluted. This method consistently yielded between
approximately 30 - 50 x 106 CD4+ T cells, to a purity of >88% as assessed by flow
cytometry (Figure 2.1).
Figure 2.1 Cell surface phenotype of murine DO11.10 T cells. Flow
cytometry histograms showing purity of CD4+-enriched T cells isolated from the spleens of
DO11.10 OVA323-339 transgenic mice as described. Open histograms represent isotype-
matched control monoclonal antibodies. The numbers shown on each histogram represent
the % positive cells relative to the isotype control. CD3 , T cells; CD19, B cells.
2.1.2 [3H]-thymidine Incorporation T Cell Proliferation Assay
This assay was used to measure the extent of T-cell proliferation. Antigen-specific
(OVA/TCR) DO 11.10 T cells were placed in 96 well tissue culture plates at a density
of 1x10s cells per well, in 200 pi of complete RPMI, in the presence of 3xl04
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CDllc+-enriched DCs or AMs that had been cultured overnight with 20 ng/ml GM-
CSF (R&D Biosystems), then pulsed for two hours with OVA323.339 peptide
(Albachem, Edinburgh, UK). To determine the optimal concentration of OVA323-3.39
peptide for use in the proliferation assays, CD4+ DO 11.10 T cells were cultured with
APCs that had been pulsed for two hours with different concentrations of OVA323-339
peptide from each batch synthesised. Although counts varied between experiments,
optimal responses for batch one were obtained between 1 and 10 pg/ml OVA323-339
peptide (Figure 2.2), and 10 pg/ml of peptide was used in all subsequent experiments
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Figure 2.2 Representative OVA323.339 peptide Batch 1 dose response
curve. APCs (3 x 104 cells/well) which had been pulsed for two hours with 0-100 pg/ml
of OVA323-339 peptide and then washed, were cultured in round-bottom 96-well plates with
CD4+ DO11.10 T cells (1 x 105 cells/well). After three days, [3H]thymidine (1 pCi/well) was
added for the final 18 hours of culture to assess T cell proliferation, depicted as counts per
minute (cpm). The data shown are the mean ± SEM of triplicate wells, and are
representative of the trend seen in three independent experiments. T only, 695 cpm; T +
100 pg/ml peptide, 937 cpm.
A second batch of peptide was titrated in a similar fashion for use in later
experiments. Again, counts varied, but with this batch optimal responses were
obtained between 10 and 100 pg/ml OVA323-339 peptide (Figure 2.3); 100 pg/ml of
peptide was used in all subsequent experiments with this second batch ofpeptide
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OVA323-339 peptide (pg/ml)
Figure 2.3 Representative OVA323-339 peptide batch 2 dose response
curve. APCs (3 x 104 cells/well) which had been pulsed for two hours with 0-100 pg/ml
of OVA323.339 peptide and then washed, were cultured in round-bottom 96-well plates with
CD4+ DO11.10 T cells (1 x 105 cells/well). After three days, [3H]thymidine (1 pCi/well) was
added for the final 18 hours of culture to assess T cell proliferation, depicted as counts per
minute (cpm). The data shown are the mean ± SEM of triplicate wells, and are
representative of the trend seen in three independent experiments. T only, 837 cpm; T +
100 pg/ml peptide, 1284 cpm.
2.1.2.1 Cell Stimulation
Cells were stimulated by the addition of OVA323-339 peptide at 10 pg/ml (peptide
batch 1) or 100 pg/ml (peptide batch 2), as determined by peptide titration (see
above), or bovine serum albumin (BSA) as a negative control, or the T cell mitogen
concanavalin A (conA) as a positive control (both at 1 pg/ml). To avoid background
proliferation by any contaminating APCs in the T cell isolate, APCs were pulsed
with OVA323-339 peptide or BSA for two hours at 37°C, and the cells washed three
times with PBS before the addition of the T cells. After the addition ofCD4+ T cells,
the plates were incubated at 37°C with 5% CO2 for four days. If required, 0.2 ml of
medium was pipetted from each well after 72 hours for protein assays. This end-
point was chosen as it allowed for maximum proliferation, and peak production of
the highest number of cytokines. The supernatant was centrifuged at 300g for five
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minutes to remove any cells, and was either assayed immediately or frozen at -70°C.
Eighteen hours before the end of the stimulation, 1 pCi per well of 35 Ci/mmol [3H]-
thymidine (ICN, Basingstoke, Hampshire, UK) was added. At the end of the
stimulation period, the cells were either immediately harvested or frozen at -20°C to
arrest [ H]-thymidine incorporation.
2.1.2.2 Cell Harvesting
Cellular nucleic acids were harvested onto filter mats (Wallac, Crownhill,
Buckinghamshire, UK) using a 96 well Tomtec plate harvester (Wallac). The mats
were dried in a 60°C oven for a minimum of one hour.
2.1.2.3 Scintillation Counting
Filter mats were sealed in plastic bags (Wallac) with 10 ml of 'Betaplate™ Scint'
liquid scintillation fluid (Fisons, Foughborough, Feicestershire), placed into holding
cassettes, and counted on a 1205 Betaplate™ liquid scintillation counter (Wallac)
allowing 20 seconds of counting from each sample. Counts per minute (cpm),
reflected T cell proliferation.
2.1.3 Cryopreservation of Cell Lines
Cell lines required for future use were harvested from tissue culture flasks using
trypsin/EDTA (0.25% Trypsin, ImM EDTA), washed, and resuspended in 1 ml FCS
per flask, then mixed with an equal volume of 90% FCS/10% dimethyl sulfoxide
(DMSO). A 1 ml volume of cells was then aliquoted into 1.5 ml CryoTubes, and
frozen slowly by wrapping in cotton wool and placing in a polystyrene box in a
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-70°C freezer for a minimum of 2 days. Cells were transferred to liquid nitrogen for
longer-term storage. To thaw cells, CryoTubes were wrapped in aluminium foil and
left at room temperature to defrost. The CryoTubes were washed with 70% ethanol
before opening, and the cells then washed several times in medium to remove DMSO
residue.
2.1.4 Maintenance of mtCC1-2 Epithelial Cell Line
The CC-10-expressing mouse Clara cell line, mtCCl-2, generated from the lungs of
a transgenic mouse expressing the SV40 Large T antigen under the control of a Clara
cell specific promoter [420], was kindly donated by Professor Franco DeMayo,
Department of Molecular and Cellular Biology, Baylor College of Medicine,
Houston, Texas, USA. The cell line was maintained in Dulbecco's Modified
Eagle Medium (DMEM) IX, supplemented with 10% FCS, 2 mM L-glutamine, 100
U/ml penicillin/streptomycin, at 37°C in 5% CO2. mtCCl-2 cells were routinely
maintained in 7500 mm (T-75) tissue culture flasks. Cultures were started at
passage 19, and continued until passage 30, before defrosting new stock. The cells
were passaged once per week and while still in the growth phase. Passaging the cells
involved removing the medium from the flask, and washing the cell monolayers with
serum-free DMEM. Trypsin-EDTA was then added, and the flask was incubated at
37°C for 5-10 minutes. The detached cells were pipetted into a polypropylene tube
with an equal volume of complete medium, and centrifuged for five minutes at 300g.
The cells were resuspended in 6 ml fresh complete DMEM, and 2 ml of the cell
suspension was added to each of 4 fresh T-75 tissue culture flasks containing 18 ml
warmed complete DMEM.
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2.1.5 Maintenance of CMT64/61 Epithelial Cell Line
CMT64/61 mouse C57BL/1CRF lung carcinoma epithelial cell line (ECACC,
Salisbury, Wiltshire, UK, reference number 86082105) was maintained in
Waymouth MB 752/1 medium, supplemented in the same way as for the mtCCl-2
cell line. CMT64/61 cells were routinely maintained in T-75 tissue culture flasks.
Cultures were fed once per week, and were passaged every four to five days while
still in the growth phase. The cells were passaged as described above, with the
exception of 20-25 minutes of incubation with trypsin-EDTA as these cells were
extremely adherent.
2.2 Cytospins
Immediately after isolation or taken directly from culture, cells were resuspended in
complete RPMI or PBS with 10% FCS, at 2.5x105 cells/ml. 200 pi of the cell
suspension was added to each sample chamber. Poly-L-lysine-coated or BDH
Superfrost plus glass slides were used. The cells were spun on a Shandon Cytopsin 3
(Shandon Inc, Pittsburgh, PA, USA) at 75g for three minutes. The slides were left to
dry for approximately 10 minutes at room temperature, then fixed for two minutes in
methanol, eosin stained in Diff-Quik®l (Dade®, Gamidor Ltd., Abingdon, Oxon,
UK) for two minutes, haematoxylin stained in Diff-Quik®2 for one minute, then
immediately rinsed in water. After air drying for 10 minutes, cytospins were wetted
in xylene, then mounted in Pertex mountant (Cellpath, Newtown, Powys, UK).
2.3 Cytokine Immunoassays
IL-10, IL-12, TGF-pl, IL-13, TNF-a, IFN-y, MEP-la, and GM-CSF levels were
measured from cell culture supernatants or BAL fluid using DuoSet® enzyme-linked
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immuno-sorbant assay (ELISA) Development System kits (R&D Systems Europe
Ltd), following the manufacturer's instructions. Plates were washed using a
HandyWash manual microplate washer (Dynatech Laboratories) and read at 450 nm
on a Revelation 3.04 microplate reader (Dynex Tecnologies, Billinghurst, West
Sussex, UK) with the correction wavelength set to 550 nm.
All standards were prepared in duplicate, as recommended by the manufacturer,
while samples were prepared in triplicate. The plate reader software drew standard
concentration curves and calculated cytokine concentrations of samples.
All samples were assayed neat, however samples for TGF-pi determination required
activation to liberate immunoreactive TGF-pi from its latent complexes. As per the
manufacturer's instructions, this was achieved by incubating the samples for 10
minutes at room temperature with IN HC1, followed by neutralisation with 1.2N
NaOH and 0.5M HEPES.
2.4 Flow Cytometry
Sample acquisition was performed on a Becton Dickinson FACScalibur. Analysis
was completed using BD CellQuest Software.
Flow cytometry was used to phenotype the isolated cells and assess the purity of
these populations. Cells for phenotyping, either from culture or directly after
isolation, were placed in a round-bottomed 96-well plate in aliquots of approximately
105 cells per well, in 200 pi of medium. The plate was then centrifuged at lOOg for
two minutes, and the supernatant in each well discarded. The cells were washed by
resuspension in 200 pi of chilled flow buffer, and centrifuged again. The supernatant
was removed and the cells were resuspended in 50 pi of a 1:10 dilution of mouse
serum, to block non-specific binding. The cells were blocked at room temperature
for 10 minutes. Antibodies were then added directly to the wells in volumes of 5 or
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10 pi, to obtain final dilutions of 1:100 or 1:50, respectively. Details of the specific
antibodies and dilutions are listed in table 2.1. The cells were incubated with the
primary antibody for 30 minutes on ice in the dark, and then washed in flow buffer,
as described above, three times. After washing, the stained cells were resuspended in
200 pi of fresh flow buffer and transferred to labelled flow cytometry tubes
containing an additional 200 pi of flow fix. Cells were run through the flow
cytometer immediately.
Antigen Clone Supplier Dilution Isotype
CD3-PE 145-2C11 BD Pharmingen 1:100 HsIgG^K
CD45R (B220)-PE RA3-6B2 1:100 rlgG2a,K
CD11b-PE M1/70 1:100 rlgG2b,K
CD11c-PE HL3 1:50 FIslgG^A.
CD80-PE 16-10A1 1:50 HslgG2,K
CD86-PE GL1 1:50 rlgG2a,K
CD54 (ICAM-1 )-PE 3E2 1:100 HslgG1tK
l-A° / l-Ea-FITC 2G9 1:100 rlgG2a,K
Ly-6G (Gr-1)-PE RB6-8C5 1:100 rlgG2b,K
CD19-PE 1D3 1:100 rlgG2a,K
Isotype control-PE A95-1 1:100 rlgG2b
Isotype control-PE A19-3 1:50 HsIgG
Isotype control-FITC R35-95 1:100 rlgG2a
Isotype control-PE R35-95 1:100 rlgG2a
Table 2.1 Primary antibodies used for phenotypic analysis. Monoclonal
antibodies were all supplied by BD Pharmingen. Dilutions were made from supplied stock.
All antigens listed above were either FITC- or PE-conjugated and did not require secondary
reagents. Abbreviations in isotype column are as follows: Hs (hamster); r (rat).
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2.5 Immunohistochemistry
All tissue sections, mounted on glass slides, were dewaxed in xylene for 10 minutes
at room temperature, then rehydrated with one-minute washes in descending grades
of alcohol (absolute, 74%, 64%) followed by a wash in deionised water. Vector
Antigen Unmasking Solution (Vector Laboratories, Inc., Burlingame, CA, USA) was
diluted 1:100 in deionised water in a covered plastic dish, and the slides were
microwaved in this solution at 1000 watts for three sets of minutes each. The slide
rack was turned after each five minute cycle. The slides were then cooled for 20
minutes in running tap water.
Next, to block non-specific staining, slides were incubated in a 0.15% solution of
hydrogen peroxide (H2O2) in tap water at room temperature for 15 minutes, then
washed twice in PBS for five minutes before being loaded onto a Shandon Sequenza
staining rack (Shandon Inc, Pittsburgh, PA, USA). All volumes for solutions added
to slides in these staining racks were 125 pi. The protocols from this point onward
for the individual antibodies are described below.
After specific staining, all tissue sections were visualised using diaminobenzidine
tetrahydrochloride (DAB) substrate solution (Dako Liquid DAB and large volume
substrate chromogen solution) for five minutes, followed by a PBS wash. The DAB
solution was prepared by according to the manufacturer's instructions: one drop (20
pi) added per ml substrate solution. The slides were removed from the Sequenza
racks, and washed in running tap water. They were lightly counterstained in
haematoxylin blue for 30 seconds, blued by dipping in Scott's tap water substitute
for 30 seconds, and dehydrated in ascending grades of alcohol (64%, 74%, absolute).
The slides were then cleared by short incubations in three changes of xylene and
mounted in Pertex mountant.
72
2.5.1 Automated anti-FITC Staining of Tissue Sections
Following the H2O2 blocking, slides were washed for five minutes in a 1:20 dilution
of OptiMax® concentrate in deionised water (OptiMax® buffer) (BioGenex, San
Ramon, CA, USA). The slides were then marked with a grease pencil and loaded
onto the BioGenex OptiMax®Plus consolidated staining system.
The following steps were automated, and the required solutions prepared in advance,
at volumes determined by the OptiMax®Plus system, depending on the number of
slides in the run. The slides were incubated in a 1:5 dilution of normal goat serum
(NGS) in OptiMax® buffer, with four drops of Avidin D blocking solution (Vector)
per ml, for 10 minutes. The positive slides were then incubated for 30 minutes in a
1:1000 dilution of rabbit anti-FITC primary antibody in NGS, with four drops of
Biotin solution (Vector) per ml. The negative slides were also incubated for 30
minutes in the same solution, prepared without the primary antibody. Three rinses of
OptiMax® buffer followed, and the slides were then incubated for another 30
minutes in a 1:300 dilution of goat anti-rabbit secondary antibody (Dako) in NGS.
After three more washes in OptiMax® buffer, the slides were incubated in Vector
R.T.U. Vectastain® Elite ABC Reagent for 30 minutes, and washed three times. The
final step was a five minute incubation in DAB substrate solution (Dako, prepared as
described in section 2.6.1) followed by three OptiMax® buffer washes.
The slides were then unloaded into more buffer, counterstained, blued, dehydrated,
cleared and mounted as described.
2.5.2 CD3 Immunostaining
Tissue sections were blocked with Vector Avidin D blocking solution for 15 minutes,
washed with PBS twice for 5 minutes, blocked with Vector Biotin solution, for 15
minutes, and washed twice again. The slides were incubated in Dako Chemate
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Antibody Diluent (Dako Corporation, Carpinteria, CA, USA) for 10 minutes,
followed by the CD3 primary antibody, (rabbit polyclonal, A0452, Dako) diluted
1:100 in Dako Diluent for the test slides or positive controls, or only Dako Diluent
for the negative controls. The primary antibody was left on for 30 minutes at room
temperature. The slides were then washed twice in PBS for five minutes, and then
biotinylated goat anti-rabbit secondary (Dako), diluted 1:300 in Dako Diluent, was
applied for 30 minutes. Two five-minute washes in PBS were followed by 30
minutes in Vector R.T.U. Vectastain® Elite ABC Reagent and another two five-
minutes washes.
2.5.3 TGF-p Immunostaining
This assay required the use of freshly cut tissue sections. After being loaded onto the
Sequenza staining racks, the slides were incubated Dako protein block for 10
minutes, followed by the TGF-P primary antibody, (chicken polyclonal, AF101-NA,
R&D Systems) diluted 1:50 in Dako Diluent for the test slides or positive controls, or
only Dako Diluent for the negative controls. The primary antibody was left on
overnight at 4°C. After warming to room temperature, the slides were washed twice
in PBS for two minutes, and then the goat anti-chicken secondary antibody (Vector),
diluted 1:250 in Dako Diluent, was applied for 30 minutes. Two two-minute washes
in PBS were followed by 30 minutes in Vector R.T.U. Vectastain® Elite ABC
Reagent and another two five-minutes washes.
2.5.4 CD11c Immunostaining
The CDllc primary antibody (hamster anti-mouse) was adsorbed with a solution of
20% mouse serum and 20% rabbit serum in PBS for two hours at 37°C to inhibit
non-specific binding. The adsorbed antibody was then centrifuged and decanted
before use.
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Once loaded onto the Sequenza racks, slides were blocked in a solution of 4 drops
Vector Avidin D blocking solution per ml of 20% NGS in PBS for 10 minutes, then
washed for two minutes in PBS, twice. The CDllc antibody was diluted 1:15 in
20% normal rabbit serum in PBS, and four drops of Vector Biotin block was added
to this solution before it was applied to the tissue sections for 30 minutes at room
temperature. Negative control slides received the same solution, without the primary
antibody. Slides were then washed twice again, and incubated with the goat anti-
hamster secondary antibody (Vector), which was diluted 1:150 in PBS, for 30
minutes at room temperature, and washed in PBS another two times. Vector R.T.U.
Vectastain® Elite ABC Reagent was applied to 30 minutes, followed by another two
five-minutes washes, and visualisation, counterstaining, clearing and mounting as
described.
2.5.5 B220 Immunostaining
Tissue sections were blocked with Vector Avidin D blocking solution for 15 minutes,
washed with PBS for three minutes, blocked with Vector Biotin solution, for 15
minutes, and washed again. The slides were incubated in Dako Chemate Antibody
Diluent for 10 minutes, followed by the B220 primary antibody, (biotinylated rat
anti-mouse, 011220A, Pharmingen) diluted 1:150 in Dako Diluent for the test slides
or positive controls, or only Dako Diluent for the negative controls. The primary
antibody was left on for 30 minutes at room temperature. The slides were given two
• (R)
two-minute washes with PBS, followed by 30 minutes in Vector R.T.U. Vectastain
Elite ABC Reagent and another two five-minute washes before completing as
described.
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2.5.6 MHC Class II Immunostaining
Tissue sections were blocked with Vector Avidin D and Biotin blocking solutions as
described above. Following one three-minute wash in PBS, Vector M.O.M. mouse
IgG block was applied for one hour at room temperature. The Vector M.O.M.
immunodetection kit is designed specifically to localise mouse primary antibodies on
mouse tissues, and was used as per the manufacturer's instructions. A two- minute
PBS wash was followed by Vector protein concentrate for five minutes, and then the
MHC class II primary antibody (mouse monoclonal, 0634ID, Pharmingen), diluted
1:50 in PBS was left on overnight at 4°C. The slides were warmed to room
temperature, then given two two-minute washes in PBS before incubating with
Vector M.O.M. secondary antibody for 10 minutes. Following another two washes
in PBS, Vector M.O.M. ABC was applied for five minutes, and the slides were given
a final two five-minute washes in PBS before moving on to the final steps.
2.6 Statistics
Statistics throughout this thesis were calculated using GraphPad InStat (version 3.01,
32 bit for Windows 95/NT, GraphPad Software, San Diego California USA,
www.graphpad.com), and followed the recommendations made by this program.
Results were considered significant if p<0.05.
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CHAPTER 3




The main hypothesis on which this thesis is based is that APCs are altered by, and
contribute to, the maintenance of the chronic inflammation seen in interstitial lung
diseases, such as CFA. In order to test this hypothesis it was necessary to use an
animal model that best mimicked the pattern of the human disease. The following
two chapters will outline the reasons for choosing the FITC model, and present data
characterising the disease seen in mouse lungs after acute (Chapter 3) and long-term
(Chapter 4) exposure to FITC.
3.1.1 Animal Models of CFA
As patients with pulmonary fibrosis most often present in the later stages of disease,
animal models ofCFA are essential in order to elucidate the early cellular events that
lead to progressive disease. They allow research to be directed towards the
understanding of the mechanisms that determine the induction, maintenance, and in
some cases, resolution, of pulmonary fibrosis in humans. Various models have been
produced, including those induced by the use of butylated hydroxytoluene and
oxygen [397], cyclophosphamide [421], ionising radiation [206], paraquat [422], and
phorbol myristate acetate [423], The most commonly used and well-studied rodent
model of lung fibrosis, however, is the bleomycin model [214,424-426],
3.1.2 The Bleomycin Model of Pulmonary Fibrosis
Bleomycin is a drug used successfully as a cytotoxic agent in the treatment of
squamous cell carcinoma, testicular tumours, and lymphomas [216,427]. Although it
was introduced largely because it has no major toxic effects on kidney or bone
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marrow, bleomycin was soon found to cause pulmonary fibrosis in humans
[212,427],
Animal models of bleomycin-induced pulmonary fibrosis have since been developed,
and having many of the histological components of CFA [214,218], are thought to
constitute a representative model of the human disease. However, as discussed in
Chapter 1, a recent study by Borzone et al. [223] showed that while the early stages
of bleomycin-induced lung damage resemble those of human pulmonary fibrosis, the
later chronic stages do not resemble the histologic pattern ofUIP that defines CFA in
humans, nor was it restrictive. It is also difficult in the bleomycin model, as well as
other models, to implicate specific immune responses to the initiating agent. As
well, due to the severity of the response to bleomycin, the majority of studies only
measure the response as far as three weeks after exposure
[92,97,219,221,244,428,429]. This makes it difficult to study the long-term effects
ofprogressive disease in this model.
3.1.3 The FITC Model of Pulmonary Fibrosis
Some of these limitations were addressed by a novel model of fibrosis developed in
this laboratory [243], This study demonstrated fibrosis in the lungs of both mice and
rats given a single surgical intratracheal dose of FITC in PBS. An acute
inflammatory response ensued, characterised by a granulocytic infiltrate which was
replaced after one week by a chronic mononuclear cell infiltrate predominated by T
lymphocytes. A chronic patchy fibrosis developed over several months, and was
localised to sites of long-term FITC deposition, while adjacent lung tissue without
FITC remained apparently normal. This study was carried out over a five month
period. FITC is a known skin-sensitising agent shown to be capable of inducing
specific immune responses [430]; specific immunity against the fluorescein hapten
can also be measured in this model by the presence of anti-FITC serum antibodies
[243],
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This model was extended by Christensen et al. [244] who found that the single
intratracheal dose of FITC, given to both BALB/c and C57BL/6 mouse strains,
caused a reproducible lung injury, quantifiable increase in lung collagen content, and
a specific immune response to the FITC. They also showed that the development of
FITC-induced fibrosis is not dependent on T cell-specific immunity. Flowever, this
study was carried out over a maximum period of three weeks, and this group do not
disagree that the immune response is important beyond their three week time limit, in
the later, chronic stages of the disease (G.B. Toews, personal communication).
Indeed, in the original paper, Roberts et al. [243] describe the appearance of
lymphocytes in the BAL at seven days post-FITC, and frozen sections showed
lymphocytic infiltrate at five months.
Thus the FITC-induced murine model of pulmonary fibrosis has several advantages
over the traditional bleomycin model. Primarily, it produces a chronic persistent
inflammation more in line with human pulmonary fibrosis, and allows for long-term
evaluation of the mice. The use of the fluorescent hapten FITC itself is another
advantage as it greatly facilitates the tracking of the ongoing response and the
progression of the disease in the tissues, and allows measurement of a specific
immune response.
The FITC-induced model of pulmonary fibrosis was further characterised for this
body of work. The original FITC model, however, used a surgical method of
intratracheal instillation. This was associated with a 30% mortality rate within 48
hours of instillation. Due to Home Office requirements for Reduction, Replacement
and Refinement, the model was modified so that the FITC was introduced into the
trachea by a non-surgical trans-oral method. This significantly reduced the mortality
rate to less than 5% in the 48 hours following instillation.
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3.1.4 Aims of Chapter
The principal aims of this chapter are to describe:
• the method, including modifications to the original method, of the FITC-
induced murine model ofpulmonary fibrosis
• the acute effects of FITC on murine lung tissue pathology
• a method of scoring the acute inflammatory response in the lungs of FITC-
treated mice
• the acute effects of FITC on the BAL cells and fluid ofmurine lungs
81
3.2 Method of Intratracheal Instillation of FITC / PBS in Mice
Female BALB/c mice, between six and eight weeks of age and 10-22 grams in
weight, were anaesthetised with 0.3 ml of Avertin given intraperitoneally. Each
mouse was rested by its front teeth on the support shown in Figure 3.1 A. A string
with a weight suspended on the end was looped around the bottom teeth to hold the
mouth open. A cold, fibreoptic light source was shone directly onto the throat to
allow visualisation of the top of the trachea. A pipette was used to dispense 50 pi of
the 2 mg/ml FITC solution or sterile, endotoxin-ffee PBS (for control mice) into a 1
ml syringe. A blunted 25-gauge needle was attached to the syringe and inserted into
the trachea of the mouse. The FITC solution or PBS was carefully delivered into the
trachea of the mouse (Figure 3. IB). The mouse was then removed from the support
and laid on its side in the cage. Mice recovered from the anaesthetic within a couple
of hours, and were monitored on a regular basis until required. Immediate death
from the above procedure occurred extremely rarely, and greater than 95% of mice
survived until the required time points.
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A
Figure 3.1 Intratracheal instillation of FITC/PBS dose. An anaesthetised
BALB/c mouse rested on the support, with a weighted string holding the lower jaw open, and
a light source illuminating the trachea (A). A 1 ml syringe with a blunted needle was used to
instil the dose of FITC or PBS (B).
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3.3 Acute Effects of FITC on Murine Lung Tissue Pathology
Murine lungs from mice given either FITC or PBS intratracheally were killed by
intraperitoneal injection of 0.5 ml pentabarbitone (Sagatal) (Merial Animal Health,
UK) at one, two, three, five, or seven days after treatment. Following perfusion and
lavage, the lungs were fixed in formalin as described in section 5.3.3, and embedded
and sectioned. Tissue sections were then stained with haematoxylin and eosin
(H&E), and a second set were stained with anti-FITC antibody.
Of 12 pairs ofmouse lungs examined on each of Days 1 and 2, after being given an
intratracheal dose of FITC, 10 showed varying amounts of FITC deposition in the
lungs, while two from each time point showed no FITC (Table 3.1). On Day 3, eight
out of 12 mice were positive for FITC. On Day 5, all four mice given an
intratracheal dose had FITC deposited in their lungs, while on Day 7, three out of
four mice showed FITC deposition. All lung sections from PBS mice stained
negatively for FITC at all time points.
# mice Day 1 Day 2 Day 3 Day 5 Day 7
total 12 12 12 4 4
FITC +ve 10 10 8 4 3
FITC -ve 2 2 4 0 1
Table 3.1 Numbers of mice treated with FITC and assessed
histologically and immunohistochemically. Mice were given a single dose of
FITC intratracheally and assessed on Day 1, 2, 3, 5, or 7.
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3.3.1 Distribution of FITC in Acute Lungs
Tissue sections (3 pm) stained with anti-FITC antibody were examined to determine
distribution of the FITC in the mouse lungs. Although FITC staining could be
variable, Figure 3.2 shows the typical distribution of FITC occurring at Day 1 and
Day 5 after treatment. At Day 1, FITC was diffusely distributed around large (not
shown) and small bronchi and blood vessels, and in the alveolar walls (Fig. 3.2A).
Heavily stained macrophages could be seen in the tissues as well. In the PBS-treated
mouse lung, however (Fig. 3.2B), the lung looked predominantly normal, although
there could be mild cellular infiltrate. Five days after FITC instillation (Fig. 3.2C),
some of the FITC had been cleared, presumably by the mucociliary apparatus, and
macrophages that were still seen heavily stained for FITC, while PBS controls
appeared normal (Figure 3.2D). However, much FITC still remained, particularly
around the bronchi and blood vessels. Areas of thickened alveolar walls and cellular
infiltrate were found, as well as anti-FITC antibody negative, normal-appearing areas




Day 1 FITC - negative control
Figure 3.2 Anti-FITC antibody stained sections of mouse lung 1 and 5
days after treatment. Mouse lungs were fixed and processed as described. Lung
sections from FITC-treated (A, C) or PBS-treated (B, D) mice on Day 1 (A, B) and Day 5 (C,
D) were stained with anti-FITC antibody, while negative controls (E) received no antibody.
Original magnification x200.
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3.3.2 Scoring of Acute FITC-induced Damage
In order to assess the inflammatory reaction in the lungs and to compare the FITC-
treated and control mice, a scoring system was devised. The scoring of peripheral
lung inflammation was performed at x200 magnification over 10 random fields in
which lungs were completely, but not overly, inflated, and where the field contained
a complete transection of at least one bronchiole less than half a field width in
diameter, and a blood vessel as well as an alveolar airway. Large bronchioles were
ignored. As the lungs were all perfused and lavaged before fixation, no comment




























2-3 cells 4-5 cells >5 cells
*
Cells around blood vessel walls
5 Defined as sub-bronchiolar tissue, beneath basement membrane and smooth muscle, not
immediately adjacent to a blood vessel
^ Scores indicative of focal expansion of alveolar walls by that number of cells
Table 3.2 Method for scoring peripheral inflammation in FITC- and
PBS-treated murine lungs.
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The highest score in each compartment per field set the score for that field. For each
section 10 fields were scored. The scores for the 10 fields were averaged to give the
score for the section. The scores for each compartment are given individually, but
were also summated to give an overall score where:
• 4 = no infiltrate in any compartment
• 5-8 = overall mild infiltrate
• 9-12 = overall moderate infiltrate
• 13-16 = overall severe infiltrate
Statistics were calculated by taking the mean value of the 10 fields per section as the
value for that animal at the time point. Using GraphPad InStat, the values for all
animals at each time point after FITC treatment were then statistically compared to
the values for all animals at the same time points after PBS treatment using a 2-tailed
Mann-Whitney U test. Significance was assumed if p < 0.05.
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Day 1 FITC Day 1 PBS
Figure 3.3 H&E stained sections of mouse lung one day after FITC (A,
B) or PBS (C) instillation. Mouse lungs were fixed and processed as described.
Sections were scored to assess damage to the lungs. Black box in A surrounds area of
enlargement shown in B. Arrows indicate granulocytic cells with lobated nuclei. Original
magnification x200. Enlargement approximately x800.
Figure 3.3 shows typical fields used to score acute FITC-induced lung damage. At
x200 magnification (A and C), both fields fulfill all requirements: a complete
transection of at least one bronchiole less than half the field width in diameter, a
blood vessel, and an alveolar airway. Figure 3.2B shows that at Day 1 after FITC
instillation, the cellular infiltrate is composed primarily of granulocytic cells.
At one day post-FITC treatment, the perivascular compartment in Figure 3.3A was
given a score of "2" as there was cellular infiltrate, but there were fewer than 20 cells
around the blood vessel walls. The bronchiolar epithelium was given a score of "3"
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as there were more than five, but fewer than 10 cells in this area. In the peri¬
bronchiolar alveolar tissue, a score of "2" was given as there were fewer than 20
infiltrating cells. Finally, in the alveolar walls there was evidence of focal expansion
by two to three cells, indicating a score of "2". A combined score of "9", calculated
by adding all the scores in the field, was then given for that field, indicating an
overall moderate infiltrate. This process would be repeated over nine additional
random fields, and the mean scores would be calculated for the animal.
In Figure 3.3C, which shows a typical field from a section of PBS treated lungs after
one day, the perivascular compartment showed fewer than 20 infiltrating cells (score
= 2), the bronchiolar epithelium had fewer than 5 infiltrating cells (score = 2), the
peri-bronchiolar epithelium shows no infiltrate (score =1), and the alveolar walls
showed evidence of focal cellular expansion by two to three cells in some areas
(score = 2). This field was then given an overall score of "7", indicating overall mild
infiltrate, which would be expected after introducing a substance into the lungs. As
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Figure 3.4 H&E stained sections of mouse lung five days after FITC
(A,B) or PBS (C) instillation. Mouse lungs were fixed and processed as described.
Sections were scored to assess damage to the lungs. Black box in A surrounds area of
enlargement shown in B. Arrows indicate cells with a mononuclear appearance. Original
magnification x200. Enlargement approximately x800.
Figure 3.4 shows typical fields from mice five days after intratracheal instillation of
FITC (A,B) or PBS (C). The scoring for the Day 5 FITC section (Fig. 3.4A) was as
follows: perivascular compartment = 2; bronchiolar epithelium = 2; peri-bronchiolar
alveolar tissue = 2; alveolar walls = 2. This gave a combined score of 8, indicating
overall mild infiltrate, bordering on moderate. This was similar to the combined
score seen at Day 1, however the nature of the infiltrate was different. At Day 1 the
infiltrate was primarily granulocytic (Fig. 3.3B), while at Day 5, it was
predominantly mononuclear (Fig. 3.4B). This finding is consistent with that of the
earlier model [243].
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The scoring for the Day 5 PBS field in Figure 3.4C was as follows: perivascular
compartment = 2; bronchiolar epithelium = 1; peri-bronchiolar alveolar tissue = 1;
alveolar walls = 1. This gave an overall score of 5, which is at the low end of the
overall mild infiltrate category. As mentioned previously, nine additional random
fields would be scored for both the FITC- and the PBS-treated sections, and the
means would be calculated. This would be repeated for each animal at each time
point, and for each treatment.
Table 3.3 and Figure 3.5 summarise the results of scoring the acute FITC-induced or
PBS control response in mouse lungs. Each of the four areas outlined in Table 3.2
were evaluated for each of the five time points (Days 1, 2, 3, 5, and 7).
In the perivascular compartment, the mean scores over each of the time points
measured in the PBS-treated control mice indicated little cellular infiltrate, in
contrast to those measured in the FITC-treated mice. The mean score for the FITC
mice was highest at Day 7, but not significantly so. However, the mean scores of the
FITC-treated mice in this compartment were significantly greater than those of the
PBS control mice over each of the days measured (p < 0.03). In the bronchiolar
epithelium, the scores were generally lower for both FITC- and PBS-treated mice,
however the mean scores for the FITC-treated mice at Days 1, 2 and 3 were
significantly higher than those of the PBS control mice (p < 0.001). Cellular
infiltrate into the peri-bronchiolar alveolar tissue of the PBS-treated mice was
minimal at all time points, but in the FITC-treated mice the cellular infiltrate
consistently scored significantly higher than in the controls (p < 0.03), and had the
highest score on Day 7. In the alveolar walls there was little, if any, cellular infiltrate
in the PBS control mice, but again, in the FITC-treated mice the mean scores were
significantly higher at each of the time points (p < 0.03). As in the previous
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Peri-bronchiolar alveolartissue mean±SEM [p,vsPBS]













































































































Day1 Day 2 Day 3 Day 5 Day7
Figure 3.5 Inflammation scores on tissue sections of FITC-treated and
PBS control mice over 7 days post-treatment. Tissue sections from FITC-
treated (□) and PBS control (□ ) mice were scored as described. Data are presented as
means ± SEM (n=12 at Day 1, Day 2, Day 3; n=4 at Day 5, Day 7).
*p<0.03 as compared to paired PBS value, by 2-tailed Mann-Whitney U test (see Table 3.3
for actual p values)
Figure 3.6 shows the combined scores for each of the five time points evaluated. The
scores were calculated by adding the mean scores from each of the four
compartments examined. In the PBS-treated mice, the combined score at Day 1
indicated an overall very mild infiltrate, but by Day 2, and through to Day 7, this
dropped to a score indicating very little, if any, infiltrate measured in any
compartment. In contrast, in the FITC-treated mice the combined scores over Days
1, 2, 3, and 5 indicated an overall mild infiltrate, bordering on moderate, and by Day
7 the score indicate an overall moderate infiltrate. As shown above, the infiltrate at
Day 1 was primarily granulocytic, indicating an acute inflammatory response. By
Day 5 the infiltrate appeared more mononuclear, suggesting a shift towards a chronic
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inflammatory state. At each time point, the overall combined score for the FITC-
treated mice was significantly higher than those of the PBS controls, indicating that
the F1TC did indeed cause an inflammatory reaction in the lungs of the mice that
cannot be attributed to the carrier solution, PBS.
12 *
Day 1 Day 2 Day 3 Day 5 Day 7
Figure 3.6 Combined inflammation scores on tissue sections of FITC-
treated and PBS control mice over 7 days post-treatment. Tissue sections
from FITC-treated and PBS control mice were scored as described. Data are presented as
means ± SEM (n=12 at Day 1, Day 2, Day 3; n=4 at Day 5).
*p<0.03 as compared to paired PBS value, by 2-tailed Mann-Whitney U test (see Table 3.3
for actual p values).
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3.3.3 Immunohistochemical Staining at Acute Time Points
Immunohistochemical staining for the cell surface protein CD3, to detect T
lymphocytes, showed that T cells are present at similar levels in the tissues at Day 1
in both FITC- and PBS-treated mice (Figure 3.7A,E). Increased numbers of T cells
were seen at Day 3 in the FITC-treated mice (B), but did not become prominent in
the tissues until Day 5, and remained at Day 7 (C,D). In contrast, PBS-treated mice
did not have increased numbers of T cells at Day 7 as compared to Day 1 (F,E). A
negative control section in shown in Fig.3.7G.
B lymphocytes were detected immunohistochemically by staining with the B220
antibody. Unlike T cells, no influx in B cells was seen in FITC-treated mouse lungs
up to Day 7, although numbers may have been slightly increased at Day 7, and
particularly around potential cell aggregates (Figure 3.8A-D). This phenomenon will
be discussed further in Chapter 4. Staining for B cells in PBS-treated mouse lungs
showed no change between Day 1 and Day 7 (E,F). A negative control section is
shown in Fig.3.8G.
TGF-P staining on tissue sections from FITC-treated mice appeared more abundant
at Day 1 as compared to sections from PBS control mice (Figure 3.9A,E ). Increased
expression was seen at Day 3 (B), and appeared to peak at Day 5, with AMs being
particularly strongly positive for the cytokine (C), with less staining evident at Day 7
(D). Staining for this cytokine was found on both alveolar macrophages and on the
lung tissue itself.
CD1 lc cell surface protein was expressed on cells present in the tissue as well as on
bronchial epithelium, but the AMs seemed to express more of this protein than other
cell types. As will be discussed in Chapter 5, this correlates well with AMs from the
BAL expressing very high levels of CDllc. No obvious change in the levels of
CDllc protein expression was seen from Day 3 to Day 7 (Figure 3.10A-C), and PBS
control mice expressed similar levels (D,E).
96
Cell surface staining for the MHC class II protein revealed that although there
appeared to be more cells expressing MHC class II in the sections from FITC-treated
mice than in PBS controls, these cells were by no means abundant (Figure 3.11A-D).
The distribution of these cells was fairly localised, although not limited, to areas of
alveolar thickening and dense cell clusters. As will be shown in Chapter 5, a
subpopulation of DCs extracted from the lung tissue expressed high levels of this
protein and indeed, examination of some of the heavily stained MHC class II-
positive cells at high magnification in situ showed dendritic-like processes,
suggesting that these are DCs (E).
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Figure 3.7 CD3 cell surface protein staining of lung tissue sections.
Sections were stained by immunohistochemistry for CD3 to detect T lymphocytes. Sections
are from FITC-treated mice on Day 1 (A) (arrows indicate positively-stained cells), Day 3 (B),
Day 5 (C), Day 7 (D) after treatment, and from PBS control mice on Day 1 (E) and Day 7 (F)
after treatment. A negative control from a Day 7 FITC-treated mouse is shown in G.
Original magnification x200.
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Figure 3.8 B220 cell surface protein staining of lung tissue sections.
Sections were stained by immunohistochemistry for B220 to detect B lymphocytes. Sections
are from FITC-treated mice on Day 1 (A), Day 3 (B), Day 5 (C), Day 7 (D) after treatment,
and from PBS control mice on Day 1 (E) and Day 7 (F) after treatment. A negative control
from a Day 7 FITC-treated mouse is shown in G. Original magnification x200.
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Figure 3.9 TGF-p protein staining of lung tissue sections. Sections were
stained by immunohistochemistry for the cytokine TGF-p. Sections are from FITC-treated
mice on Day 1 (A), Day 3 (B), Day 5 (C) (arrows indicate positively stained alveolar
macrophages), and Day 7 (D) after treatment, and from PBS control mice on Day 1 (E) after
treatment. A negative control from a Day 7 FITC-treated mouse is shown in F. Original
magnification x200.
100
Day 3 FITC B Day 5 FITC
' /
C Day 7 FITC D Day 3 PBS
/
» W" ( V vfV r
-tk \£rr" ^XZ L • v
Day 7 PBS F -ve control
r.V V
L . A-2}*/r x..i
. f *— » • c***"'
./-<» 1 _A*A-/ 1-
/V
Figure 3.10 CD11c cell surface protein staining of lung tissue sections.
Sections were stained by immunohistochemistry for CD11c. Sections are from FITC-treated
mice on Day 3 (A), Day 5 (B), and Day 7 (C) (arrows indicate positively stained alveolar
macrophages) after treatment, and from PBS control mice on Day 3 (D) and Day 7 (E) after
treatment. A negative control from a Day 7 FITC-treated mouse is shown in F. Original
magnification x200.
101












> * , , »
~A
^ f •" r ,
-ve control
Figure 3.11 MHC class II cell surface protein staining of lung tissue
sections. Sections were stained by immunohistochemistry for MHC class II. Sections are
from FITC-treated mice on Day 3 (A), Day 5 (B), and Day 7 (C) after treatment, and from
PBS control mice on Day 3 (D) after treatment. A heavily stained DC with classic dendritic
processes (arrows) from a Day 3 FITC section is shown in E (magnification approximately
x1000). A negative control from a Day 7 FITC-treated mouse is shown in F. Original
magnification x200.
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3.4 Acute Effects of FITC on BAL
In order to assess the acute effects of FITC on BAL cells and fluid, mice were killed
one, two, three or seven days after receiving the FITC (or PBS for controls)
intratracheally. BAL was collected and processed as described in section 5.3.2.
3.4.1 Total Cell Counts
Figure 3.12 shows the total cell count from BAL in PBS control vs. FITC-treated
mice for all four time points. At one day post-instillation, the total cell count from
the BAL was 0.97 ± 0.05 x 105 in the PBS control mice vs. 1.27 ± 0.17 x 105 in the
FITC-treated mice (n=3). Two days post-instillation, cell counts increased in both
groups of mice, but again, there were slightly more in the FITC-treated group: 1.90
±0.21 xlO5 PBS vs. 2.07 ± 0.27 FITC (n=3). After three days, total cell counts from
the PBS-treated mice fell to near-normal levels (1.35 ± 0.00 x 105), while those from
the FITC-treated mice dropped slightly, but were significantly greater (1.86 ± 0.05 x
105; p < 0 .02) than those from PBS-treated mice (n=3). Finally, at seven days post-
instillation, little difference was seen between the two groups, but cell counts had
increased in both (n=8).
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Day 1 Day 2 Day 3 Day 7
Figure 3.12 Total BAL cell counts measured 1, 2, 3, or 7 days after
intratracheal instillation of FITC or PBS. BAL was collected at the time points
indicated from both treated (FITC) and control (PBS) mice, and prepared as described. The
data represent the means ± SEM (Day 1-3, n=3; Day 7, n=8).
*
p < 0.02 as compared to paired FITC value, by paired Student's f-test.
3.4.2 Differential Cell Counts
In order to assess the types of cells present in the BAL fluid in treated vs. control
mice, cytospin preparations of the BAL cells were made as described in section 2.2.
Differential counts were performed by counting 300 cells per slide on random fields
at xlOO magnification. Figure 3.13 compares the values for FITC- and PBS-treated
mice at each of the time points for macrophages, and Figure 3.14 compares values
for polymorphonuclear cells (PMNs). Figures 3.15 and 3.16 show typical cytospin
fields at each of the time points for both FITC- and PBS-treated mice. The
remainder of the cells were lymphocytes, but as they comprised less than 1% of the
population in all cases, numbers are not shown.
As will be discussed in section 5.4, a typical BAL cell population from a normal
mouse is comprised of 98 ± 1% mononuclear cells; remaining cells were
predominantly PMNs, and rarely, lymphocytes. Figure 3.13 shows that in the PBS-
treated mice, macrophage levels in the BAL fluid dropped slightly one day after
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treatment, and correspondingly, in Figure 3.14, their PMN levels rose, but by Day 2
levels of both cell types return to normal, and this is continued into Days 3 and 7.
In the FITC-treated mice, however, macrophage levels in the BAL dropped to 69.4 ±
3.2%, with a corresponding increase in PMNs (29.9 ± 3.2%), indicative of an acute
inflammatory reaction. At Day 2 the macrophage numbers rose and PMNs decreased
(90.8 ± 5.6% macrophages; 9.1 ± 5.7% PMNs), but even at Day 3, macrophage
numbers remained slightly below those from the PBS-treated mice, and PMN
numbers remained slightly higher. By Day 7, macrophage and PMN numbers had
returned to normal value. These results demonstrated that the FITC did indeed cause












Day 1 Day 2 Day 3 Day 7
Figure 3.13 Percentage of BAL macrophages counted on cytospin
preparations in treated (FITC) versus control (PBS) mice over four time
points. Cytospins were prepared as described. Three hundred cells per slide were
counted at x100 magnification. The data represent means ± SEM (Day 1-3, n=3; Day 7,
n=8).
*










Day 1 Day 2 Day 3 Day 7
Figure 3.14 Percentage of BAL PMNs counted on cytospin
preparations in treated (FITC) versus control (PBS) mice over 4 time
points. Cytospins were prepared as described. Three hundred cells per slide were
counted at x100 magnification. The data represent means ± SEM (Day 1-3, n=3; Day 7,
n=8).
*
p < 0.01 compared to paired PBS value, by paired Student's f-test.
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Day 1 Day 2 Day 3
Figure 3.15 Typical microscope fields of BAL cells from PBS-treated
mice used for differential counting. BAL was prepared as described, and 300
cells per slide were counted over random fields. A slight increase in PMN numbers is seen
one day after PBS instillation (A), gradually reducing to normal levels by Day 2 (B), Day 3 (C)
and Day 7 (not shown). The majority of cells are macrophages, with the occasional
lymphocyte (not present in fields shown above).
Day 1 Day 2 Day 3
Figure 3.16 Typical microscope fields of BAL cells from FITC-treated
mice used for differential counting. BAL was prepared as described, and 300
cells per slide were counted over random fields. A significant increase in PMN numbers is
seen at Day 1 after FITC instillation (A), decreasing over Days 2 (B) and 3 (C), although
levels remain higher than normal. The majority of cells are still macrophages, with the
occasional lymphocyte. By Day 7 (not shown), differential count had returned to normal.
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3.4.3 Cytokine Production
In order to compare cytokine production in between FITC-treated and PBS control
animals, BAL fluid was collected and processed as described in section 5.3.2, and
assayed by ELISA as described in section 2.3. The BAL fluid was assayed for TNF-
a, the classic inducer of inflammatory responses, IFN-y, which appears mainly after
the induction of the adaptive immune response, and TGF-J3, which plays a central
role in wound healing and tissue repair, and is thought to play a major role in the
initiation of pulmonary fibrosis [83,279,284]. As discussed in Chapter 1, TGF-(3 is
secreted in a latent form, and only becomes biologically active after removal or
conformational alteration of the non-convalently associated latency-associated
peptide 1, to yield the active dimer [259,262],
3.4.3.1 TNF-a
Figure 3.17 shows that for both FITC- and PBS-treated mice, levels of TNF-a in the
BAL fluid decreased over seven days. TNF-a production was measured at Day 1 in
the PBS-treated mice at 20.0 ± 2.4 pg/ml. This level dropped below the level of
detection of the R&D DuoSet ELISA assay (15.625 pg/ml) at Days 2, 3, and 7, the
latter two being significant decreases as compared to the day one value (p < 0.04). In
the FITC-treated mice, TNF-a was measured in the BAL fluid at Day 1 at 29.1 ± 6.5
pg/ml. This decreased only slightly by Day 2, and then significantly decreased to
undetectable levels at Days 3 and 7, as compared to the Day 2 level (p < 0.04).
Comparing the TNF-a levels between the two groups ofmice shows that at both two
and three days after treatment, TNF-a is significantly higher in the BAL fluid from
FITC-treated mice than from PBS controls (p < 0.03).
BAL fluid from normal mice contains no detectable TNF-a [431], As it is a potent
proinflammatory mediator, its presence therefore, suggests the initiation of an
inflammatory response. Detectable levels of TNF-a in the PBS control mice at Day
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1 could be due to the intratracheal instillation process itself, and indeed, levels of the
cytokine fell below the level of detection by Day 2. In the FITC-treated mice,
however, TNF-a levels were consistently, and often significantly, higher than those















Figure 3.17 TNF -a production measured in BAL fluid from FITC-treated
and control mice over 7 days. BAL fluid was collected, processed and assayed as
described. Data are presented as means ± SEM (Day 1, 2, 3, n=12 PBS- and FITC-treated
mice; Day 7, n=16 PBS- and FITC-treated mice)
*p<0.03 by paired Student's t-test, **p<0.04 by Student's t-test.
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3.4.3.2 IFN-r
IFN-y production was measured in the BAL fluid as described. Figure 3.18 shows
that there was no significant change in levels of IFN-y production in PBS-treated
control mice compared at Days 1, 2, 3, or 7. Although there was a slight drop in
IFN-y levels in FITC-treated mice at Day 3 as compared to Day 1 or 2, this decrease
was not statistically significant. These data must be interpreted with caution as the
detection level for the R&D murine IFN-y DuoSet ELISA is 31.25 pg/ml, and as
such, all values measured fell below that limit.
30
Day 1 Day 2 Day 3 Day 7
Figure 3.18 IFN^y production in BAL fluid from FITC- and PBS-treated
mice measured over seven days. BAL fluid was collected, processed and assayed
as described. Data are presented as means ± SEM (Day 1, 2, 3, n=12 PBS- and FITC-
treated mice; Day 7, n=16 PBS- and FITC-treated mice).
IFN-y is one of the major Thl cytokines, and has profound suppressive effects on the
production of ECM, including collagen and fibronectin [247]. In vivo administration
of IFN-y may also cause a reduction of ECM in animal models of fibrosis [255], and
even attenuates bleomycin-induced lung fibrosis in mice [256]. The inflammatory
response in CFA is thought to most closely resemble a Th2-type immune response,
and in murine models of lung disease, a predominantly Th2-type response to injury is
more likely to develop into pulmonary fibrosis than a Thl-type response, due to the
110
profibrotic effects of many Th2 cytokines, such as IL-13 and MCP-1 [16,80]. As
will be shown in the next chapter, the intratracheal administration ofFITC did lead to
pulmonary fibrosis, so the lack of IFN-y in the initial stages was perhaps not
surprising.
3.4.3.3 TGF-p
Both total (latent + active) and active TGF-P were measured in the BAL fluid
samples as described in section 2.3. BAL fluid was also collected at tive days after
treatment from both FITC- and PBS-treated mice. Figure 3.19 shows total TGF-P
levels present in the BAL fluid over seven days post-treatment. The detection limit
for the R&D human TGF-P DuoSet ELISA is 31.25 pg/ml, so the results can only
suggest possible trends as the values are all below this limit. It would appear that
total TGF-P levels were slightly increased at Day 1 and possibly Day 2 after
treatment in both PBS- and FITC-treated mice, falling to lower levels by Days 3, 5
and 7. Although not significant, at Day 2 total TGF-P was present at higher levels in
the FITC-treated mice than in the PBS controls. Differences between the two groups















Day 1 Day 2 Day 3
f □ PBS
□ FITC
Day 5 Day 7
Figure 3.19 Total TGF-p levels measured in BAL fluid samples from
FITC-treated and control mice at Days 1, 2, 3, 5, and 7 after treatment.
Data are presented as means ± SEM (Day 1, 2, 3, n=12 PBS- and FITC-treated mice; Day 7,
n=16 PBS- and FITC-treated mice).
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Active TGF-P was also measured (Figure 3.20), and again the results must be
interpreted with caution as the values all fall below the ELISA detection limit. In the
PBS control mice, there was no detectable active TGF-p over the seven days. At
Day 2 in the BAL fluid from the FITC-treated mice, however, there was a detectable
level of TGF-P, and it was significantly higher than the corresponding PBS control at
the same time point (p < 0.05). This mimics the trend seen in the samples measured
for total TGF-P, although in that case the difference was not significant.
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Day 1 Day 2 Day 3 Day 5 Day 7
Figure 3.20 Active TGF-p measured in BAL fluid samples from FITC-
and PBS-treated mice at Days 1, 2, 3, 5 and 7 after treatment. Data are
presented at means ± SEM (Day 1, 2, 3, n=12 PBS- and FITC-treated mice; Day 7, n=16
PBS- and FITC-treated mice)
*p < 0.05 as compared to paired PBS value, by Student's f-test.
Khalil et al. [279] have shown that AMs from patients with CFA secrete biologically
active TGF-p, while those from normal lung secrete only the latent form of the
molecule. These observations are consistent with the bleomycin model in the rat
which shows that active TGF-P from AMs is critical to the pathogenesis of
inflammation and fibrosis [233,432,433]. In the model described here, however,
very little total (and therefore latent) TGF-P is secreted in the BAL fluid of PBS- or
FITC-treated mice, and only on Day 2 after FITC treatment is any active form of the
molecule found. These findings are not consistent with published data regarding
CFA, and may be unique to this model. Further discussion will be found at the end
ofChapter 4.
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3.5 Conclusions and Discussion
The FITC model of murine pulmonary fibrosis was originally developed to study the
involvement of the immune system in the development of this disease [243],
Initially, FITC was delivered in one dose by surgical instillation. Home Office
requirements, however, necessitated a new method of delivery. As described in
section 3.2, this method involves non-invasive intratracheal instillation of the FITC
in two doses, spaced six weeks apart. This chapter has described the acute effects of
FITC on murine lungs from one day to seven days after the initial FITC dose.
Lung sections stained with anti-FITC antibody showed that FITC was successfully
deposited in the lungs of the majority ofmice at all time points (Table 3.1). As will
be discussed in section 4.4.3, however, much of this FITC may be cleared from the
lungs, and the remainder may not be sufficient to cause fibrosis. One day after
instillation, the FITC was widely distributed throughout the blood vessel walls, larger
and smaller airways, and reached the alveolar walls in some areas (Figure 3.2).
Macrophages heavily stained for FITC were evident throughout the lung. Much of
the FITC was cleared by Day 2, presumably by these macrophages and the
mucociliary apparatus, and by Day 5 FITC showed a patchy deposition. There was
focal evidence of alveolar oedema, particularly at Day 5, and of an acute
inflammatory response (Figure 3.4). The cellular infiltrate on Days 1 and 2 was
predominantly granulocytic (Figure 3.3), gradually becoming more mononuclear
over Days 3-7 (Figure 3.4), indicating a shift from an acute to a chronic
inflammatory response.
In order to measure the inflammatory response to FITC, a scoring system was
developed by giving numerical scores for the cellular infiltrate seen in each of 10
fields, in four separate compartments, which were evaluated for each lung section.
These scores were then combined to give an overall score which rated the severity of
infiltration.
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The individual compartment scores showed that there was significantly more cellular
infiltration in the lungs of the FITC-treated mice in each of the perivascular
compartment, the peri-bronchiolar tissue, and the alveolar walls over Days 1-7, as
compared to the lungs of the PBS control mice (Figure 3.5). In the bronchiolar
epithelium, the difference was significant over Days 1-3. This demonstrates that the
inflammatory process is dynamic, and that different compartments of the lung are
involved at different times.
The combined inflammation scores showed that the FITC-treated mice had an overall
mild, bordering on moderate, infiltrate up to Day 5, which became moderate by Day
7 (Figure 3.6). These scores were all significantly higher than those of the PBS
control mice which had scores indicating very mild, if any, cellular infiltrate.
Encouragingly, no severe inflammation was seen, correlating well with the mild
onset of clinical CFA in which patients normally present at a late stage of disease.
This scoring system allows for direct measurement of the cellular infiltrate in the
lungs of mice after injury, and is ideal for comparing the severity of the
inflammatory reaction caused by the intratracheal instillation of FITC or PBS.
Immunohistochemical staining of paraffin lung sections for the T cell marker CD3
showed that T cell numbers increased in the FITC-treated lungs over the first week,
becoming very prominent in the tissues by Day 5 and particularly in areas of alveolar
thickening (Figure 3.7). T cell numbers in PBS-treated lungs remained low. B cells
were stained with the B220 antibody and in contrast to the T cells, did not become
prominent in the FITC-treated lungs at any time point (Figure 3.8). Slightly
increased numbers of B cells may have been present at Day 7 in areas of alveolar
thickening and cell aggregates. PBS control mouse lung sections showed no change
in B cell numbers from Day 1 to Day 7. Sections were also stained for the
profibrotic cytokine TGF-|3 (Figure 3.9). TGF-P protein was expressed on AMs,
bronchial epithelium and alveolar walls in the FITC-treated mice. Expression in the
PBS control mice was mainly on AMs. TGF-p protein expression appeared higher in
FITC-treated mice at Dayl than in PBS-treated mice, and peaked at Day 5. Staining
for the CDllc cell surface protein was evident on both cells and the bronchial
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epithelium in both FITC- and PBS-treated mice, with the strongest expression seen
on the AMs (Figure 3.10). There was no obvious change in CDllc expression
between time points in either group of mice. Finally, cell surface staining for the
MHC class II protein was limited to specific cells that were strongly positive and, on
closer examination, often showed dendritc-like processes, suggesting that they were
DCs (Figure 3.11). More positive cells were seen in the sections from FITC-treated
mice, and seemed to be localised to areas of alveolar thickening and cell aggregation.
Examination of the cellular components of the BAL fluid in FITC-treated and control
mice showed that while total cell counts did not vary much between groups over the
seven days (with the exception of Day 3, at which FITC-treated mice had
significantly more cells in their BAL fluid than the control mice) (Figure 3.12), the
proportions of cells were variable (Figures 3.13, 3.14). At Day 1, the BAL fluid of
the FITC-treated mice had significantly more PMNs, and proportionally fewer
macrophages than the PBS-treated mice. Although not significantly different from
controls, the percentage of PMNs in the BAL fluid of FITC-treated mice remained
consistently higher over the seven days. This would indicate that a classic acute
inflammatory response occurred in the lungs of the FITC-treated mice, as opposed to
the reaction seen in the PBS controls.
Inflammatory cells, including AMs, participate in the lung tissue injury and repair
process by secreting various mediators that play a host of roles. The cytokines
examined for this body of work were TNF-a, IFN-y, and TGF-p, and the profile
obtained by ELISA analysis of the BAL fluid was mixed.
As expected, production of the proinflammatory mediator, TNF-a, was significantly
higher in the FITC-treated mice than in the PBS controls (Figure 3.17). Levels were
highest at Day 1, and gradually decreased over the seven days. No detectable IFN-y
was found in the BAL fluid from either of the groups of mice (Figure 3.18), which
might suggest the absence of a Thl cytokine profile, mirroring other animal and
human studies [16], In fact, IFN-y has been used as a therapeutic agent in a study of
CFA patients, with promising results [103].
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Both latent and active TGF-(3 levels in the BAL fluid were undetectable in both
groups of mice at all time points, with the exception of Day 3, at which detectable
latent and active levels were measured in the BAL fluid from the FITC-treated mice
alone (Figures 3.19, 3.20). This is surprising, as TGF-P has been measured in the
murine bleomycin model at 24 hours [216,235,434], This may be a finding unique
to the FITC model of pulmonary fibrosis, and will be discussed further at the end of
Chapter 5.
The examination of the acute response to the intratracheal instillation of FITC in
mice has shown that an acute inflammatory reaction, predominated by neutrophils,
occured at Day 1, and gradually shifted towards a more chronic inflammatory state
by Day 7. Quantification by scoring the cellular infiltrate showed that the acute
response seen in the lungs of the FITC-treated mice was significantly greater than
that seen in the PBS control mice, and thus the response could not be attributed to the
PBS alone. The presence of TNF-a and absence of IFN-y in the BAL fluid
suggested an inflammatory state that was not of the Thl type, correlating with
published data on CFA in both humans and animals. The absence of the profibrotic
cytokine TGF-p requires further examination.
The next step in the characterisation of the murine FITC model of pulmonary fibrosis
is to examine the longer-term effects of FITC on the mouse lungs, and the results








This chapter will describe the long-term effects of the intratracheal instillation of
FITC into murine lungs. Work in the Immunobiology Group (Gareth Stewart, PhD
thesis, University of Edinburgh, 2002) had shown that, unlike the original model,
using the modified nonsurgical method of FITC instillation did not induce fibrosis
after a single instillation. This is most likely due to the difference in the lung
penetrance between the two methods. A second dose given six weeks after the initial
dose was therefore necessary.
4.1.1 Aims of Chapter
The principal aims of this chapter are:
• To describe the long-term pathological effects of FITC-instillation on murine
lung tissue in terms of histology and cell surface protein staining
• To describe a method of obtaining quantitative data that reflects the chronic
inflammatory and fibrotic changes in the lungs of FITC-treated mice
• To describe the long-term effects of FITC on murine lungs as reflected by
cytokine production measured in the BAL fluid
• To discuss the implications of the acute inflammatory process, which is
followed by a progressive, chronic pulmonary fibrosis induced in the lungs of
mice by FITC instillation in terms of application to the human disease
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4.2 Long-term Effects of FITC on Murine Lung Tissue
Pathology
In order to assess the longer-term pathological effects of FITC on murine lungs, mice
were given an intratracheal dose of FITC or PBS as described in section 3.2. Some
mice were killed at six weeks after the first dose. Remaining mice were given a
second intratracheal dose at six weeks, and were killed seven days, six weeks or 14
weeks after this second dose (Figure 4.1). Three different series of mice were set up
in this fashion, and will be identified as Series 2, 3 or 4. Series 1 mice were groups
of mice that were set up specifically for one time point, e.g., four FITC-treated and
four PBS-treated mice set up just for a six week time point. Series 2 and 3 mice were
each set up from one large group of mice, and the required number of mice were
randomly selected at each time point.
The numbers of FITC-treated mice at each time point, which included animals taken
from all series ofmice, are presented in Table 4.1. At six weeks after the first dose,
of nine mice given FITC treatment, only four showed FITC-positive stained lung
sections, while the remaining five were negative for FITC. None of the mice showed
any sign of fibrotic disease. Although a single dose of FITC did induce
inflammation, as shown in Chapter 3, it was not sufficient to induce fibrotic changes.
Six weeks after the initial dose, most of the FITC that managed to penetrate into the
deep lung had been cleared, most likely by the macrophages. Thus, a second dose
was given to the mice, six weeks after the first.
Of eight pairs of lungs examined three days after the second dose, five stained
positively with the anti-FITC antibody, while only three were negative (Table 4.1).
Of the five positives, all showed signs of disease on histological examination. Seven
days after the second dose, eight out of 13 mice had FITC present in their lungs, and
all eight scored positive for disease. Again at six and 14 weeks after the second dose
of FITC, the majority of mice given FITC had FITC present in their lungs, and all
FITC-positive lung sections were also positive for disease. Importantly, no mouse
given PBS developed any sign of disease at any time point. Administration of the
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second dose, then, was sufficient to induce disease in the lungs of the majority of
mice. Of those mice given FITC that did not develop disease, possible explanations
include clearance from the lungs or technical failure of the FITC instillation. Further
discussion will follow in section 4.4.3.
# of Mice 6 wks 2nd + 3d 2nd + 7d 2nd+ 6 wks 2nd+ 14 wks
total 9 8 13 11 4
FITC +ve 4 5 8 8 3
FITC -ve 5 3 5 3 1
+ve with disease 0 5 8 8 3
-ve with disease ! 0 0 0 0 0
Table 4.1 Numbers of mice treated with FITC and assessed
histologically and immunohistochemically. Mice were given one dose of FITC
intratracheally and were assessed after six weeks. Remaining mice were given a second
dose at six weeks and assessed after three days (2nd + 3d), 7 days (2nd + 7d), six weeks (2nd
+ 6wks), and 14 weeks (2nd + 14 wks). Numbers of mice that were FITC-positive (+ve),
FITC-negative (-ve), FITC-positive with signs of disease (+ve with disease) and FITC-
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4.2.1 Six Weeks Post-Dose 1
Six weeks after the initial dose, examination of full lung sections revealed some
deposition of FITC was still evident in the tissue, along with evidence of chronic
inflammation in some areas (Figure 4.2). Both the FITC deposition and the
inflammation, however, were not widespread, and in some mice were not evident at
all. As mentioned, previous work in the laboratory had shown that mice given only a
single FITC dose did not go on to develop fibrosis, so a second dose was given to the
mice six weeks after the first dose.
Figure 4.2 H&E and anti-FITC stained sections of mouse lung 6 weeks
after single dose Of FITC. H&E section shows mononuclear inflammation around
airway and small areas of thickened alveolar walls (arrow). Anti-FITC section shows
moderate inflammation in areas of FITC deposition. Original magnification x200.
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4.2.2 Second Dose + Seven Days
Seven days after a second intratracheal dose of FITC was administered, areas of
inflammation could be seen around many airways (Figure 4.3A), similar to that seen
at seven days after the initial dose, and in contrast to the PBS control mice (Fig.
4.3B). FITC deposits were quite dense in these inflamed areas (Fig. 4.3C).
Figure 4.3 H&E and anti-FITC stained sections of mouse lung seven
days after the second FITC dose. H&E stained section of FITC-treated mouse lung
(A) shows inflammation around the airway, in contrast to the PBS-treated lung (B). FITC-
treated mouse lung stained with anti-FITC antibody shows deposition around airway (C).
Black box surrounds enlargement shown in (D), which shows FITC deposition in tissues,
surrounded by cellular infiltrate, and present in macrophages. Original magnification x200.
Enlargement approximately x800.
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The inflammatory cells were mostly mononuclear at this time point, including many
T cells (Figure 4.4A) and some B cells (Fig. 4.4B). Although several cell types
express CDllc, the macrophages/DCs stained strongly for this protein (Fig. 4.4C).
MHC class II staining revealed a small number of strongly stained cells (Fig. 4.4D).
As will be shown in Chapter 5, macrophages isolated from the lung typically
expressed high levels of CDllc, and moderate MHC class II, while DCs expressed
low levels of CDllc but very high levels of MHC class II. Antibodies for
immunohistochemical staining of F4/80 (primarily found on macrophages, but also
on DCs) and costimulatory molecules CD80 and CD86 were not available. Finally,
TGF-|3 stained sections showed that abundant amounts were present in the lungs at
this time point, with the macrophages staining very strongly (Fig. 4.4E).
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Figure 4.4 FITC-treated mouse lung sections at seven days after the
second FITC dose stained for cell surface proteins. Sections were stained by
immunohistochemistry for CD3, to detect T cells (A), B220, to detect B cells (B), CD11c and
MHC class II, both found on macrophages and DCs, among other cells (C, D, respectively)
(arrows in D indicate positive cells), and TGF-p (E). Representative MHC class II negative
control shown in F. Original magnification x200.
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4.2.3 Second Dose + Six Weeks
Six weeks after the second dose of FITC, many areas of the lung had thickened
alveolar walls, occasionally with loss of architecture, and continued cellular
infiltration (Figure 4.5A). Loss of architecture was evident particularly in areas of
FITC deposition (Fig. 4.5B). Much of the FITC had been cleared, presumably by the
macrophages, but it was still evident in the tissues, diffuse in some areas (Fig. 4.5C),
and sparingly in others (Fig. 4.5E). Large aggregates ofmononuclear-type cells were
also evident (Fig. 4.5D).
The inflammatory cells at this time point consisted of primarily T cells, which were
spread fairly evenly throughout the damaged tissue (Figure.4.6A), and B cells (Fig.
4.6B). MHC class II staining showed strongly positive cells spread throughout the
tissue, and interestingly, some in the mononuclear cell aggregates (Fig. 4.6C). TGF-
P staining showed even more diffuse staining than at the previous time point (Fig.
4.6D).
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Figure 4.5 H&E and anti-FITC stained sections of mouse lung six
weeks after the second dose of intratracheal FITC. Enlarged H&E section
shows extensive thickening of alveolar walls, and evidence of continued inflammation (A).
Anti-FITC staining in B depicts loss of alveolar wall architecture in areas of FITC deposition.
Heavy (C) and light (E) FITC staining are both evident at this time point. Black box in (C)
surrounds enlargement shown in (D), which depicts mononuclear nature of cellular
aggregate. Anti-FITC negative control (FITC-treated mouse lung) is shown in F. Original
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Figure 4.6 FITC-treated mouse lung sections at 6 weeks after the
second FITC dose stained for cell surface proteins. Sections were stained by
immunohistochemistry for CD3 (A), B220 (B), MHC class II (C), and TGF-p (D). Original
magnification x200.
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4.2.4 Second Dose + 14 Weeks
The final time point examined was 14 weeks after the second FITC dose, or five
months and two doses in total. Areas of severe fibrosis with obliteration of alveolar
wall architecture and large fibrous deposits were found adjacent to areas of normal
lung tissue (Figure 4.7A,B). Areas of chronic inflammation were also evident.
Although the majority of FITC had been cleared away, some was still evident with
accompanying fibrosis of the alveoli (Fig. 4.7C,D).
T lymphocytes, bearing the CD3 cell surface protein, were still present, but in lower
numbers than at previous time points, and their distribution was more localised
(Figure 4.8A). B220-positive B lymphocytes were relatively few in number, and did
not seem to be located in the fibrotic areas of the lung (Fig. 4.8B). CD1 lc-bearing
cells showed the same pattern as seen at previous time points, indicating the presence
of possibly both macrophages and DCs (Fig. 4.8C). MHC class II stained cells were
distributed sparingly throughout the tissue, and were again found in the mononuclear
cell aggregates (Fig. 4.8D). Finally, TGF-[3 staining indicated that much of this
cytokine was still being produced in the lungs of mice after five months (Fig. 4.8E).
A representative negative control section is shown in F.
The mononuclear cell aggregates that became evident from six weeks after the
second FITC dose were comprised mainly of B220+ B lymphocytes (Figure. 4.9A),
but also contained CD3+ T lymphocytes (Fig. 4.9B), and MHC class II+, possibly
DCs (Fig. 4.8D). These aggregates appeared to be similar to those described by
Wallace et al. [371] in patients with CFA. They suggested these aggregates might be
evidence of a local humoral immune reaction. Further discussion of these aggregates
can be found in section 4.4.1.
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Figure 4.7 H&E and anti-FITC stained sections of mouse lung 14
weeks after the second FITC dose. H&E stained sections show extensive fibrotic
changes (A) with inflammation (arrow), and loss of architecture with fibrous deposits next to
normal lung tissue (B). Anti-FITC staining is less extensive than seen at previous time points
(C). Black box surrounds enlargement shown in D, which displays thickened alveolar walls
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Figure 4.8 FITC-treated mouse lung sections at 14 weeks after the
second FITC dose stained for cell surface proteins. Sections were stained by
immunohistochemistry for CD3 (A), B220 (arrows indicate positively stained cells) (B),
CD11c (C), MHC class II (D), and TGF-p (E). Representative B220 negative control is
shown in F. Original magnification x200.
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Figure 4.9 B220 and CD3 stained lung sections at 14 weeks after the
second dose of FITC, showing mononuclear cell aggregates. Mononuclear
cell aggregates in lung tissue on same section contain predominantly B cells, which stain for
the B220 protein (A,B), also T cells, which are CD3 positive (C,D). Black boxes surround
enlargements shown to the right of original picture. Original magnification x200.
Enlargements approximately x800.
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4.2.5 Scoring of FITC-induced Damage
In order to assess the damage caused by the intratracheal instillation of FITC, and to
compare between FITC-treated and control animals, and between different time
points, a scoring system was devised based on the system of Ashcroft et al. [435],
They proposed a continuous numerical scale of fibrosis in human lung samples based
on microscopical examination of randomly selected fields. In each field, the score
was applied to the degree of fibrosis that occupied more than 50% of the field,
excluding fields predominantly occupied by malignant tumour deposits, portions of
large bronchi or blood vessels, or inflammatory exudates in air spaces. Table 4.2





1 Minimal fibrous thickening of alveolar or bronchiolar
walls
2
3 Moderate thickening of walls without obvious damage to
lung architecture
4
5 Increased fibrosis with definite damage to lung structure
and formation of fibrous bands of small fibrous masses
6
7 Severe distortion of structure and large fibrous areas;
"honeycomb lung" is placed in this category
8 Total fibrous obliteration of the field
Table 4.2 Ashcroft criteria for grading of human lung fibrosis.
The system described above was devised for use on human biopsies, although many
groups have used it to assess murine lung fibrosis [96,239,325,428,436-446].
Several modifications were made to adapt it to use on mouse lung tissue sections for
these studies.
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Ashcroft et al. [435] examined the human tissue sections at xlO magnification; this
was changed to x40 magnification to allow for the difference in size between human
and murine acini. To allow for differences between FITC-positive and FITC-
negative areas of the lung, sections stained with the anti-FITC antibody were chosen
for examination. A field was therefore considered FITC-positive if more than 50%
of the tissue within that field was stained, and negative if less than half the field was
stained. Following the proposal of Ashcroft et al. [435], damage was assessed by
firstly trying to assign fields to an odd number on their scale, and only using even
numbers if there was difficulty deciding between two odd numbered grades. The
recommended number of fields scored per biopsy was 40 - 50. On the mouse lung
sections, 36 FITC-positive and 36 FITC-negative fields were found to cover nearly
the entire section, proceeding from one outside edge in non-overlapping rows. Areas
in which there was poor inflation or overinflation (usually at lobe margins) were
ignored. The sections were scored on a multiheader microscope, and a consensus
score was reached between observers for each field. The mean score for fibrosis was
determined for both the FITC-positive and the FITC-negative areas.
Examination of the Ashcroft scores of the lung sections at each of the time points
clearly showed that two intratracheal doses of FITC do cause pulmonary fibrosis in
mice (Figure 4.10). Six weeks after the initial dose, scores from both FITC- and
PBS-treated mice indicated very little change from the normal, with no significant
differences between fields. Three days after the second intratracheal dose, however,
the FITC-positive fields from the sections of the FITC-treated mouse lungs had an
mean score of 0.99 ± 0.01, indicating minimal fibrous thickening of the alveolar or
bronchiolar walls. This Ashcroft score was significantly greater than the scores for
the FITC-negative fields of those same sections, and for the PBS controls (p <
0.001). At each of the remaining time points, the FITC-positive fields scored
significantly higher scores than the corresponding FITC-negative fields and the PBS
controls (p < 0.001).
The scores of the FITC-positive fields increased with each successive time point,
reaching a high score of 3.26 ± 0.16 at 14 weeks after the second dose of FITC,
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indicating that these mouse lungs showed moderate thickening of the walls without
obvious damage to the lung architecture. As the scores for each lung were obtained
by taking the mean of the scores for each of the 36 FITC-positive fields, many fields
had much higher scores, indicating more severe fibrotic damage. As these areas
were also found surrounded by normal areas of lung, it demonstrates the patchy
nature of the FITC-induced disease, which parallels that of the human disease.
Figure 4.11 compares the Ashcroft scores at each time point in terms of percentage
of FITC-positive fields. At six weeks after the first dose, 99% of FITC-positive
fields had an Ashcroft score of "0", indicating normal lung. Three days after the
second dose, 55.1% of FITC-positive fields had a score of "1", indicating most
positive fields showed only minimal signs of disease, and no fields received scores
higher than "3". Seven days after the second dose of FITC, most positive fields were
scored at either "0" or "1", again indicating few signs of disease, but by this time
point, approximately 25% of FITC-positive fields received scores of "2-3" or higher.
At six weeks after the second dose of FITC, 55% of the positive fields received
Ashcroft scores of "1", and 35% of remaining fields were scored at "2-3" or above.
Finally, at 14 weeks after the second FITC dose, 61% of FITC-positive fields were
scored at "2-3", indicating moderate signs of fibrotic change. Score of "4-5" were
given to 23% of positive fields, and 3% received scores of "6-7", the range in which
"honeycomb" changes are placed. Only 13.2% of positive fields were scored at "1",
and no fields at this time point received a score of "0".
Thus, the severity of fibrosis in FITC-positive fields increased with time. It is also
important to note that all sections from all PBS control mice received Ashcroft scores
of "0" at each time point, as did the three and seven day time points.
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p values 6 wks 2nd + 3d 2nd + 1 wk 2nd + 6 wks 2nd + 14 wks
+ve : -ve ns < 0.001 < 0.001 < 0.001 < 0.001
+ve : PBS ns <0.001 < 0.001 < 0.001 < 0.001
-ve : PBS ns ns ns ns ns
Figure 4.10 Ashcroft scores comparing severity of fibrosis in FITC- and
PBS-treated mice at various time points. Mice were given one intratracheal dose
of FITC or PBS, and their lungs were scored six weeks later. Remaining mice were given a
second dose after six weeks and lungs were scored on Days 3, 7, or Weeks 6 or 14 after this
second dose. Lung sections were scored as described. "FITC +ve" and "FITC -ve" indicate
scored sections of lung from FITC-treated mice that did, or did not, stain with the anti-FITC
antibody, respectively. "PBS" indicates anti-FITC stained, scored lung sections from PBS-
treated mice. Table shows p values comparing the different sections scored for each time
point, "ns" = not significant. See Table 4.1 for numbers of mice in each group.








Figure 4.11 Comparison of Ashcroft scores as a percentage of FITC-
positive fields for each long-term time point. Ashcroft scores were measured
as described. The percentage of FITC-positive fields receiving each degree of Ashcroft
score were calculated from all scores from all long-term time points. 6wks, n=56 fields;
2nd+3d, n=138; 2nd+7d, n=243; 2nd+6wks, n=237; 2nd+14wks, n=76.
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4.3 Long-term Effects of FITC on BAL Fluid
BAL fluid was collected and processed as described in section 5.3.2 from the mice at
each of the time points indicated.
4.3.1 Total Cell Counts
No significant changes in the total mean cell count in the BAL fluid were seen
between the FITC- and PBS-treated mice at any of the time points examined,
although the counts for the first two time points up to and including 2nd dose + 7 days
were slightly increased as compared to normal counts from untreated mice (Figure
4.12). At the 2nd dose + 6 week time point, the cell count in the BAL fluid of the
FITC-treated mice was decreased as compared to the PBS control, but not
significantly so. At 14 weeks after the second dose the counts for both groups
dropped back to normal levels, however again, this difference was not significant.
3
untreated 6wks 2nd+7d 2nd+6wks 2nd+14wks
Figure 4.12 Total BAL fluid cell counts measured from untreated mice,
and at six weeks after the first intratracheal dose of FITC or PBS, seven
days, six weeks and 14 weeks after the second dose. BAL fluid was collected
and processed as described from untreated, and both FITC- and PBS-treated mice. Cells
were centrifuged and counted as described. Data represent means ± SEM (untreated, n=6;
6wks, n=9; 2nd+7d, n=11; 2nd+6wks, n=3; 2nd+14wks, n=9).
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4.3.2 Differential Cell Counts
To assess the cell types present in the BAL fluid of FITC-treated vs. control mice in
Series 3, cytospin preparations were made as described in section 2.2, and
differential counts were performed as described in section 3.4.2. At all time points
except for 2nd dose + 6 weeks, BAL macrophages comprised over 96% of the total
cell population, and there were no differences between the FITC- or PBS-treated
mice (Figure 4.13). The rest of the cell population consisted of either lymphocytes
or neutrophils, but neither was particularly dominant. At six weeks after the second
dose, although there was no difference between the FITC- or PBS-treated mice,
macrophages made up 90.4 ± 1.9 % of the total population in the BAL fluid ofFITC-
treated mice, as compared to 91.5 ± 1.5 % for the PBS control mice. In both cases,
the majority of the remaining cell population was comprised of lymphocytes. This
suggests that the cause was not the FITC treatment, but was an anomaly of this
particular group of mice. However, other possibilities, such as infection, or cells
moving to the tissues or draining lymph nodes, cannot be ruled out.
6wks 2nd+7d 2nd+6wks 2nd+14wks
Figure 4.13 Percentage of BAL fluid macrophages counted on cytospin
preparations from FITC- or PBS-treated mice over four time points.
Three hundred cells per slide were counted over random fields at x100 magnification. Data
represent means ± SEM (6wks, n=9; 2nd+7d, n=11; 2nd+6wks, n=3; 2nd+14wks, n=9).
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4.3.3 Cytokine Production
BAL fluid was collected, processed and assayed as described. As for the short-term
time points, the BAL fluid was assayed for TNF-a, IFN-y, and TGF-(3 from the mice
in Series 1 and 2.
4.3.3.1 TNF-a
Levels of TNF-a in mice at acute time points were increased in FITC-treated mice as
compared to PBS-treated mice at Days 1 and 2 after instillation, with levels
becoming undetectable in both groups from Day 3 (Figure 3.17).
The results from Series 1 (Figure 4.14) can only be interpreted with caution as
cytokine levels all fall around the 15.625 pg/ml lower detection limit of the R&D
DuoSet mouse TNF-a ELISA assay. In Series 1 long-term mice, levels of TNF-a in
the BAL fluid remained undetectable at all time points except six weeks after the
second dose. In this case, the TNF-a levels were significantly higher than those of
the FITC-treated mice at the same time point (p < 0.01). Apart from this, although
the levels of TNF-a did seem to increase slightly over the five months, there were no
significant changes between the FITC- and PBS-treated mice, or between any of the
time points.
In Series 2, however, a different pattern emerged (Figure 4.15). In this series of
mice, all of which were set up at the same time, levels of TNF-a in the BAL fluid
were well above the lower detection limit of the ELISA. At six weeks after the first
dose, levels were detectable in both groups of mice, although they were slightly
higher in the FITC-treated mice. Seven days after the second dose, TNF-a levels
had risen in the BAL fluid of the PBS-treated mice (67.4 ± 10.9 pg/ml), but although
considerably higher than those of the FITC-treated mice (31.1 ± 8.5 pg/ml), the
difference was not statistically significant. Six weeks after the second dose the levels
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in the FITC-treated mice had increased above those of the PBS controls, although
again, not significantly. Finally, at 14 weeks after the second dose TNF-a levels in
the BAL fluid of both FITC-treated mice and controls remained elevated, but there
was no significant difference between them. As with Series 1 mice, there were no
significant differences between any of the time points.
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25 *
6wks 2nd+7d 2nd+6wks 2nd+14wks
Figure 4.14 TNF-a production measured in BAL fluid from FITC-treated
mice and PBS controls over four time points in Series 1 mice. BAL fluid
was collected, processed, and assayed as described. BAL fluid from FITC- and PBS-treated
mice was collected at six weeks after the first dose, seven days, six weeks or 14 weeks after
the second dose. Data are presented as the mean ± SEM (6wks, n=2 sets of four FITC- and
four PBS-treated mice; 2nd+7d, n=5 sets; 2nd+6wks, n=2 sets; 2nd+14wks, n=8 sets).
*p<0.01 by paired Student's f-test.
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6wks 2nd+7d 2nd+6wks 2nd+14wks
Figure 4.15 TNF-a production in BAL fluid from FITC-treated and PBS
control mice over four time points in Series 2 mice. Data are presented as
means ± SEM (n=1 set of four FITC-treated and four PBS-treated mice at each time point).
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4.3.3.2 IFN-y
IFN-y was measured in the BAL fluid from mice in Series 1 and 2 as described. The
lower detection limit for this R&D ELISA is 31.25 pg/ml and therefore the levels of
IFN-y measured in the BAL fluid from mice in Series 1 (Figure 4.16) must be
interpreted with caution as they all fall below this limit. fFN-y levels in the BAL
fluid ofmice assessed at acute time points were all undetectable (Figure 3.18).
In Series 1 mice, the levels of IFN-y in the BAL fluid were similar six weeks after
the first dose in both FITC-treated and PBS control mice. At seven days after the
second dose, however, IFN-y levels decreased in the FITC-treated mice as compared
to the levels at six weeks after the first dose, and this decrease became significant at
six weeks after the second dose (p < 0.04). IFN-y levels had increased by 14 weeks
after the second dose in the FITC-treated mice. IFN-y measured in the BAL fluid of
PBS-treated control mice did not change significantly over any of the time points,
and in fact was significantly higher than the paired FITC levels for each of the last
three time points (p < 0.02), however, as all levels fell below the lower detection
limit for this assay, any increases in levels of the cytokine may not have any
biological effect, and further investigation is required.
A different pattern was seen in the BAL fluid from mice in Series 2 (Figure 4.17).
Although the difference in levels of IFN-y between the FITC-treated and PBS control
mice was not significant at any time point, the levels of the cytokine had fallen by
seven days after the second dose. A significant increase to detectable levels was then
seen six weeks after the second dose, as compared to the previous time point (p <
0.02), again for both groups of mice, with levels dropping back down below the level
of detection by 14 weeks after the second dose. This may reflect a possible infection




Figure 4.16 IFN-y production measured in BAL fluid from FITC-treated
mice and PBS controls over four time points in Series 1 mice, bal fluid
was collected, processed, and assayed as described. bal fluid from FITC- and pbs-treated
mice was collected at six weeks after the first dose, seven days, six weeks or 14 weeks after
the second dose. Data are presented as the mean ± SEM (6wks, n=2 sets; 2nd+7d, n=5
sets; 2nd+6wks, n=2 sets; 2nd+14wks, n=8 sets).
**p<0.04 by Student's Ftest; *p<0.02 by paired Student's f-test.
6wks 2nd+7d 2nd+6wks 2nd+14wks
Figure 4.17 IFN-y production in BAL fluid from FITC-treated and PBS
control mice over four time points in Series 2 mice. Data are presented as
means ± SEM (n=1 set of four FITC-treated and four PBS-treated mice at each time point).
*p<0.02 by Student's f-test.
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4.3.3.3 TGF-J3
As previously described, both active and total TGF-P were measured in the BAL
fluid ofmice in Series 1 and 2. At acute time points, total TGF-p levels in the BAL
fluid were increased at Day 2 in the FITC-treated mice (32.7 ± 5.8 pg/ml) as
compared to the PBS controls (19.4 ±1.5 pg/ml), although not significantly (Figure
3.19). A significant increase in active TGF-P was seen at the same time point,
however (31.3 ± 3.4 pg/ml FITC vs. 14.5 ± 2.4 pg/ml PBS) (Figure 3.20). All other
values at all other acute time points were below the level of detection for this assay
(31.25 pg/ml).
BAL fluid from mice in Series 1 showed total TGF-P levels below the lower limit of
detection for this assay at all long-term time points examined (Figure 4.18). Also, no
significant differences were detected between the levels measured for FITC-treated
mice and the PBS control mice. There did appear to be a slight increase in the total
TGF-P levels in FITC-treated mice at seven days after the second dose compared to
the previous time point, which had then decreased by six weeks after the second dose
to a level slightly below that of the PBS controls, and by 14 weeks after the second
dose, levels of the total cytokine had increased in both groups ofmice.
Similarly, the active form of the cytokine was present at similar levels in the BAL
fluid of the FITC-treated and PBS control mice over all the time points evaluated
(Figure 4.19). However, levels did increase above the lower detection limit at six
weeks after the first dose, falling again seven days after the second dose, and only
reaching detectable levels again 14 weeks after the second dose. Six weeks after the
second dose active TGF-P had increased again, significantly in the FITC-treated
mice (p < 0.02) although not significantly more than the paired PBS value. Five
months after the first dose, active TGF-P levels in both FITC-treated and PBS
control mice had significantly increased as compared to seven days post-second dose
(p < 0.005), and were detectable above the lower detection limit of the assay (43.9 ±
5.5 pg/ml FITC, 42.0 ±4.1 pg/ml PBS). It would be possible then, that in Series 1
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mice the intratracheal instillation of FITC or PBS may have caused a decrease in the
production of active TGF-P in the BAL fluid, and that this level increased
afterwards. This change, however, is not attributable to the instillation of the FITC
itself.
BAL fluid from mice in Series 2 showed overall higher levels of total TGF-P than in
Series 1, however there were no significant differences between the FITC-treated
mice and PBS control mice at any time point (Figure 4.20). Measured total cytokine
levels remained slightly above or below the lower detection limit of the assay,
although at six weeks after the first dose the levels in the BAL fluid of the FITC-
treated mice seem marginally higher than the rest. A significant reduction in the
measured total TGF-P levels in the FITC-treated mice was seen at the 2nd+14 week
time point, as compared to both the 2nd + 7 day time point (p < 0.04).
Active TGF-P measured in the BAL fluid from the mice in Series 2 was generally
undetectable, falling only slightly above or below the assay's lower detection limit
(Figure 4.21). The levels in the three later time points are marginally higher than in
the earliest time point. As in the total TGF-P assay, no significant differences




Figure 4.18 Total TGF-(3 levels measured in BAL fluid from Series 1
mice treated with FITC or PBS and examined at various time points.
Data are presented as means ± SEM (6wks, n=2 sets of four FITC- and four PBS-treated
mice; 2nd+7d, n=5 sets; 2nd+6wks, n= 2 sets; 2nd+14wks, n=8 sets).
□ PBS
□ FITC
Figure 4.19 Active TGF-p levels measured in BAL fluid from Series 1
mice treated with FITC or PBS and examined at various time points.
Data are presented as means ± SEM.
*p<0.03 by Student's f-test.
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6wks 2nd+7d 2nd+6wk 2nd+14wks
Figure 4.20 Total TGF-(3 levels measured in BAL fluid from Series 2
mice treated with FITC or PBS and examined at various time points.
Data are presented as means ± SEM (n=1 set of 4 FITC- and 4 PBS-treated mice per time
point).
*p<0.04 by Student's f-test.
50
6wks 2nd+7d 2nd+6wks 2nd+14wks
Figure 4.21 Active TGF-p levels measured in BAL fluid from Series 2
mice treated with FITC or PBS and examined at various time points.
Data are presented as means ± SEM.
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4.4 Conclusions and Discussion
Chapters 3 and 4 have described the disease pattern seen in the modified murine
FITC model of pulmonary fibrosis originally described by Roberts et al. [243], In
the modified model, a two-dose nonsurgical method of intratracheal instillation was
used rather than the original single surgical dose. Chapter 3 described the acute
effects of the FITC in the lung tissue and the BAL fluid in this modified model from
one day to seven days, while Chapter 4 has described the long-term effects from six
weeks after the initial dose, to seven days, six weeks, and 14 weeks after the second
dose.
4.4.1 Responses to FITC in the Tissue
As described in Chapter 3, examination of the mouse lungs up to one week after the
initial dose showed an acute inflammatory response characterised by alveolar wall
oedema and a granulocytic infiltrate which disappeared over a week, and in some
areas was replaced by a chronic mononuclear infiltrate. FITC deposition was found
surrounding the large and smaller airways and blood vessels, and in the alveolar
walls. Much of the FITC, however, was presumably removed by the resident
macrophages.
In order to obtain quantitative data enabling the comparison of acute inflammation
between FITC- and PBS-treated animals after the first dose, a method of scoring was
devised. Four different compartments in the lung were scored and the scores then
combined to form an overall score. The overall scores clearly demonstrated that the
inflammation present in the lungs of the FITC-treated mice was significantly greater
than that measured in the PBS control mice, which had little, if any, signs of an
inflammatory response. A second intratracheal dose of FITC, or PBS, was given to
the remaining mice six weeks after the first dose. By this method, 14 weeks after the
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second dose, up to 75% of the animals had developed fibrotic changes in the lungs in
response to the administration of two doses of FITC, while no changes were seen in
the lungs of any of the PBS-treated mice (Table 4.1).
The acute granulocytic inflammatory cell infiltrate evident from Day 1 became
predominantly mononuclear by six weeks after the initial dose as apoptotic
granulocytes would be mainly cleared by macrophages. The mononuclear infiltrate
remained over the subsequent long-term time points, indicating a chronic state of
inflammation. A patchy distribution of FITC was visible on immunohistochemically
stained lung sections, and persisted until the final time point at 14 weeks after the
second dose. Areas in which the FITC was visible often showed thickening of the
alveolar walls, deposition of fibrous tissue, and occasionally mononuclear cell
aggregates while adjacent areas remained normal.
Immunohistochemical staining showed that lymphocytes did not become prominent
in the tissues until Day 5 after the first dose of FITC, and that they remained present
at all subsequent time points. Although T cell differentiating antibodies were not
available, CD3 protein staining showed that T cells were the predominant
lymphocytes present in the tissues, while B cells predominated in the mononuclear
cell aggregates that can develop in the later stages, suggesting the potential for an
immunological basis for the continuing inflammation. This is supported by the
finding of anti-FITC antibodies in the serum up to six weeks after a single, surgical
intratracheal dose of FITC [243], Christensen et al. [244] reported that the induction
of fibrosis in the original model was not T-cell dependent, but did agree that T cell
immunity could be important in later stages (Galen Toews, personal
communication).
Alterations in T lymphocytes may be of particular interest in determining the
pathogenesis of CFA, given that recruitment of lymphocytes to the lung is a well-
documented feature of the disease [447], As lymphocytes tend to be
underrepresented in BAL fluid, the extent to which they may contribute to the
pulmonary inflammatory response may be underestimated [407,448], T cells secrete
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chemoattractants for a variety of cell types including neutrophils, monocytes, and
eosinophils [449], and it has been proposed that in vivo secretion of macrophage-
derived growth factors may be locally driven by interaction with T cells participating
in the inflammation elicited by fibrogenic injury [450],
However, as discussed in Chapter 1, the role of T cells in the pathogenesis of
bleomycin-induced pulmonary fibrosis has not been fully elucidated. In vivo T cell
depletion with anti-T cell antibodies has been shown to completely abrogate
bleomycin-induced pulmonary fibrosis [220], while Helene et al. [451] have reported
that bleomycin-induced pulmonary fibrosis is T cell-independent. Studies in athymic
nude mice, which lack functional T cells, have been equally unclear. One study
demonstrated that bleomycin was not fibrogenic in nude mice [215], and another
showed the same in mice with silica-induced pulmonary fibrosis [452], while a third
reported histologically similar fibrosis in nude and euthymic mice after bleomycin
treatment [364], with a the same finding in asbestos-induced pulmonary fibrosis
[453],
Similar studies in the single-dose FITC model are also conflicting. Christensen et al.
[244], reported that depletion of CD4 T cells from FITC-treated BALB/c mice
ablated the development of a specific immune response to FITC, but that these mice
had similar increases in lung collagen content compared to control mice. They found
the same responses in both BALB/c severe combined immunodeficiency (SCID)
mice and C57BL/6 mice carrying a selective deletion of the recombination activating
gene. However Roberts et al. [243], who developed the original FITC model, found
that while FITC-treated SCID mice showed severe inflammation seven days after
instillation similar to that seen in immunocompetent FITC-treated mice, although
without the presence of T cells, by three months no scarring or infiltrate was seen
despite the presence of fluorescent FITC. This was in direct contrast to the scarring
and infiltrate found in the immunocompetent mice at the same time point
(unpublished data). This is illustrated by the figures in Appendix 2.
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Further examination of the T lymphocyte population in the FITC model is required.
Immunohistochemical staining for Thl and Th2 cytokines would be beneficial in
determining whether FITC-induced pulmonary fibrosis resembles a Thl-type or
more likely, a Th2-type immune response, and whether the T cells present are major
sources of those cytokines. Staining for CD8+ and CD4+ T cells subsets would also
be useful, if such antibodies for use on paraffin sections become available. CFA is
associated with a predominantly CD8+ T cell infiltrate [368], and preliminary
experiments performed on the single surgical dose FITC model, in which 50% of
CD4+ or CD8+ T cells were depleted 24 hours before FITC instillation, suggested
that CD8+ cells may cause most of the epithelial cell damage. CD4+ T cells,
however, may promote anti-self epithelial cell antibody production [119,120], which
could also perpetuate the epithelial cell damage. The use of anti-T cell antibodies, or
possibly setting up the FITC model in athymic nude mice may also help to elucidate
the role of T lymphocytes in FITC-induced pulmonary fibrosis.
The lymphocyte aggregates seen in the later stages in the FITC model are similar to
the B lymphocyte aggregates observed in patients with CFA as reported in the
literature [105,370]. They were described most recently by Wallace et al. [371], who
found evidence of a local humoral immune response associated with these
aggregates. They described the presence of follicular DCs in the aggregates, which
are associated with antigen presentation to B lymphocytes, indicating that a humoral
response had occurred in the lungs of these patients. The B cell aggregates seen in
the FITC model also showed cells that stained positively for MHC class II (Figure
4.8D), which may indicate the presence ofDCs and possibly a local humoral immune
reaction.
Wallace et al. [371] proposed that these B cell aggregates may be involved in the
pathogenesis of CFA for two reasons. First, that the aggregates were not found to be
topographically associated with large honeycomb spaces, nor near any evidence of
infection. The B cell aggregates found in the FITC model appear to be similarly
removed from such areas. Second, a link between increased B cells in biopsy
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specimens and poor prognosis in CFA patients, as suggested previously [105], might
suggest that the humoral response is significant in CFA pathogenesis.
Turner-Warwick and Doniach [113] described the presence of non-organ-specific
circulating autoantibodies in approximately 40% of patients with CFA, which have
since been shown to include antinuclear antibodies, anti-DNA topoisomerase II
antibodies, and anti-cytokeratin 8 antibodies [112,115,116,118], Moreover, immune
complexes have been identified in the blood, BAL fluid and tissue of patients with
CFA [108,110]. Although it has been suggested that autoantibodies are secondary to
lung injury and inflammation [106], Wallace et al. [119,120] have reported the
presence of autoantibodies against alveolar lining cells in the serum of patients with
CFA, thus identifying the suspected autoantigen as being endogenous and specific to
the lung. Further study into these B cell aggregates is essential to determine the role
of both B cells and the humoral immune response in FITC-induced pulmonary
fibrosis. Most important, perhaps, is establishing the presence of these same anti-self
antibodies in the plasma of FITC-treated mice. Comparing the severity of FITC-
induced disease after administration of B cell-depleting antibodies, or in a B cell
knockout mouse, could also provide useful information.
The cell surface proteins CDllc and MHC class II are both found on lung
macrophages and DCs although, as will be shown in Chapter 5, they were expressed
at different levels on the two cell types from the mice examined.
Immunohistochemical staining of lung sections from the FITC-treated mice at all
time points showed cells expressing varied levels of both CDllc and MHC class II.
CDllc is known to be expressed on both neutrophils and monocytes in the lung
[454,455], and high expression of CD1 lc has been reported on bronchial epithelium,
particularly in the acute phase of influenza A virus infection after ovalbumin
challenge [456]. Interestingly in this study, CD1 lc expression was not detectable in
the recovery phase, while expression seemed fairly constant in the progressive FITC
model. As anti-CDllc antibody stained other structures in the FITC-treated lung, it
is difficult to comment on the distribution of CD1 lc-expressing cells. However,
some individual cells stained very strongly for cell surface CDllc protein,
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suggesting they may be macrophages. Kumar et al. [450] have proposed that in vivo
secretion ofmacrophage-derived growth factors may be locally driven by interaction
with the T cells participating in the inflammation elicited by fibrogenic injury. The
cell surface protein F4/80, often used as macrophage marker although its expression
is not exclusive to these cells, was not suitable for use on mouse paraffin sections.
The MHC class II antibody, however, was very specific, and showed that cells
positive for this protein were present from Day 1 after the initial dose, and persisted
throughout the five months. Often, very strongly MHC class II+ cells, bearing
dendritic-like processes, were found in and around the mononuclear cell aggregates,
suggesting a possible role for DCs in antigen presentation to the lymphocytes, and a
possible humoral immune reaction.
Cell surface TGF-P appeared to be highly expressed in the lungs of the FITC-treated
mice, particularly at the earlier time points, but also in the later stages. Although this
correlates well with published data showing that TGF-p is produced by type II
epithelial cells in the lung [250], and plays a major role in the pathogenesis of lung
fibrosis [235,267,279,281,434], it was not corroborated in the BAL fluid, as will be
discussed in the following section. Interestingly, in a murine Th2-type model of
allergic airway inflammation induced by group 1 allergen, Der p 1, only very weak
TGF-P staining was detected on lung sections [457].
The measurement of hydroxyproline content of hydrolyzed lung as a marker of
collagen content is the most widely accepted method of quantifying lung fibrosis
biochemically, although other methods for obtaining semi-quantitative data could be
used, such as reverse transcription-polymerase chain reaction for selected genes. As
the methodology for measuring hydroxyproline content was not available, a system
of scoring the pathology was devised, based on the method of Ashcroft et al. [435]
(Table 4.2). The fibrosis scores for all time points examined after the second FITC
dose were significantly more severe in areas of FITC deposition as compared to areas
of no FITC on the same sections, and as compared to the PBS controls (Figure 4.10),
and the severity of fibrosis increased with the later time points (Figure 4.11). By this
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method, it was clearly shown that the administration of two intratracheal doses of
FITC lead to pulmonary fibrosis in the majority of mice. One of the shortfalls of this
model, however, is that not all the mice given FITC intratracheally developed
pulmonary fibrosis. This will be discussed in detail in Section 4.4.3. In the future,
image analysis could also be considered as an alternative method of quantifying
fibrosis in the lungs.
4.4.2 Responses to FITC in the BAL
In the BAL, evidence of a granulocytic infiltrate was seen in the high PMN count
and correspondingly decreased macrophage count at Day 1, gradually returning to
normal over seven days (Figures 3.13, 3.14). Little change, if any, was seen in the
lungs of the PBS control mice.
MEP-la is a member of the C-C chemokine family and increased expression has
been demonstrated in BAL immune cells of patients with CFA [458], MlP-la
protein has also been found in the lungs ofmice with bleomycin-induced injury, and
it has been proposed that it is regulated by TNF-a and IL-6 [219,459]. However,
BAL fluid from FITC- and PBS-treated mice collected between Day 1 and Day 7 did
not show any MlP-la. This may have been because tissue levels are not reflected in
the BAL, and should be confirmed by other methods, such as gene expression in the
lung tissue.
4.4.2.1 TNF-a
Cytokine production in the BAL fluid was measured at both acute and long-term
time points after FITC instillation. Levels of TNF-a were increased to 29.1 ± 6.5
pg/ml in the FITC-treated mice immediately after they were given the first dose of
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FITC, and gradually decreased to levels similar to those of the PBS control mice over
seven days (Figure 3.17). TNF-a is a potent proinflammatory mediator that plays a
critical role in acute pulmonary injury and in the regulation of fibroblast growth [75].
The increased levels of TNF-a found in the BAL fluid of the FITC-treated mice at
the acute time points are consistent with the initiation of inflammation in response to
acute injury.
Over the long-term time points, the BAL fluid from two series of mice was analysed
for the presence of TNF-a. In Series 1 mice, TNF-a was only detectable at six
weeks after the second dose, and only in the PBS control mice (Figure 4.14). In
Series 2 mice, TNF-a was detectable at all time points measured, and although there
were no significant differences between the treated and control mice, levels were
higher in the PBS control mice at seven days after the second dose of FITC (Figure
4.15). One possible reason for the discrepancy between the two series is that perhaps
the Series 2 mice had an underlying infection causing an inflammatory reaction.
Regardless, examination of the differences in levels of TNF-a between the FITC-
treated and PBS control mice in both series showed that, apart from the 2nd + 6 weeks
time point in Series 1, no significant differences were found. Again, the possibility
of an underlying infection may be the reason for the anomaly in Series 1. Notably,
Fujita et al. [288] demonstrated that overexpression of TNF-a in mouse lungs results
in increased levels of TNF-a protein in the BAL fluid, measured between 60 and 90
ng/ml, while control mice had levels of approximately 1-3 ng/ml. This group found,
however, that these mice did not develop pulmonary fibrosis. The TNF-a protein
levels in the BAL fluid of the FITC- and PBS-treated Series 2 mice did not rise
above 75 pg/ml. Even if tissue levels are found to be much higher, and despite its
role in the acute inflammation caused by FITC instillation, it seems unlikely that
TNF-a by itself plays a major role in the pathogenesis of FITC-induced pulmonary
fibrosis, although it may work in concert with other cytokines, as discussed below.
The role of TNF-a in the development of pulmonary fibrosis has not been fully
elucidated, although its importance has been highlighted in many studies. TNF-a
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mRNA is increased in the lungs of patients with CFA [296]. Anti-TNF-a antibody
administration prevents the development of both bleomycin-induced pulmonary
fibrosis [220] and silica-induced pulmonary fibrosis [460]. TNF-a overexpression
has been shown to lead to the development of pulmonary fibrosis, while deficiency
can confer resistance [461],
However, there is evidence to suggest that TNF-a by itself may not produce
pulmonary fibrosis. Another murine model ofTNF-a overexpression produced mice
with severe alveolitis and progressive pulmonary fibrosis [292], however further
study revealed that TNF-a alone was unable to produce significant pulmonary
fibrosis in these mice in the long term [288]. Maeda et al. [236] were unable to
detect any differences in TNF-a expression in BAL cells between mice given
intraperitoneal bleomycin and controls. Furthermore, gene transfer studies with TNF-
a revealed an induction of limited pulmonary fibrosis compared to that with TGF-p
[293], There is also evidence to suggest that TNF-a may even inhibit fibrosis by
enhancing the production of fibroblast collagenases and PGE2 [290,462],
Most likely, however, TNF-a acts indirectly by stimulating diverse lung cells to
produce certain fibrogenic cytokines, such as TGF-P, which has more direct
fibrogenic activity [246,277,293]. In the modified FITC-induced model of
pulmonary fibrosis it would appear that while TNF-a did contribute to the acute
inflammation that occurred after the first dose of intratracheal FITC, either its
presence was not required for the fibrotic changes that occurred in the later stages, or
more likely, it was involved in the initiation of fibrosis. The role of TNF-a in this
model requires further study. Immunohistochemical staining of tissue sections with
anti-TNF-a would be useful, as the tissue concentrations of cytokines are not
necessarily reflected in the BAL fluid. Other possible routes of investigation include
the use ofTNF-a receptor knockout mice, or anti-TNF-a antibody administration.
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4.4.2.2 IFN-y
EFN-y measured in the BAL fluid of mice was not found at detectable levels at any of
the acute time points evaluated, nor were there any differences found in the levels
between the FITC-treated and PBS control mice (Figure 3.18). The long-term time
points were evaluated in Series 1 and 2 mice. In Series 1, levels of IFN-y remained
below the level of detection, although there was a trend in which PBS control mice
had higher levels than the FITC-treated mice (Figure 4.16). Although the differences
were statistically significant at the three later time points, levels were still below the
detection limit of the assay. In Series 2, there were no differences in IFN-y levels
between the treated and control mice at any time point, although again, there was a
trend showing slightly higher levels in the PBS control mice (Figure 4.17). There
was a significant increase in IFN-y levels in both treated and control mice at six
weeks after the second dose of FITC, as compared to the previous time point, but as
this occurred in both groups of mice it was not attributable to the either the FITC or
PBS treatments.
IFN-y is a Thl cytokine, while the inflammation in CFA is most often characterised
as being Th2-like [16]. IFN-y has been shown to inhibit fibroblast collagen
synthesis, and diminished production may also enhance collagen deposition in
pulmonary fibrosis [247,250]. As discussed in Chapter 1, it is thought that decreased
Thl-type IFN-y may occur concomitantly with a rise in Th2 cytokines such as IL-4
and IL-5, thus shifting the cytokine balance towards a profibrotic response
[74,100,101], Studies of blood and lung tissue from CFA patients have found
absolute and relative deficits in IFN-y as compared with other Th2 cytokines
[74,250,251,257], Administration of IFN-y has been used therapeutically to treat
bleomycin-induced pulmonary fibrosis [96,255,256], and has even shown promising
results in clinical trials [103],
The low levels of IFN-y found in the BAL in the FITC-induced model of pulmonary
fibrosis suggest the inflammation may resemble a more Th2-type response, and
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indicate a limited or an indirect role for this cytokine. As for TNF-a, the use of
immunohistochemical staining, IFN-y knockout mice, or anti-IFN-y antibodies would
help to provide a much clearer picture of the perhaps indirect role IFN-y may play.
4.4.2.3 TGF-p
TGF-P is a multifunctional cytokine that is synthesised in a latent form covalently
bound to a latency-associated peptide [283]. The presence of the latency-associated
peptide protein renders the TGF-P biologically inactive, and acts to facilitate transit
of TGF-p from the cell [259]. Signaling through TGF-p receptors requires exposure
of the active site of the ligand through conformational change or through cleavage of
the latency-associated peptide [259,283]. Both total (consisting of active and latent)
and active TGF-P were measured in the BAL fluid from the FITC-treated mice and
PBS controls over both acute and long-term time points. No significant differences
were found in the levels of total TGF-P between treated and control mice over the
first seven days after FITC or PBS instillation, and levels were generally below the
limit of detection for the assay (Figure 3.19). This was also true of active TGF-P in
these same samples with the exception of Day 2, at which detectable levels were
measured in the BAL fluid of FITC-treated mice, and were found to be significantly
higher than those of the PBS controls (Figure 3.20).
Long-term time points were assessed in Series 1 and 2 mice. In Series 1 mice,
although there was some variation in levels, total TGF-p was not found at detectable
levels in the BAL fluid, nor were there any significant differences between FITC-
treated mice and PBS controls (Figure 4.18). Active TGF-P was present at
detectable levels at six weeks after the first intratracheal instillation, and again at 14
weeks after the second instillation, and while significant differences were seen
between the different time points, levels between the FITC- and PBS-treated mice
were not significantly different, and therefore any changes could not be attributed to
the FITC treatment (Figure 4.19). In Series 2 mice, as for Series 1 mice, there were
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no significant differences in the levels of active or total TGF-P between the FITC-
treated and PBS control mice (Figures 4.20, 4.21).
The above data suggest that TGF-P has only minimal involvement in the
pathogenesis of FITC-induced pulmonary fibrosis, and possibly only in the acute
stages, although TGF-P is thought to be responsible for repair rather than acute
damage in bleomycin-induced pulmonary fibrosis [265]. Immunohistochemical
staining of tissue sections from FITC-treated mice, however, showed a relative
increase in extracellular TGF-P as compared to PBS controls. Tissue TGF-P is not
quantifiable, and even if an increase did exist it may not be pathogenic. Such
discrepancies, however, have been reported in the literature, and it has been
suggested that BAL fluid cytokine levels may not represent tissue concentrations
[429],
The gene coding for TGF-P is expressed by type II pneumocytes [276], and the
detection of extracellular TGF-P by immunohistochemistry and collagen gene
expression by in situ hybridisation are found in the same areas of fibrosis in the
human lung, which suggests that TGF-P is directly involved in mesenchymal cell
production of ECM [275,287]. However, the production of TGF-P by AMs in
humans with fibrosis has been reported to be decreased, while BAL levels remained
normal [282], and BAL cells from bleomycin-treated mice were reported to express
decreased levels of TGF-P on Day 1 after treatment, which returned to only normal
levels by Day 15 and on to Day 29 [236].
Overexpression of active TGF-P has been shown to induce severe and progressive
pulmonary fibrosis in both the rat and in C57BL/6 mice [67,463]. Recently, Kolb et
al. [464] compared the response of "fibrosis-resistant" BALB/c mice and "fibrosis-
prone" C57BL/6 mice [465] to the overexpression of active TGF-P 1 using adenoviral
gene transfer. They reported that despite having higher levels of the transgene
protein in the lung, the BALB/c mice developed significantly less fibrosis than the
C57BL/6 mice in response to active TGF-P 1, and that this difference seemed to be
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downstream from TGF-P 1. Several studies demonstrating strain differences in TGF-
P expression upon stimulation have led to the hypothesis that the reduction in TGF-P
upregulation in the lung tissue of BALB/c mice results in their inability to develop
pulmonary fibrosis. The most relevant of these studies demonstrated an increase in
TGF-P mRNA by bleomycin treatment in fibrosis-prone C57BL/6 mice but not in
fibrosis-resistant BALB/c mice [270,465].
The results of Kolb et al. [464] and those presented in this thesis are discordant with
this hypothesis, however. Pulmonary fibrosis induced by the surgical method of
FITC instillation develops in both BALB/c and C57BL/6 mice, and is more severe in
the BALB/c mice [244], The work presented in this thesis has shown that the two
dose nonsurgical method of FITC instillation also produced a severe, progressive
pulmonary fibrosis that did not appear to be dependent on the increased production
of TGF-P in the BAL fluid or possibly in the tissues.
The development of a TGF-P-independent model of pulmonary fibrosis could have
important implications in the study of CFA, providing insight into new pathways
involved in the pathogenesis of this disease. Indeed, recently Moore et al. [62]
reported that the absence of CCR2 signaling confers protection from pulmonary
fibrosis in mice given FITC by the surgical method. Although they postulate that
alterations in TGF-P may contribute to the protection seen in the absence of CCR2,
evidence to the contrary may lead to novel pathways in the disease pathogenesis, and
ultimately, to novel treatments.
The absence of increased TGF-P levels in the BAL fluid of FITC-treated mice is only
a preliminary finding, however, and requires more investigation. The assay used to
detect TGF-P is intended for human samples, and although the manufacturer
approved its use for murine samples (R&D, personal communication), it may lack
sensitivity. Also, as discussed above, the BAL fluid cytokine levels may not
represent tissue concentrations. Several methods have been developed to examine
the role TGF-P plays in the pathogenesis of pulmonary fibrosis that could be applied
to the FITC-induced model. Systemic administration of TGF-P neutralising
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antibodies reduced the degree of collagen accumulation in both a model of
glomerulonephritis and a bleomycin model of pulmonary fibrosis [273,274], More
recently, intranasal administration of an adenoviral vector carrying the gene for
decorin, a ubiquitous proteoglycan known to be an important negative regulator of
TGF-(3 [466,467], effectively blocked the fibrogenic response to bleomycin in mice
[429],
4.4.3 Evaluation of the Modified FITC Model of Pulmonary Fibrosis
The fibrosis measured in the FITC-treated mice over a total of five months, and with
two intratracheal doses of FITC, appeared chronic and progressive, giving this model
an advantage over other rodent models, such as bleomycin, which cause a transient
fibrosis after acute injury that kills the animals after a short period of time or leads to
complete resolution. As the FITC-treated animals appeared healthy even after five
months, this model could be extended in order to draw further parallels with the
human disease. It would also be interesting to see if these animals eventually
developed adenocarcinomas, as did nine out of 15 BALB/c mice in the original
model [243] at 18 months (unpublished data). The chronic inflammation remained
evident until 14 weeks after the second dose of FITC, lending support to the
hypothesis that persistent inflammation plays a vital role in the development of
pulmonary fibrosis.
Measurement of BAL cytokines suggests that this model may resemble a Th2-like
immune response. As discussed in Chapter 1, it has been suggested that an
imbalance between Thl and Th2 cytokine responses may lead to abnormal responses
to injury, and may thus be involved in the pathogenesis of CFA [6]. Expression of
the Th2 cytokines IL-4 and IL-5 appears to be increased with a concomitant
reduction in expression of the Thl cytokine IFN-y [74,100,101]. As EFN-y
expression was very low in the FITC-treated mice (although also in the controls),
measurement of IL-4 and IL-5 in the FITC model could be very useful, particularly if
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increased expression could be shown in only the FITC-treated mice. Based on the
evidence presented in this thesis, the FITC model of pulmonary fibrosis could
possibly be TGF-p-independent, opening up unique avenues for investigation into
CFA pathogenesis. However as local microenvironments in the tissue are not
reflected in the BAL fluid, which is diluted as part of the collection procedure,
cytokine levels may be significantly higher in the tissues and thus require further
investigation, ideally through knockout mice or the administration of anticytokine
antibodies. B lymphocyte aggregates containing MHC class II+ cells suggest that
antigen presentation may be occurring, leading to a local humoral immune response
that may be an important factor in the pathogenesis of FITC-induced pulmonary
fibrosis.
Problems with this model of murine pulmonary fibrosis are still evident, however.
At the long-term time points, the nonsurgical intratracheal instillation of FITC failed
in approximately 25% of the animals (Table 4.1), and of those that did receive the
FITC dose, not all had the same amount deposited in the lungs, and not all developed
pulmonary fibrosis to the same degree. The success rate, in terms of actual FITC
deposition, appeared to be higher in animals assessed at the acute time points (Table
3.1), however as discussed below, this could be due to some animals being able to
clear the FITC more quickly, particularly if they received a smaller dose.
The variations in dose and disease severity may be caused by several factors. First,
the investigator is not able to see exactly where the blunted needle delivers the dose.
Indeed, upon dissection FITC has occasionally been found in the trachea walls.
Second, the weights of the mice can vary, and since only a standard dose of
anaesthetic was given, some of the mice may have recovered the cough reflex and
expelled the FITC in this way. Again occasionally, FITC was seen around the
mouths of some of the mice. Finally, FITC is insoluble in PBS and remains fairly
particulate in solution. This can be beneficial as it ensures a patchy deposition, and
may even be essential, as Christensen et al. [244] found that dose reductions below
the solubility threshold resulted in no fibrosis. However it can also mean that some
mice get a much higher dose than others if the solution is not mixed thoroughly.
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Also worth considering, however, is the role host defense may play in the
pathogenesis of FITC-induced pulmonary fibrosis. Mice for this project were
pathogen-free upon arrival, and usually received the first FITC or PBS dose within
days. Some mice did not, however, and since none of the mice were isolated in any
way, it is possible that some may have contracted an infection before the
intratracheal instillation that could have had an effect on their response to the FITC,
or even their ability to clear the FITC deposits. Ideally, the mice would have been
kept in isolator cages for the duration of the experiment, and further work could take
this into consideration. This could be an explanation as to why some mice developed
pulmonary fibrosis on exposure to FITC while others did not. However, it would
also be useful to investigate the effects an underlying infection, which may induce a
Thl- or a Th2-type response, may have on the response of the mice to FITC. Would
an underlying Th2-type infection predispose mice to the Th2-type response
associated with pulmonary fibrosis? Conversely, would an underlying infection with
a Thl-type response confer some degree of protection from FITC-induced
pulmonary fibrosis? These questions would ideally be addressed when continuing
this work.
The use of other substances in which FITC is soluble, such as DMSO, were
examined while investigating the original model, however they resulted in a very
high rate of death. Christensen el al. [244], who extended the surgical FITC method,
used sonication to disperse the particulate nature of FITC, although they then had to
reduce the dose by 50%. Sonication of the FITC at lower doses could be further
investigated in this two-dose model.
Standardisation of the dose of FITC is essential for this model of pulmonary fibrosis,
however the consistent finding that PBS-treated mice do not develop any lung
pathology is the most conclusive evidence of the effectiveness of FITC as a
pulmonary fibrosis-inducing agent. Once standardised, this model has great potential
for studying novel pathways in the pathogenesis of pulmonary fibrosis, and further
investigation should be pursued in the anticipation of novel and effective treatments
for patients with CFA.
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CHAPTER 5
Isolation of Antigen Presenting Cells from Murine
Lungs
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5.1 Introduction: Methods for Isolation of Lung APCs
In normal lung, DCs represent less than 1% of all lung cells and both the isolation
and purification of enriched populations require multiple steps [137,158]. Lung DCs
have no specific differentiation markers, and thus cannot be isolated by direct
immunoselection [137]. However, as discussed in Chapter 1, their various cell
surface markers, including products encoded by the MHC class I and II genes,
costimulatory molecules, adhesion molecules, and FcRs, can be used to differentiate
DCs from other cell types, and to characterise their phenotype and function [137].
While methods for the isolation of DCs from other tissues were in place in the
laboratory at the outset of this project, the methodology of DC isolation from mouse
lung had not been developed. Thus, in order to study the function of murine lung-
derived DCs, it was necessary to optimise methods for obtaining enriched
populations of these cells.
5.1.1 Alveolar Macrophage Isolation
The isolation of AMs by BAL is a fairly standard and straightforward technique.
Macrophages obtained by lavage include resident AMs and intraluminal
macrophages (those that reside within the lumen of the bronchi and bronchioles).
Although a distinction between these two cell populations cannot be made, in rats
and mice the typical procedure of placing a catheter in the trachea results in
obtaining a majority ofAMs [184].
The general outline of the BAL technique for mice involves cannulating the trachea,
filling the lungs with fluid, and then withdrawing the fluid. This is repeated several
times and the lavage fluid is pooled and centrifuged. The technique is usually
optimised by adjusting the volume, and/or temperature, of fluid used to lavage the
lungs, the lavage fluid itself (i.e. saline or tissue culture medium), and the number of
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lavages, and so can differ between investigators [185]. Yields from the BAL of
normal mice can range from 0.06 - 1.36 x 106 AMs, and typically more than 95% of
the BAL cells are AMs [179,468,469],
5.1.2 Dendritic Cell Isolation
"...as DC are only a trace population in all tissues their preparation in sufficient
numbers is extremely tedious.'''' [470]
No one technique to isolate DCs from whole lung results in a completely pure
population and thus a combination of techniques is used. The isolation procedure
typically has two stages. The purpose of the first stage is to obtain a single-cell
suspension of lung cells, and the methods involved are, for the most part, consistent
among groups who isolate these cells. The second stage, in which a DC-enriched
population is sought, varies greatly among groups, and involves any number of
techniques that exploit the various properties of contaminating cells; for instance, the
phagocytic or autofluorescent properties of the main contaminant, lung interstitial
macrophages.
5.1.2.1 DC Isolation - Stage 1: Single Lung Cell Suspension
The first stage of the isolation procedure requires BAL, perfusion of the pulmonary
vasculature, enzymatic digestion of the tissue, and density fractionation
[155,471,472], Perfusion is required to remove peripheral blood cells from the
pulmonary vasculature. BAL removes a large proportion of resident AMs which,
like DCs, express the cell surface molecule CDllc [137,157], and have been shown
to suppress DC-initiated T cell proliferation [182,194,473-475], Enzymatic digestion
of the lung tissue to extract viable interstitial lung cells is most often accomplished
with collagenase, although there are a number of different types of this enzyme
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available that vary in their effectiveness [155], DNase is usually included in the
enzyme solution to minimize cell loss due to DNA-induced clumping. Proteolytic
enzymes such as elastase and hyaluronidase are not recommended as they can
damage structures on the cell surface, such as FcRs [471], Density fractionation
separates pulmonary mononuclear cells from the dissociated cells, resulting in low
density DC- and interstitial macrophage-enriched lung cells [137], Table 5.1
compares the methods used by various groups in the first stage of the isolation
procedure.
To further enrich the DC population and eliminate the interstitial macrophages, many
groups include a short adherence step to separate nonadherent lymphocytes from
adherent cells, and subsequently an overnight adherence step to separate the loosely
adherent cells from the firmly adherent macrophages [154,183], The adherence step,
however, has two disadvantages. First, DC function and phenotype may be affected
significantly by either the time in overnight culture, which has been shown to down-
regulate skin DC antigen-processing capacity [476,477] and increase accessory
molecule expression [478], or as a result of interacting with other cells from the
pulmonary interstitium which are still present. For example, interstitial
macrophages, which continue to contaminate the loosely adherent fraction, have
been shown to enhance the ability of DCs to present antigen [154,479], Second, the
overnight enrichment requires a very high number of cells initially, as many are lost
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5.1.2.2 DC Isolation - Stage 2: Enrichment for DCs
In the rat, Gong et al. [151,183] used a novel microdissection method to separate the
lung parenchyma from the airway epithelium in order to study separately airway
epithelial DCs and interstitial lung DCs. After perfusing the pulmonary vasculature,
the lungs were inflated with a solution containing agarose, dispase, DNase and FCS.
The lungs and attached trachea were removed and placed in ice-cold PBS to solidify
the agarose. This allowed for the lung parenchyma to be dissected from the
tracheobronchial tree. The lung tissue was then cut into pieces and digested with
collagenase and DNase I, and the resulting cell suspension subjected to density
fractionation.
The cells were then separated into FcR+ and FcR" cells by rosetting with antibody-
coated sheep erythrocytes. The FcR" cells were incubated overnight in GM-CSF to
improve survival, and with Dynabeads that would be taken up by any remaining
phagocytic cells. The Dynabead-containing phagocytic cells were subsequently
removed with a magnetic particle concentrator, and the nonphagocytic cells spun
over a metrizamide gradient to remove B and natural killer cells. Finally, residual
FcR+ cells were removed by immunopanning for MHC class II+ cells. This
technique yielded a population that was >98% pure for interstitial lung DCs, however
the final cell yield was only lxl05 DC from 10 rats.
Holt et al. [141,471] also described a method to extract DCs from rat lungs, which
involved perfusion, repeated endobronchial lavage, and removal of the lungs. The
lungs were then sliced mechanically to 500 pm, and digested in collagenase/DNase
for 90 minutes. Rapid filtration through cotton wool was followed by a five-step
discontinuous Percoll gradient, plastic adherence, and finally rosetting, to remove the
majority of FcR+ cells. Although absolute numbers were not indicated, their yield
was approximately 15% MHC class II+ cells per gram of rat lung, from this final cell
suspension.
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Armstrong et al. [479] isolated lung DCs from the rat as well, finely mincing the
lung tissue and digesting in collagenase/DNase I. Interstitial cells were released by
vigorous stirring of the mixture at 37°C for 90 minutes, followed by nylon wool
filtration and density fractionation. Phagocytic cells were removed by magnetic
separation following incubation with carbonyl iron particles, and the nonphagocytic
pulmonary DCs were isolated by flow cytometric cell sorting based on MHC class II
expression. Their final cell yield was lxl05 DCs per rat.
Using murine lungs, Lipscomb and colleagues [137,155] described a multistep
enrichment protocol that gave a 92-99% pure population. Following density
fractionation, lung cells underwent a short adherence step to remove non-adherent B
cells, and then an overnight adherence step to remove firmly adherent macrophages
from the loosely adherent (LAd) cells.
Masten and Lipscomb [137] (and personal communication) report that DCs represent
11±3% of the total LAd population. LAd cells were next incubated with FITC-latex
beads (to identify and eliminate phagocytic cells), and FcRs were blocked by
preincubation with anti-CD16/CD32. The cells were also stained with anti-I-Ad/I-Ed
antibodies (to identify MHC class II-expressing cells) and anti-CD45R/B220
antibodies (to identify B cells). Lung DCs were then obtained in high purity by flow
cytometry, sorting for FITC-bead" (nonphagocytic), B220", MHC class II-expressing
cells. This method yielded 2.5x103 lung DCs per mouse.
More recently, Vermaelen et al. [138] described a different method for murine lung
DC isolation. After perfusing, mincing, enzymatic digestion and red blood cell lysis,
they labelled their lung cells with a variety of antibodies and used cell sorting to
purify the lung DCs, among other populations. They selected for CDllc+/low
autofluorescence, and found that >90% of these cells were also MHC class II+. As
they had manipulated these cells very little before analysing, they found that the DCs
showed an immature phenotype, but overnight culture of these DCs in GM-CSF
resulted in a more mature phenotype, with upregulation of CD40, MHC class II,
CD86, ICAM-1.
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Gonzalez-Juarrero and Orme [158] also described a method using mouse lungs.
They did not perform a BAL, but perfused directly. Lungs were minced and enzyme
digested, then subjected to red cell lysis treatment. CD1 lc+ cells were then selected
from the single cell suspension after incubation with CDllc MACS microbeads,
giving a purity of 80-90% CDllc+ cells. Macrophages were removed by overnight
plastic adherence. Although cell numbers were not reported, they found that lung
DCs constituted <1% of the total number of cells in the lung.
As discussed in Chapter 1, lung DCs show considerable phenotypic heterogeneity,
and each of the groups whose methods are described above obtained one or more
populations of lung DCs showing different cell surface phenotypes.
5.1.3 Aims of Chapter
The aims of this chapter are:
• To explain the choice of methods of isolation used in this body ofwork
• To describe the method used for the isolation ofBAL cells
• To describe the development of the isolation method for DCs used throughout
this thesis
• To discuss the phenotyping of the two cell populations
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5.2 Choice of Method for APC Isolations
In order to study the biology of DCs in the lung it was necessary to develop a
protocol that would combine maximum cell yield with minimum disruption of
function. As only one investigator performed the perfusions and isolations, there
also had to be low numbers of mice in the experimental groups to avoid excessive
processing time and consequent cell death.
It was decided that the first stage of the isolation should follow the standard protocol
of BAL, perfusion, enzymatic digestion and gradient centrifugation, although with a
unique modification. For the second stage, various methods used by other groups
were evaluated. Plastic adherence to remove contaminating macrophages was
attempted several times, however since the starting number of cells was low, the final
yield from this method was extremely low. The agarose/rosetting/immunopanning
methods of Gong et al. [151] were not attempted as their cell yield (lxlO5 DCs per
10 rats) indicated that it was not a practical method for a small number of mice. The
methods of Holt et al. [471] used similar multiple steps on rat lungs which, again,
were not deemed practical in this case. Cell sorting to select for appropriately
stained lung DCs, as used by Armstrong et al. [479] was the most attractive method,
however this technology was not available. Finally, the methods described by
Vermaelen et al. [138] and Gonzalez-Juarrero and Orme [158] were not published at
the time this project was being developed.
Thus, the method described hereafter was developed to obtain a minimally
manipulated population of cells that contained APCs from the lung, including DCs,
which could be used to examine their function in a murine model of pulmonary
fibrosis. The method is adapted from a method described for the isolation of Clara
cells from the mouse lung [480],
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5.3 Development of Method for Lung APC Isolation
5.3.1 Lung Perfusion
Female BALB/c mice, between six and eight weeks old, were killed by
intraperitoneal injection of 0.5 ml Sagatal. The mouse was laid on its back, and the
ventral surface skin removed. A midline incision was made to enter the peritoneal
cavity, the folds of the peritoneum were lifted back, the gastrointestinal tract
displaced to the right, and the major dorsal blood vessels were cut to allow drainage
of blood. The diaphragm was punctured just below the xiphisternum and opened,
and the rib cage removed to expose the lungs. The trachea was separated from the
covering muscle and underlying oesophagus. Once exposed, forceps were pushed
under and left in place to extend the trachea. A scalpel was used to create a small
hole on the anterior surface near the top of the trachea, between the rings of cartilage.
A 0.96 mm cannula (Portex, Ltd., Hythe, Kent, UK) attached to a 2 ml syringe was
inserted into the trachea, stopping approximately 2/3 of the way down, well away
from the main bronchi. The cannula was secured in place with surgical silk.
The apex of the heart was gripped with a haemostat and the tip cut off with scissors,
exposing the right ventricle. A second cannula with a diameter of 1.7 mm (SLS,
Ltd., Coatbridge, Lanarkshire, Scotland), attached to a gravity feed of sterile 0.15M
saline, was inserted into the left ventricle. The flow of saline, which was maintained
at a steady drip so as not to overinflate the heart, caused the right atrium to swell, and
subsequently the right atrium was cut to allow the fluid to exit. Using the syringe
attached to the intratracheal cannula, the lungs were artificially ventilated 3 or 4
times with approximately 0.8 - 1.2 ml of air, until they were free of blood and
appeared completely white. Figure 5.1 illustrates the dissection and perfusion
techniques.
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Figure 5.1 Perfusion Of murine lungs. (A) Uninflated murine lungs cannulated
in situ, before perfusion. (B) After perfusion, showing partial inflation of lungs, and complete
clearing of blood.
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5.3.2 Collection of BAL Fluid and Cells
Collection of BAL fluid was typically performed after the perfusion, however it was
found that collecting BAL fluid prior to perfusing made no difference to the quantity
or content.
While still in situ, the lungs were lavaged with two washes of 0.8 ml and 0.6 ml ice
cold PBS, which were collected in a sterile Eppendorf tube and stored on ice. BAL
fluid was then spun at 300g for seven minutes. The supernatant volume was
estimated and recorded, pipetted into a new Eppendorf, and spun again at 1 OOOg for
five minutes to remove all trace cellular debris and contaminants. This second
supernatant was then collected, aliquoted and stored at -70°C. Recovered BAL fluid
volumes were typically between 1-1.3 ml. The cells remaining from the first spin
were pooled and counted, and used for cytospins or as APCs in T cell proliferation
assays. BAL cell counts from normal BALB/c mice averaged 1.41 ± 0.15 x 105
cells/mouse (n=20). For cytospins, BAL cells were resuspended at 1 x 106/ml in
PBS or medium containing 10% FCS, and cytospins were prepared as per the
protocol described in section 2.3. BAL cells destined for T cell proliferation assays
were resuspended in complete RPMI and plated onto 96 well round-bottomed tissue
culture plates and cultured overnight in complete RPMI. T cells were added the
following day, as per the protocol described in section 2.1.2.1.
5.3.3 Lung Inflation/Enzymatic Digestion
After perfusing the pulmonary vasculature to remove peripheral blood cells, and
collection of BAL fluid, the lungs were carefully excised, and those that were to be
used for immunohistochemistry were immediately inflated with 1.2 ml 4% formalin
and immersed in 4% formalin for 24 hours before processing. Lungs to be used for
cell isolation were placed in RPMI prior to further processing. A maximum of four
mice per treatment or control group could be processed as larger numbers required
more time, and thus leading to increased cell death, and lower cell yields.
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Several different enzymes, enzyme concentrations and combinations, and digestion
times were investigated to maximise cell yield in the subsequent steps (Figure 5.2).
The initial protocol involved incubating minced lung in a warmed (37°C) RPMI
solution containing 0.4 mg/ml collagenase type IV for 90 minutes. Cell yields were
quite low however, averaging 2.7 ± 0.5 x 105 cells/mouse (n=8).
As lung tissue is extremely difficult to digest, a solution of 2.5 mg/ml trypsin was
substituted for the collagenase IV. The trypsin solution was also used to inflate the
lungs before mincing, thus maximizing the enzyme's contact with as much of the
lung as possible. In this way, it was also possible, and necessary, to decrease the
digestion time from 90 minutes to 45 minutes. These changes increased cell yields
63%, to 3.4 ± 0.3 x 105 per mouse (n=17).
As cell yields were still very low, it was decided to use collagenase IV (at 0.7 mg/ml)
instead of the trypsin in the digestion solution. Trypsin is a very strong proteolytic
enzyme, and as inflation of the lungs with enzyme made it possible to digest the lung
tissue more thoroughly, trypsin's action was perhaps too harsh, particularly
considering the cells were to be used in functional assays. Collagenase IV is
routinely used to digest lung tissue as it has low tryptic activity and thus maintains
receptor integrity. This modification of the method increased cell yields to 4.0 ± 0.4
x 105per mouse (n=13).
Cell numbers were still limited, however, as a maximum of four mice per treatment
group could be used. Dispase is a mixture of neutral proteases that cleave at the level
of the basement membrane, and is recommended for the gentle dissociation of animal
tissues to release individual cells. In combination with the collagenase IV, and at a
concentration of 2 pg/ml, it was found that dispase increased cell yields significantly
to 6.6 ± 0.6 x 105 per mouse (n=14), as compared to all previous combinations.
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Collagenase IV Trypsin+infl. Collagenase IV Collagenase IV
(n=8) (n=17) +infl. /dispase+infl.
(n=13) (n=14)
Figure 5.2 Comparison of methods of enzymatic digestion of murine
lung tissue used in the isolation of DCs. Murine lungs were perfused and
lavaged before removal. Infl. = inflation of lungs with enzyme solution. Each experiment (n)
represents the final cell count from between 3-6 mice. Data are presented as mean±SEM of
each experiment.
*p<0.001, **p<0.01, as determined by one-way ANOVA with Tukey-Kramer multi-comparison
tests
Although cell yields were improved considerably, phenotyping of these cells
indicated that purity was very low, with the APCs being only a minor subpopulation.
In an attempt to improve cell purity, the enzyme solution was changed again to one
containing 0.7 mg/ml collagenase A (Roche Diagnostics GmbH, Mannheim,
Germany) and 30 pg/ml type IV bovine pancreatic DNase I, as recommended by B.J.
Masten (personal communication) of the University of Albuquerque, New Mexico,
USA whose group routinely isolates highly purified populations of lung DCs [137].
Although the final cell yields dropped to 3.2 ± 0.2 x 105 per mouse (n=38), the purity
had greatly improved, with the APCs representing the majority of the cells in the
population.
Therefore, the final protocol called for the lungs to be inflated with the warmed
enzyme solution (collagenase A/DNase I) and then minced and incubated in more
wanned enzyme solution in a tissue culture dish for 45 minutes at 37°C. Tissue from
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no more than 2 sets of lungs was combined at any one time as pooling more resulted
in loss of cells.
5.3.4 Isolation of CD11c+-Enriched APCs from Digested Lung Tissue
The digested lung tissue was coarsely strained by passing it through a metal strainer
using a syringe plunger, and then finely strained through a 40 pm filter (BD
Biosciences, Heidelberg, Germany) directly into a 50 ml polypropylene tube. The
cells were washed twice in incomplete RPMI that was supplemented with 10% FCS,
2 mM L-glutamine, 100 U/ml penicillin and 100 pg/ml streptomycin, but no P-2-
mercaptoethanol. This additive, necessary for optimal murine lymphocyte
proliferation, was added to the medium at 5xlO~5M just before culture as it inhibits
the enzymatic action of collagenase (as stated in Roche data sheet). The anti-
protease action of FCS was not found to significantly reduce the action of the
collagenase.
Percoll gradients were prepared by mixing 4 ml PBS with 2.675 ml Percoll
(Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, UK) and filter
sterilising this mixture into one 50 ml Falcon tube. One gradient was prepared for
each pair of lungs. Cells from each set of two lungs were resuspended after the final
wash in 10 ml incomplete RPMI, and 5 ml of this cell suspension was layered onto a
gradient. The gradients were spun for 30 minutes at room temperature, at lOOOg.
The upper layers were then removed leaving a pellet enriched for mononuclear cells,
and the contents from no more than two gradients were pooled.
The cells were washed once and resuspended in 400 pi ice cold MACS buffer and
100 pi CD1 lc microbeads (Miltenyi Bitoec) as per the manufacturer's protocol. The
cells were incubated for 15 minutes at 4-6°C, then washed in 10-20X the volume of
MACS buffer. As the cell count at this stage was consistently less than 107 per tube,
the cells in each tube, derived from two pairs of lungs, were resuspended in 500 pi
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MACS buffer and run over a single MACS column primed with 500 pi MACS
buffer. As per the manufacturer's protocol, the columns were then washed three
times with 500 pi MACS buffer, and each column was eluted with 1 ml complete
RPMI, and the cells counted.
This method consistently yielded between 1x10s - 5x105 CD1 lc+-enriched APCs per
mouse, which showed >99% viability as determined by trypan blue dye exclusion.
Figure 5.3 illustrates the final isolation protocol.
Figure 5.3 Final protocol for the isolation of CD11c+-enriched APCs
from murine lungs.
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5.4 Phenotypic Characterisation of CD11c+-Enriched DCs
and BAL Cells
Cell surface marker expression on CD1 lc+-enriched DCs and BAL cells was
characterised by flow cytometry using the monoclonal antibodies detailed in Table
2.1 following the protocol described in section 2.4. Cytospin preparations were
made following the protocol described in section 2.2.
5.4.1 Freshly Isolated Cells
Freshly isolated cells from both the BAL and the lung tissue were examined only by
microscopy as they were not used in any functional analyses. Figure 5.4 shows a
typical field from a cytospin preparation of pooled, freshly isolated CD1 lc+-enriched
cells from the lungs of four wild-type BALB/c mice. The isolated population was
mixed, and was comprised of, on average, 44±8% mononuclear cells, 29±9%
granulocytes, and 27+7% lymphocytes (n=13). Also present were the occasional
epithelial cell and red blood cell.
Figure 5.4 shows a typical field from a cytospin preparation of pooled, freshly
isolated BAL cells from the lungs of four wild-type BALB/c mice. The isolated
population showed 98 ± 1% (n=ll) mononuclear cells, with the remaining cells
being PMNs, and rarely, lymphocytes. Many of the cells showed dendritic-like
processes similar to those seen on the lung DCs (Figure 5.4).
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Figure 5.4 Cytospin preparation of freshly isolated CD11c+-enriched
lung cells. A typical field representative of the mixed population of cells present at the
end of the isolation procedure (x400 original magnification). "DC" = dendritic cell; PMN =
polymorphonuclear cell.
Figure 5.5 Cytospin preparation of freshly isolated mouse BAL cells.
A typical field representative of the homogenous population of cells in the BAL fluid of normal
BALB/c mice (x400 original magnification).
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5.4.2 Cultured Cells
All cells used for functional analyses were cultured overnight in 96-well plates.
5.4.2.1 BAL Cells
BAL cells were prepared as described in section 5.3.2. Figure 5.6 shows a cytospin
preparation of BAL cells after overnight culture in complete medium. The
population consists of primarily large mononuclear cells, with fewer cells showing
the dendritic-like processes. As with the freshly isolated BAL cells, the population
was comprised of 98% mononuclear cells.
Figure 5.6 Cytospin preparation of BAL cells cultured overnight in
medium. A typical field, at x400 original magnification.
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BAL cells were also stained for flow cytometric analysis, as described in section 2.4.
In order to distinguish live from dead cells, TO-PRO-3 (TP3) (Molecular Probes,
Inc., Eugene, Oregon, USA) staining was used. The TP3 fluorophore is a cyanine
nucleic acid stain that is impermeable to living cells, but intercalates with the DNA
of dead/dying cells. It is almost nonfluorescent unless bound to DNA or RNA.
Figure 5.7(A) shows the dot plot histogram of TP3 (in FL4) vs. forward scatter (fs)
of these cells. Back-gating on the whole unstained population revealed where the
live cells lay. Figure 5.7(B) shows the dot plot histogram of forward scatter (fs) vs.
ss of the whole, unstained population, with the gate R1 surrounding the live cells,
comprising 39% of the total population, which was subsequently analysed.
The BAT cells were stained for CDllc, MHC class II, CD80, CD86, ICAM-1,
CD lib, CD40. Antibodies to detect contaminating B cells (CD 19) and T cells
(CD3) were also included. Figure 5.8 shows the corresponding single-stain
histograms. After overnight culture in medium alone, the BAF cells were 73 ± 6%
CD1 lc+, 16 ± 4% MHC class II+, 61 ± 8% CD80+, 22 ± 3% CD86+, 91 ± 2% ICAM-
1+, 47 ± 6% CDllb+, and 34.5 ± 8% CD40+ (n=4). Contaminating T and B cells
were negligible (1.0 ± 0.3% and 0.8 ± 0.1%, respectively).
When BAF cells were double stained for both CD1 lc and MHC class II (Figure 5.9),
the histogram showed a population in which the majority of cells (87.6%) were
highly CDllc+, and expressed mid-range MHC class II. These findings are
consistent with murine BAF macrophages, which have been reported to highly
express CD1 lc, but only express low levels ofMHC class II [131,190].
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Figure 5.7 Dot plot representations of typical BAL cell preparation. (A)
Dot plot of BAL cell population stained with TP3 showing fluorescence versus forward
scatter. Gate R1 surrounds the live cell population. (B) Light scatter plot of whole, unstained
BAL population. Gate R1, obtained by back gating from plot A, surrounds the live cell
population.
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Figure 5.8 Cell surface phenotype of murine BAL cells Flow cytometry
histograms showing live BAL cells, which were isolated as described above and stained for
various cell surface markers. Open histograms represent isotype-matched control
monoclonal antibodies. The numbers shown on each histogram represent the percent
positive cells relative to the isotype control.
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Figure 5.9 Murine BAL cells stain for both CD11c and MHC class II
surface markers. BAL cells were stained with both CD11c and MHC class II antibodies
and assessed by flow cytometry. Percentages of cells in each quadrant of the dot plot are
shown.
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5.4.2.2 CD11c+-Enriched Lung Cells
CD1 lc+-enriched lung cells were prepared as described in section 5.3.3. Figure 5.10
shows a cytospin preparation of these cells after overnight culture in complete
medium supplemented with 20 ng/ml recombinant GM-CSF (R&D Biosystems).
Although the population was still a mixed one, there were a higher proportion of







Figure 5.10 Cytospin preparation CD11c+-enriched lung cells after
overnight culture in GM-CSF. A typical field representative of the mixed population
of cells present, but with a higher percentage of mononuclear cells than the freshly isolated
population (Fig. 5.3) (x400 original magnification)
CD1 lc+-enriched lung cells were also stained for flow cytometric analysis, as
described in section 2.4. As for the BAL cells, TP3 was used to distinguish live from
dead cells. Figure 5.11 shows the dot plots for these cells. The live cells comprised
approximately 28% of the total population, and it was these cells that were analysed
for cell surface marker expression.
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The lung cells were stained for CDllc, MHC class II, CD80, CD86, ICAM-1,
CD1 lb, and CD40. Antibodies to detect contaminating granulocytes (Gr-1), T cells,
and B cells were also included in the panel. Figure 5.12 shows representative
corresponding single stain histograms. In four separate experiments, the percent
positivity for each surface marker was as follows: CDllc, 85 ± 5; MHC class II, 51
± 4; CD80, 16 ± 4; CD86, 78 ± 6; ICAM-1, 97 ± 2; CDllb, 45 ± 5; CD40, 33 ± 4;
Gr-1, 22 ± 6; CD3, 41 ± 4; CD19, 34 ± 5. These results reflect the mixed population
of cells obtained by this method, and show considerable contamination by
granulocytes, T cells, and B cells. However, as DCs represent less than 1% of the
total cells in the lung, the surface levels of CD1 lc, MHC class II, and accessory cell
markers were reasonably high.
In order to identify the APCs in this mixed population, the lung cells were also
stained with both CDllc and MHC class II, as this would eliminate other
contaminating cells. Figure 5.13 shows the corresponding dot plot. The three
populations of cells which were identified are (i) MHC class IIhlgh, CD1 lclow (lower
right quadrant); (ii) MHC class IIlow, CDllclow (upper left quadrant); (iii) MHC class
IIhlgh, CDllcmid (upper right quadrant). Interestingly, the first two populations are
the same as those reported by Gonzalez-Juarrero and Orme [158], although the third
population differs.
The MHC class II and CDllc double staining showed different patterns on the dot
plots for the BAL macrophages and the CD1 lc+-enriched APCs (Figures 5.9 and
5.13, respectively). The BAL macrophages are larger cells that expressed high levels
of CDllc and mid-range MHC class II, while the smaller CD1 lc+-enriched APCs
expressed low levels of CD1 lc, and generally high levels ofMHC class II.
However, to determine if the APCs were, in fact, free from macrophages, freshly
isolated lung cells were also examined by flow cytometry. The dot plot of CDllc
versus MHC class II is shown in Figure 5.14. Interestingly, the large population of
cells that stain MHC class IIrnid, CD1 lchlgh (upper right quadrant) is not present in the
APC dot plot, but appears to match that of the BAL cells, suggesting that the
189
majority of cells in the APC population are, indeed, DCs. The most likely
explanation for this is that contaminating macrophages adhere firmly to plastic after
overnight incubation, while DCs are only loosely adherent [154], When pipetting the
cells out of the wells for flow cytometric analysis, the macrophages would not have
loosened and would remain attached to the plate, while the DCs would have become
unattached. Thus, for further study of the DCs, lung cell isolates were routinely
cultured overnight in GM-CSF, and subsequently removed to fresh 96-well plates by
pipetting. This resulted in fewer overall cells, but a population devoid of
contaminating macrophages.
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Figure 5.11 Dot plot representations of a typical CD11c+-enriched APC
(DC) preparation. (A) Dot plot of TP3 staining, gated around live cell population (R1).
(B) Light scatter plot of whole, unstained population, back-gated on the live cell population







Figure 5.12 Cell surface phenotype of murine lung CD11c+-enriched
APCs (DCs). Flow cytometry histograms showing single staining for cell surface markers
on APCs cultured overnight in medium and GM-CSF. Open histograms represent isotype-
matched control monoclonal antibodies.
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Figure 5.13 Dot plot representation of murine lung CD11c+-enriched
APCs (DCs) stained for both CD11c and MHC class II surface markers
after overnight culture in GM-CSF. Isolated lung cells were stained with both
CD11c and MHC class II antibodies and assessed by flow cytometry. Percentages of cells
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Figure 5.14 Dot plot representation of freshly isolated murine lung
CD11c+-enriched APCs (DCs) stain for both CD11c and MHC class II
surface markers. Isolated lung cells were stained with both CD11c and MHC class II
antibodies and assessed by flow cytometry immediately after isolation. Percentages of cells
in each quadrant of the dot plot are shown.
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5.5 Conclusions and Discussion
DCs in the lung constitute an extremely small proportion of the total number of cells,
and require multiple steps for isolation, enrichment and purification. Ideally,
effective procedures for isolating fairly pure populations of lung DCs take advantage
of the phagocytic properties of lung macrophages, and the high MHC class II
expression of DCs [137].
Ideal separation, however, was not possible for this project as only a limited number
of animals could be used at one time. Higher numbers resulted in increased cell
death, as the lungs could not be processed immediately. Attempts to delay cell death
by keeping extracted lungs on ice or in warmed medium did not resolve the problem.
The optimal cell yield was obtained by using a maximum of four mice per
experimental group. The main contaminant in the isolated population was
macrophages, however again, the low starting number of cells meant that plastic
adherence, the method of choice to remove macrophages, was not possible as the
final cell yield was negligible. Fluorescence-activated cell sorting to separate DCs
from macrophages was not available at the time.
The final protocol used to isolate DCs from murine lungs thus made a number of
modifications to the published methods: the lungs were perfused using a modified
protocol by Oreffo et al. [480]; BAL was collected using standard methods; in a
unique addition to published methods, the lungs were inflated with warmed
collagenase A/DNase I solution before being minced and digested further in the
solution to obtain a single cell suspension; Percoll purification to remove epithelial
cells and other cellular debris; positive selection for CDllc+ cells, having removed
the CDllc+ BAL cells; overnight culture in GM-CSF, with removal to new tissue
culture plates.
Flow cytometric analysis revealed that the majority of cells in the BAL formed a
distinct macrophage population. The CD1 lc+-enriched lung cells, however, showed
contamination by other cell populations, and considerable heterogeneity. Although
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heterogeneity of lung DCs is well documented [138,154,158], the contamination
needed to be addressed.
As the cells would mainly be used for functional studies, other contaminating cells,
such as neutrophils and T lymphocytes, which do not possess antigen-presenting
capacity, would not be a problem. B cells, though, are capable of antigen
presentation, and when activated can stimulate a mixed lymphocyte reaction
[481,482], Masten and Lipscomb [157], however, showed that lung DCs were far
superior to B cells at stimulating antigen-specific CD4+ T cell proliferation when
given OVA323-339 peptide, and that B cells presented very little peptide when
administered in a short pulse, as compared to peptide being present continuously in
the cultures. Therefore this protocol would be followed for future functional assays.
The main concern however, was that there were still contaminating macrophages
present which would affect subsequent functional studies. However, flow cytometric
analysis of freshly isolated lung cells compared to those cultured overnight indicated
that the main population missing in the latter seemed to correspond to the BAL
macrophage population. Since macrophages are known to adhere firmly to plastic,
while DCs are only loosely adherent and are easily dislodged with pipetting
[155,472,483], removing the cells for phenotypic analysis resulted in a population of
cells that was only minimally contaminated by macrophages. Removing the cells
from the wells in which they were cultured overnight in GM-CSF became a routine
addition to the method. Thus, in terms of antigen presentation, the population of
cells isolated by the method described above could, for the body of this work,
justifiably be called DCs.
Finally, it was necessary to determine the extent of maturation of the DCs, some of
which is inevitable during the multiple isolation steps. Vremec et al. [484] suggested
that CDllb is a marker of DC maturation, and this was supported by Masten and
Lipscomb [157], who also found that the level of CDllb and MHC class II
expression on lung DCs correlated with one another. Similar levels of expression of
both these markers were found on the lung DCs isolated in this project suggesting
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that, while they may have been partially activated by the isolation process, they were
still not completelymature, and thus ideal for further functional studies.
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CHAPTER 6




The aim of this chapter was to determine if the biological ability of lung APCs was
modulated in FITC-induced pulmonary fibrosis. In order to do so, the ability of lung
APCs to present antigen to T cells, and the cytokine response induced under these
conditions, were evaluated.
The investigation of the paradigm that CD4+ Th2 cells may play a major role in the
pathogenesis of CFA [6,16,74,257] overlooks the fact that antigen processing and
presentation by APCs is an initial step in immune recognition that eventually leads to
the development of Th2-like responses. Following capture, APCs process and
present antigenic peptides bound to MHC molecules to naive T cells. In addition,
they express costimulatory molecules that are required to provide a "second signal"
for optimal induction of T cell activation, clonal expansion and differentiation.
Without this second signal, the outcome of ligation of the T cell receptor is anergy
rather than immunity [485].
There are a number of professional APCs, such as DCs, macrophages, and B cells,
capable of capturing and processing foreign antigen for presentation to T cells,
however DCs are the most specialised of the APCs. In this chapter, the ability of
both lung DCs and AMs to stimulate T cell proliferation in the context of the FITC
model of pulmonary fibrosis will be examined together with the cytokine responses
that they induce in T cells.
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6.1.1 Aims of Chapter
The aims of the experiments described in this chapter are:
• To determine if both CDllc+-enriched DCs and BAL AMs from FITC-
treated mice differ in their ability to induce T cell proliferation from APCs
from PBS control mice
• To determine if IL-13, IFN-y, IL-10, and IL-12 are produced in the cell
cultures described above
• To discuss the significance of these results, and the relevant key scientific
questions that remain to be answered
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6.2 T Cell Proliferation Assays
T cell proliferation assays, described in detail in sections 2.1.1 and 2.1.2, were used
to assess how FITC treatment affected the ability of lung APCs to present antigen.
Antigen-specific T cell proliferation assays were used to give a relatively easy
measure of APC-dependent T cell activation. It was decided to pulse APCs with
peptide before introducing T cells rather than with whole OVA protein, as the APCs
were not as efficient at presenting whole protein (data not shown). In addition, while
DCs are efficient presenters of peptide after only brief pulsing, B cells require
nonlimiting peptide to demonstrate antigen presenting activity [157], and this helped
to ensure that T cell stimulation was directed by APCs in the cultures, without
interference from contaminating B cells. Briefly, purified lung APCs were pre-
incubated with OVA323-339 peptide for two hours, and then subsequently washed to
remove the peptide. The optimum dose of peptide was determined for each batch
from a dose-response curve (section 2.1.2). Purified antigen-specific CD4+ DOl 1.10
T cells, expressing T cell receptor-a(3 specific for OVA323-339, were isolated from the
spleens of DOl 1.10 transgenic mice, and were cultured together with the APCs for
four days. BSA was added as a negative control for antigen specificity, or the T cell
mitogen conA as a positive control for cell viability. [ H]-thymidine was added to
the cultures 18 hours before the end of the stimulation. The cells were then
harvested and counts per minute (cpm), reflecting T cell proliferation, were obtained
using a liquid scintillation counter.
Since the predominant interest was in APCs from fibrotic lungs, APCs from only
long-term time points, plus the Day 7 time point, were used in the assays. CD1 lc+-
enriched lung DCs were isolated at each time point for use in these assays, and AMs
from the BAL fluid were isolated at six weeks after the first dose of FITC, one week
after the second dose, and six weeks after the second dose. AMs were not available
from a sufficient number of experiments at Day 7 or 14 weeks after the second dose
for a suitable number of repetitions, but the individual experiments are shown.
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Because the purity of DCs was quite variable, as described in Chapter 5, the actual
number ofDCs was not consistent between preparations, and thus T cell proliferation
also varied. This may also have occurred because of the heterogeneity of lung DCs,
making it possible that the different subtypes of DCs were present in different
numbers in each preparation. For these reasons, the data were first evaluated and
compared as individual experiments before being combined in order to compare time
points.
6.2.1 CD11c+-enriched DCs
6.2.1.1 Day 7 DCs
CD1 lc+-enriched DCs isolated from mouse lungs seven days after the first dose of
FITC or PBS, pre-incubated with OVA323-339 peptide, and cultured together with
antigen-specific DO11.10 CD4+ T cells induced T cell proliferation that was variable
in magnitude (Figure 6.1). Out of six separate experiments, two showed that DCs
from FITC-treated mouse lungs ("FITC DCs") stimulated significantly more T cell
proliferation than DCs from PBS control lungs ("PBS DCs") (Figure 6.1 A, p<0.04;
Figure 6.IB, p<0.02), however the remaining four showed no significant differences
between the two groups. Combining the data from all six experiments showed no





























































PBS Frrc PBS FITC







APC + T +
BSA (cpm)
(neg. control)
APC + T +
conA (cpm)
(pos. control)
6.1A 7d DCs 189±23 2901226 616175 8092213368
6.1B 146±33 133127 274178 2044712983
6.1C it 4621153 328126 494148 6049017945
6.1D n 1693+366 18181162 600111682 6102214113
6.1E 11 257120 370111 8371145 6591413431
6.1F 11 332159 223116 958161 3744614926
Figure 6.1 Day 7 OVA323-339-pulsed DCs from FITC-treated mice
stimulate similar levels of CD4+ DO11.10 T cell proliferation as DCs from
PBS control mice. Freshly isolated CD11c+-enriched DCs (3 x 104 cells/well) from Day
7 mice were pulsed for two hours with OVA323-339 peptide, washed, then cultured in round-
bottom 96-well plates with CD4+ DO11.10 T cells (1 x 105 cells/well). After three days,
[3H]thymidine (1 pCi/well) was added for the final 18 hours of culture to assess T cell
proliferation, depicted as counts per minute (cpm). The data shown are the mean ± SEM of
minimum triplicate wells from six independent experiments. Control values are shown in the
accompanying table.
*p<0.04 (A), p<0.02 (B) as compared to paired PBS value, by paired Student's f-test.
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6.2.1.2 Six Week DCs
OVA323-339-pulsed CD11 c+-enriched DCs isolated from mouse lungs six weeks after
the first dose of FITC were cultured together with DO 11.10 CD4+ T cells. These
DCs appeared to be less efficient at stimulating T cell proliferation than those
isolated from PBS-treated mice (Figure 6.2). This trend was repeated in all five
separate experiments, although statistical significance was only seen in one of those
(Figure 6.2A, p<0.01).
6.2.1.3 2nd Dose + 7 Day DCs
CD1 lc+-enriched DCs isolated from FITC-treated mice one week after a second dose
of FITC induced less CD4+ T cell proliferation than DCs from the lungs of PBS
control mice at the same time point (Figure 6.3). Although the difference between
the two groups was not significant, this trend was consistent in four out of five
individual experiments, while the fifth showed no difference between groups
(Fig.6.3D).
6.2.1.4 2nd + 6 Week DCs
At six weeks after the second dose of FITC, OVA323-339-pulsed CD1 lc+-enriched
DCs from mouse lungs did not stimulate CD4+ DO 11.10 T cells to proliferate
significantly more or less than DCs from the lungs of PBS control mice at the same
time point in three out of four T cell proliferation assays (Figure 6.4B,C,D). In only
one experiment, DCs from FITC-treated lungs stimulated significantly less T cell
proliferation than DCs from PBS control lungs (Fig.6.4A, p<0.008), and as such this

































APC + T +
BSA (cpm)
(neg. control)
APC + T +
conA (cpm)
(pos. control)
6.2A 6wk DCs 1064±110 1735+87 2468+181 15043+3959
6.2B 11 1471±415 1071+116 1240+227 11838+2095
6.2C ct 2251+182 3315+1033 1989+633 43043+4932
6.2D u 1426±239 2866+1235 2452+269 16333+2299
6.2E (i 678±91 877+79 643+157 17498+1609
Figure 6.2 Week 6 OVA323-339-pulsed DCs from FITC-treated mice
stimulate less CD4+ DO11.10 T cell proliferation than DCs from PBS
control mice. Freshly isolated CD11c+ enriched DCs (3 x 104 cells/well) from six week
mice were pulsed for two hours with OVA323-339 peptide, washed, then cultured in round-
bottom 96-well plates with CD4+ DO11.10 T cells (1 x 105 cells/well). After three days,
[3H]thymidine (1 pCi/well) was added for the final 18 hours of culture to assess T cell
proliferation, depicted as counts per minute (cpm). The data shown are the mean ± SEM of
minimum triplicate wells for five independent experiments. Control values are shown in
accompanying table.












































































APC + T +
BSA (cpm)
(neg. control)
APC + T +
conA (cpm)
(pos. control)
6.3A 2na+7d DCs 4705+1565 5841±262 6248±681 64283±12420
6.3B " 3700±712 4402±1784 4071±590 63477±8993
6.3C " 2075±1745 2344±638 4992±799 39593±9835
6.3D " 2098±367 3632±880 2230±86 35536±6130
6.3E u 3428±745 3977±94 3106±425 25369±815
Figure 6.3 2nd Dose + 7 Day OVA323-339-pulsed DCs from FITC-treated
mice stimulate less CD4+ DO11.10 T cell proliferation than DCs from
PBS control mice. Freshly isolated CD11c+-enriched DCs (3 x 104 cells/well) from 2nd
Dose + 7 Day mice were pulsed for two hours with OVA323-339 peptide, washed, then cultured
in round-bottom 96-well plates with CD4+ DO11.10 T cells (1 x 105 cells/well). After three
days, [3H]thymidine (1 pCi/well) was added for the final 18 hours of culture to assess T cell
proliferation, depicted as counts per minute (cpm). The data shown are the mean ± SEM of
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APC + T +
BSA (cpm)
(neg. control)
APC + T +
conA (cpm)
(pos. control)
6.4A 2nd+6wk DCs 2084±357 2288+137 29581428 1859812500
6.4B
"
1398±182 743173 19291129 2281814576
6.4C " 35651546 35611105 37321537 107245112921
6.4D
u
2183183 22981873 599211071 2614317765
Figure 6.4 2nd Dose + 6 Week OVA323-339-pulsed DCs from FITC-treated
mice stimulate similar levels of CD4+ DO11.10 T cell proliferation as
DCs from PBS control mice. Freshly isolated CD11c+-enriched DCs (3 x 104
cells/well) from 2nd Dose + 6 Week mice were pulsed for two2 hours with OVA323-339 peptide
and, washed, then cultured in round-bottom 96-well plates with CD4+ DO11.10 T cells (1 x
105 cells/well). After three days, [3H]thymidine (1 pCi/well) was added for the final 18 hours
of culture to assess T cell proliferation, depicted as counts per minute (cpm). The data
shown are the mean ± SEM of minimum triplicate wells of four independent experiments.
Control values are shown in the accompanying table.
*p< 0.008 as compared to paired FITC value, by paired Student's f-test
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6.2.1.5 2nd Dose + 14 Week DCs
In three out of five separate experiments, OVA323-339-pulsed CDllc+-enriched DCs
from the lungs of mice isolated 14 weeks after the second dose of FITC were poorer
stimulators of CD4+ DOl 1.10 T cell proliferation than DCs from PBS control mice at
the same time point (Figure 6.5A,C,E). In one of these experiments, the difference
between groups was statistically significant (Fig6.5A, p<0.04). Again, however, this
can only be identified as a trend as the remaining two experiments for this time point




















































APC + T +
BSA (cpm)
(neg. control)
APC + T +
conA (cpm)
(pos. control)
6.5A 2nd+14wk DCs 3322±1554 345011682 27961705 2161815635
6.5B
u
2239±396 29071254 29251445 136614112473
6.5C " 1848±695 18311382 24571768 78617122997
6.5D " 13321230 15151235 14411153 2986012961
6.5E M 1332+21 22881401 2340+216 4002514789
Figure 6.5 2nd Dose + 14 Week OVA323-339-pulsed DCs from FITC-
treated mice stimulate similar levels of CD4+ DO11.10 T cell proliferation
as DCs from PBS control mice. Freshly isolated CD11c+-enriched DCs (3 x 104
cells/well) from 2nd Dose + 14 Week mice were pulsed for two hours with OVA323.339 peptide,
washed, then cultured in round-bottom 96-well plates with CD4+ DO11.10 T cells (1 x 105
cells/well). After three days, [3H]thymidine (1 pCi/well) was added for the final 18 hours of
culture to assess T cell proliferation, depicted as counts per minute (cpm). The data shown
are the mean ± SEM of minimum triplicate wells of five independent experiments. Controls
are shown in the accompanying table.
*p< 0.04 as compared to paired FITC value, by paired Student's Ftest.
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6.2.1.6 Combined DC Results
As it was difficult to see a trend between time points, and because of the variation in
cpm between experiments, a method of normalising the data was developed in order
to compare the results of the T cell proliferation assays (Figure 6.6). For each
experiment, proliferation (cpm) for the replicate wells was averaged to obtain a final
value. This was done for wells containing DCs from both PBS- and FITC-treated
mice. The final FITC count was subtracted from the final PBS count, and this value
was expressed as either a positive or negative percentage of the PBS value. All the
percentages for each experiment were then combined to obtain a final percentage,
indicative of the percentage of the greater or reduced T cell proliferation induced by
DCs from FITC-treated mice as compared to those from PBS control mice. This
process was repeated for the acute Day 7 time point, and for each of the long-term
time points.
At Day 7 after the first FITC dose, DCs from the lungs of FITC-treated mice
stimulated, on average, more T cell proliferation than DCs from PBS control mice.
By six weeks, however, this trend changed dramatically, with FITC DCs stimulating
less proliferation than PBS DCs. This difference between the two time points was
significant (p<0.03). One week after the second dose of FITC was administered,
FITC DCs again stimulated less T cell proliferation than PBS DCs, although their
ability to stimulate the T cells had improved. Six weeks after the second FITC dose,
FITC and PBS DCs had similar abilities to stimulate T cell proliferation, although
FITC DCs were still not as efficient. Finally, 14 weeks after the second dose of
FITC, although not significant, the efficiency of FITC DCs as T cell proliferation
stimulators had dropped dramatically, nearing the six week levels.
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Figure 6.6 Difference in ability of CD11c+-enriched DCs from the lungs
of FITC-treated mice to stimulate T cell proliferation at different time
points, expressed as a percentage of the value for DCs from PBS
control mice. Freshly isolated CD11c+-enriched DCs (3 x 104 cells/well) from mice at
each time point were pulsed for two hours with OVA323.339 peptide, washed, then cultured in
round-bottom 96-well plates with CD4+DO11.10 T cells (1 x 105 cells/well). After three days,
[3H]thymidine (1 pCi/well) was added for the final 18 hours of culture to assess T cell
proliferation, and was measured as counts per minutes (cpm). For each separate
experiment, the combined cpm from replicate wells with DCs from FITC-treated mice was
subtracted from the combined cpm from those with DCs from PBS-treated mice. This value
was then expressed as a percentage of the PBS cpm, and all percentages were then
combined to obtain the final value shown above. These calculations were made for each
time point (7d, n=6 separate experiments; 6 wks, n=5; 2nd+7d, n=5; 2nd+6wks, n=4;
2nd+14wks, n=5).
*p<0.03 by Student's Mest.
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6.2.2 BAL Alveolar Macrophages
The T cell proliferation was much lower in all experiments using BAL AMs than
they were in experiments using DCs. This finding is consistent with reports in the
literature of AMs being less efficient at stimulating T cell proliferation than lung
DCs [181,486], although it must be noted that AMs were not cultured with GM-CSF
as were the DCs, which may have also been a factor in the lower stimulating abilities
of the AMs.
6.2.2.1 Day 7 BAL AMs
There was no significant difference in the abilities of OVA323-339-pulsed BAL AMs
from FITC- or PBS-treated mice to stimulate DO11.10 T cells to proliferate (Figure
6.7). This statement is based on the results from only two independent experiments,
however, and ideally should be repeated to determine if this is, in fact, the trend.
6.2.2.2 6 Week BAL AMs
Interestingly, OVA323-339-pulsed AMs isolated from the BAL fluid ofmice six weeks
after the first FITC dose were more efficient at stimulating DO11.10 T cells to
proliferate than AMs from PBS control mice at the same time point (Figure 6.8).



















PBS FITC PBS FITC







APC + T +
BSA (cpm)
(neg. control)
APC + T +
conA (cpm)
(pos. control)
6.7A 7d AMs 462±153 328±26 657±218 11710+12657
6.7B « 2886±535 2760±310 1663±186 13959±3835
Figure 6.7 Day 7 OVA323-339-pulsed AMs from the BAL of FITC-treated
mice stimulate more CD4+ DO11.10 T cell proliferation than DCs from
PBS control mice. Freshly isolated BAL AMs (3 x 104 cells/well) from Day 7 mice were
pulsed for two hours with OVA323.339 peptide, washed, then cultured in round-bottom 96-well
plates with CD4+ DO11.10 T cells (1 x 105 cells/well). After three days, [3H]thymidine (1
pCi/well) was added for the final 18 hours of culture to assess T cell proliferation, depicted as
counts per minute (cpm). The data shown are the mean ± SEM of minimum triplicate wells






































APC + T +
BSA (cpm)
(neg. control)
APC + T +
conA (cpm)
(pos. control)
6.8A 6wk AMs 1226±144 1703±207 1655±344 15453±1479
6.8B u 1560±145 958±109 2071±320 8982±822
6.8C " 281±45 265±64 2078±219 43122±3286
Figure 6.8 Week 6 OVA323-339-pulsed AMs from the BAL of FITC-
treated mice stimulate more CD4+ DO11.10 T cell proliferation than DCs
from PBS control mice. Freshly isolated BAL AMs (3 x 104 cells/well) from six week
mice were pulsed for two hours with OVA323.339 peptide, washed, then cultured in round-
bottom 96-well plates with CD4+ DO11.10 T cells (1 x 105 cells/well). After three days,
[3H]thymidine (1 pCi/well) was added for the final 18 hours of culture to assess T cell
proliferation, depicted as counts per minute (cpm). The data shown are the mean ± SEM of
minimum triplicate wells of three independent experiments. Control values are shown in the
accompanying table.
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6.2.2.3 2nd Dose + 7 Day BAL AMs
As was seen at the six week time point for the same cells, at one week after the
second dose of FITC, OVA323-339-pulsed AMs from the BAL are more efficient
stimulators of the proliferation ofDO11.10 CD4T T cells than AMs from the BAL of
PBS-treated mice (Figure 6.9). This trend was consistent over three separate










































APC + T +
BSA (cpm)
(neg. control)
APC + T +
conA (cpm)
(pos. control)
6.9A 2na+7d AMs 1493±150 2357±807 1584±164 46167+10999
6.9B
(i
2908±471 3583±815 3907±682 41682+8127
6.9C " 1585±84 2098±367 2230±86 35536+6130
Figure 6.9 2nd Dose + 7 Day OVA323-339-pulsed AMs from the BAL of
FITC-treated mice stimulate more CD4+ DO11.10 T cell proliferation than
DCs from PBS control mice. Freshly isolated BAL AMs (3 x 104 cells/well) from 2nd
Dose + 7 Day mice were pulsed for two hours with OVA323.339 peptide, washed, then cultured
in round-bottom 96-well plates with CD4+ DO11.10 T cells (1 x 105 cells/well). After three
days, [3H]thymidine (1 pCi/well) was added for the final 18 hours of culture to assess T cell
proliferation, depicted as counts per minute (cpm). The data shown are the mean ± SEM of
minimum triplicate wells, and are representative of the trend seen in three independent
experiments. Control values are shown in the accompanying table.
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6.2.2.4 2nd Dose + 6 Week BAL AMs
Again, OVA323-339-pulsed AMs from the BAL of FITC-treated mice, at six weeks
after the second FITC dose, were more potent stimulators of CD4+ DOl 1.10 T cell
proliferation than PBS control BAL AMs at the same time point (Figure 6.10). In
two out of three separate experiments, the level of proliferation was significantly
greater with the FITC BAL AMs than with the PBS BAL AMs (Fig.6.10B, p<0.01;
Fig.6.10C, p<0.001), but as the third experiment showed no difference between the






































APC + T +
BSA (cpm)
(neg. control)
APC + T +
conA (cpm)
(pos. control)
6.1 OA 2na+6wk AMs 1639±196 2879±898 12241158 2118415181
6.10B u 2000±236 1652±255 52241926 2722312951
6.10C it 1223±130 1740±170 23611294 3420712471
Figure 6.10 2nd Dose + 6 Week OVA323-339-pulsed AMs from the BAL of
FITC-treated mice stimulate more CD4+ DO11.10 T cell proliferation than
DCs from PBS control mice. Freshly isolated BAL AMs (3 x 104 cells/well) from 2nd
Dose + 6 Week mice were pulsed for two hours with OVA323-339 peptide, washed, then
cultured in round-bottom 96-well plates with CD4+ DO11.10 T cells (1 x 105 cells/well). After
three days, [3H]thymidine (1 pCi/well) was added for the final 18 hours of culture to assess T
cell proliferation, depicted as counts per minute (cpm). The data shown are the mean ±
SEM of minimum triplicate wells of three independent experiments. Control values are
shown in the accompanying table.
*p<0.01 (B), p<0.001 (C), as compared to paired PBS value, by paired Student's t-test.
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6.2.2.5 2nd Dose + 14 Week BAL AMs
There were insufficient BAL AMs from this time point to perform more than one T
cell proliferation experiment, which showed that OVA323-339-pulsed BAL AMs from
FITC-treated mice were less efficient at stimulating T cell proliferation than BAL

















APC + T +
BSA (cpm)
(neg. control)
APC + T +
conA (cpm)
(pos. control)
6.11 2nd+ 14wk AMs 1022±240 994±194 2279±485 25361±1643
Figure 6.11 2nd Dose + 14 Week OVA323-339-pulsed AMs from the BAL of
FITC-treated mice may stimulate less CD4+ DO11.10 T cell proliferation
than DCs from PBS control mice. Freshly isolated BAL AMs (3 x 104 cells/well)
from 2nd Dose + 14 Week mice were pulsed for two hours with OVA323-339 peptide, washed,
then cultured in round-bottom 96-well plates with CD4+ DO11.10 T cells (1 x 105 cells/well).
After three days, [3H]thymidine (1 pCi/well) was added for the final 18 hours of culture to
assess T cell proliferation, depicted as counts per minute (cpm). The data shown are the
mean ± SEM of minimum triplicate wells of one experiment. Control values are shown in the
accompanying table.
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6.2.2.6 Combined BAL AM Results
The method for analysing the T cell proliferation assay results obtained from the
BAL AMs was the same as that used for the DCs (Figure 6.12). Interestingly, the
DCs and BAL AMs behaved reciprocally. At Day 7 after the initial dose of FITC,
FITC AMs induced slightly less T cell proliferation than PBS AMs at the same time
point, although this value was obtained from only two experiments. By six weeks,
although not signficant, the ability of FITC AMs to stimulate T cell proliferation had
increased dramatically. FITC AMs remained considerably more efficient at T cell
stimulation than PBS AMs at both one and six weeks after the second dose of FITC.
Only a single T cell proliferation assay was performed with BAL AMs obtained from
mice 14 weeks after the second dose of FITC, so the result can only be interpreted
with caution as several more repeats should be performed to identify any trend. This
single assay showed that at this late time point, FITC AMs were able to induce less T
cell proliferation than PBS AMs, suggesting reversal of the trend seen at previous


























Figure 6.12 Difference in ability of AMs from the BAL of FITC-treated
mice to stimulate T cell proliferation at different time points, expressed
as a percentage of the value for DCs from PBS control mice. Freshly
isolated AMs (3 x 104 cells/well) from the BAL of mice at each time point were pulsed for two
hours with OVA323-339 peptide, washed, then cultured in round-bottom 96-well plates with
CD4+ DO11.10 T cells (1 x 105 cells/well). After three days, [3H]thymidine (1 pCi/well) was
added for the final 18 hours of culture to assess T cell proliferation, and was measured as
counts per minute (cpm). For each separate experiment, the combined cpm from replicate
wells with AMs from FITC-treated mice was subtracted from the combined cpm from those
with AMs from PBS-treated mice. This value was then expressed as a percentage of the
PBS cpm, and all percentages were then combined to obtain the final value shown above.
These calculations were made for each time point (7d, n=2 separate experiments; 6 wks,
n=3; 2nd+7d, n=3; 2nd+6wks, n=3; 2nd+14wks, n=1).
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6.3 Cytokine Production
To measure cytokine protein production, supernatants were taken from the wells of
the T cell proliferation assays 72 hours after the addition of the APCs. The
supernatants were processed as described in section 2.1.2.1, and assayed by ELISA
as described in section 2.3. In many experiments, protein expression was found in
wells containing APCs from both treated and non-treated animals. The levels
measured in the wells containing APCs from PBS control animals may reflect
cytokine expression by the activated T cells or background expression by the APCs
themselves. However, since the purpose of these preliminary studies was to examine
the effect that FITC treatment had on the APCs compared to the controls, it was the
difference between the two groups that was of interest.
The cytokines chosen for evaluation were firstly IL-12, a Thl-type cytokine known
to be a potent inducer of IFN-y from T cells [487], shown to attenuate bleomycin-
induced pulmonary fibrosis in mice [97], and which has the potential to switch the
response from a fibrotic Th2 phenotype to a more favourable Thl phenotype
[488,489], Secondly IL-10, a Th2-type cytokine known to be a potent inhibitor of
IL-12 production [490], and whose expression is thought to be delayed compared to
that of IL-12 in vivo, making it a possible downregulator of the IL-12 response [491],
IL-10 produced by lung DCs has also been shown to mediate tolerance induced by
respiratory exposure to antigen [492], and AMs have been shown to have increased
expression of the IL-10 gene in interstitial lung disease [86]. Thirdly, supernatants
were analysed for the presence of IFN-y, a Thl-type cytokine known to have
profound suppressive effects on the production of ECM proteins [247], has been
shown to ameliorate effects of bleomycin-induced fibrosis in mouse lungs [255], and
has been used in preliminary clinical trials as a treatment for CFA [103,493], Finally
IL-13, which has similar biological properties to IL-4, and has been implicated in the





Seven days after the first dose of FITC, supernatants taken from wells to which
CD1 lc+-enriched DCs from FITC-treated mice were added ("FITC DC
supernatants") had significantly more IL-13 protein than supernatants from wells to
which CD1 lc+-enriched DCs from PBS-treated mice were added ("PBS DC
supernatants") (p<0.0006, n=9) (Figure 6.13). At six weeks after the first dose,
levels of cytokine expression were much lower, and there was no significant
difference between either group of supematants. Seven days after the second dose of
FITC, a significant difference was seen between the two groups again, with protein
levels in the FITC DC supernatants again being higher (p<0.05, n=13), and at six
weeks after the second FITC dose (p<0.04, n=15). The trend continued at 14 weeks
after the second dose, although the difference in IL-13 expression between the two
groups of supernatants was not significant.
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Figure 6.13 IL-13 protein production in supernatants from T cell
proliferation assays containing CD11c+-enriched DCs. T cell proliferation
assays were prepared as described. In each separate experiment, after 72 hours in culture,
0.2 ml of supernatant was removed from each well, centrifuged to remove any remaining
cells, and protein expression was measured by ELISA. "PBS" = supernatant from wells to
which CD11c+-enriched DCs from PBS-treated mice were added. "FITC" = supernatant from
wells to which CD11c+-enriched DCs from FITC-treated mice were added. (Day 7,
*p<0.0006, n=9; 6 Weeks, n=12; 2nd Dose + 7 Days, *p<0.05, n=13; 2nd Dose + 6 Weeks,
*p<0.04, n=15; 2nd Dose + 14 Weeks, n=9).




No significant difference was seen in IFN-y protein expression between Day 7 FITC
or PBS DC supernatants (Figure 6.14) but six weeks after the first FITC dose, PBS
DC supernatants had higher levels of the cytokine than FITC DC supernatants
(p<0.002, n=T7). By seven days after the second dose of FITC, however, this trend
was reversed with significantly more IFN-y found in the FITC DC supernatants than
in the PBS DC supernatants (p<0.05, n=13), and was continued at six weeks after the
second dose (p<0.03, n=15), and at 14 weeks after the second dose, although the
difference at this time point was not significant.
6.3.1.3 DCs: IL10, IL-12p70
No IL-10 or IL-12p70 protein was found in the supernatants of wells to which DCs
from FITC- or PBS-treated DCs were added.
223
Figure 6.14 IFN-y protein production in supernatants from T cell
proliferation assays containing CD11c+-enriched DCs. T cell proliferation
assays were prepared as described. In each separate experiment, after 72 hours in culture,
0.2 ml of supernatant was removed from each well, centrifuged to remove any remaining
cells, and protein expression was measured by ELISA. "PBS" = supernatant from wells to
which CD11c+-enriched DCs from PBS-treated mice were added. "FITC" = supernatant from
wells to which CD11c+-enriched DCs from FITC-treated mice were added. (Day 7, n=9; 6
Weeks, *p<0.002, n=17; 2nd Dose + 7 Days, *p<0.05, n=13; 2nd Dose + 6 Weeks, *p<0.03,
n=15; 2nd Dose + 14 Weeks, n=11).





Supernatants from T cell proliferation assays containing BAL AMs were only
available for the 6 Weeks, 2nd Dose + 7 Days, and 2nd Dose + 6 Weeks time points
for the IL-13 assays (Figure 6.15). At six weeks after the first dose, although very
little protein is present (lower detection limit of the R&D IL-13 ELISA is 39.1
pg/ml), the supernatants from wells to which BAL AMs from FITC-treated mice
were added ("FITC AM supernatants") expressed significantly more IL-13 protein
than supernatants from wells to which BAL AMs from PBS control mice were added
("PBS AM supernatants") (p<0.03, n=15). At the next two time points, however, at
seven days and six weeks after the second dose of FITC, no difference was seen
between the two groups of supernatants.
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6 Weeks .n 2nd Dose + 7 Days
pbs Frrc
Figure 6.15 IL-13 protein production in supernatants from T cell
proliferation assays containing BAL AMs. T cell proliferation assays were
prepared as described. In each separate experiment, after 72 hours in culture, 0.2 ml of
supernatant was removed from each well, centrifuged to remove any remaining cells, and
protein expression was measured by ELISA. "PBS" = supernatant from wells to which
CD11c+-enriched DCs from PBS-treated mice were added. "FITC" = supernatant from wells
to which CD11c+-enriched DCs from FITC-treated mice were added. (6 Weeks, *p<0.03,
n=15; 2nd Dose + 7 Days, n=6; 2nd Dose + 6 Weeks, n=9).
*Statistical significance as compared to paired PBS value, as determined by paired Student's
f-test.
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6.3.2.2 BAL AMs: IFN-y
PBS and FITC AM supernatants were available for the 6 Weeks, 2nd Dose + 6
Weeks, and 2nd Dose + 14 Weeks time points only. At six weeks after the first dose
of FITC, and at six weeks after the second dose, no significant difference was seen
between the FITC AM and PBS AM supernatants (Figure 6.16). At 14 weeks after
the second dose, however, PBS AM supematants had significantly more IFN-y
protein than FITC AM supernatants (p<0.04, n=3), although it should be noted that
this result was based on fewer experiments than the other time points.
6.3.2.3 BAL AMs: IL-10, IL-12
No IL-10 or IL-12p70 protein expression was detected in FITC or PBS, DC or AM
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Figure 6.16 IFN-y protein production in supernatants from T cell
proliferation assays containing BAL AMs. T cell proliferation assays were
prepared as described. In each separate experiment, after 72 hours in culture, 0.2 ml of
supernatant was removed from each well, centrifuged to remove any remaining cells, and
protein expression was measured by ELISA. "PBS" = supernatant from wells to which
CD11c+-enriched DCs from PBS-treated mice were added. "FITC" = supernatant from wells
to which CD11c+-enriched DCs from FITC-treated mice were added. (6 Weeks, n=15; 2nd
Dose + 6 Weeks, n=9; 2nd Dose + 14 Weeks, p<0.04, n=3).
*Statistical significance as compared to paired FITC value, as determined by paired
Student's f-test.
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6.4 Conclusions and Discussion
6.4.1 DCs in T Cell Proliferation Assays
Much of the available functional data on DCs in the lung has been obtained from
studies of asthma, which is regarded as a Th2-mediated disease. As discussed in
detail in Chapter 1, these functional studies have revealed that while DCs have
inherent Thl-promoting activity [495-498], DCs at mucosal surfaces such as the lung
induce responses that are polarised towards Th2-type immunity [499-502], possibly
because the uptake and subsequent presentation of antigen by the airway DCs occurs
within an environment rich in IL-10 and PGE2, which are known to suppress IL-12
production, a Thl cytokine, in DCs [165,503].
There is no published data on the in vitro functional abilities of lung DCs from a
fibrotic environment, so while the experiments presented in this chapter are
preliminary, they provide insight into this neglected area.
6.4.1.1 FITC DCs May Be Less Efficient In Vitro T Cell Stimulators
The results of the T cell proliferation assays evaluated singly at each time point
suggest a trend for FITC DCs to be less efficient T cell stimulators than PBS DCs
from control mice (Figures 6.1-5). When the results from each time point were
calculated as the difference between the two groups (PBS-FITC) and expressed as a
percentage of the PBS value, and then combined, this trend became more prominent
(Figure 6.6). At all time points, with the exception of Day 7, FITC DCs stimulated
less T cell proliferation than PBS DCs. At Day 7 this trend was reversed, and there
was a significant difference between this time point and the 6 Week time point. It
would appear that it is only once the acute phase has passed that FITC DCs become
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less efficient T cell stimulators, as the difference was greatest at six weeks after the
first dose and at 14 weeks after the second dose.
There could be several explanations as to why FITC DCs present antigen less
efficiently. Certainly this could be a protective mechanism as it would prevent local
maturation of DCs leading to increased T cell activation and subsequent damage. As
discussed in Chapter 1, murine DCs have been classified into two subsets: mature
(DC1) and immature (DC2), although it is not clear if these cells are derived from
one common progenitor, or if they represent two distinct lineages. The mature DCs
express high levels ofMHC class II on their surface and produce IL-12, which drives
Thl differentiation. The immature DCs express low levels of MHC class II and
produce IL-10, which favours Th2 differentiation [171]. Resting, steady-state lung
DCs preferentially prime for low-level Th2 immunity, and under normal
circumstances, this response would be expected to resolve towards a protective Thl
response as antigen exposure continued unless, as in the case of some allergic
responses, incomplete immune deviation leads to a persistent pathogenic Th2
response [165], Therefore, FITC DCs may be held in the "DC2" lineage,
maintaining their immature status, and thus their poor T cell stimulatory abilities in
vitro, and contributing to the continuing pathogenic Th2 response in vivo.
In addition, the potent capacity of DCs to activate immunologically naive T cells is
related to their high constitutive expression of MHC class II and T cell costimulatory
molecules, such as CD40, CD80 and CD86. Deficiency or absence of expression of
these molecules reduces the antigen presenting function of DCs, and may render
them potentially tolerogenic; presentation of antigen to T cells by APCs in the
absence of costimulatory molecules induces T cell anergy [485], Studies of tolerance
have shown that immature DCs, expressing low levels of CD86, are able to induce
tolerance [504], and thus the FITC DCs may also be maintained in a tolerogenic
state. Thus, nontolerogenic DCs may become tolerogenic in FITC-induced fibrosis
by blocking their ability to provide costimulatory signals, by modification with
suppressive cytokines such as IL-4 [505], or TGF-(3 which has been shown to induce
tolerance in splenic DCs [178], or by preventing their maturation.
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However, the DCs isolated from the lungs of treated and control mice for these
experiments were exposed to GM-CSF overnight before contact with the T cells.
GM-CSF matures DCs, and leads to a marked increase in their overall potency as
APCs [149,165,479], yet the FITC DCs appeared to respond poorly to GM-CSF in
vitro. As the mucosal immune system has a unique immunological milieu that acts,
in part, via the DCs to induce different T cell phenotypes, the following question has
arisen: does the milieu act to irreversibly differentiate DCs or are the DCs
tolerogenic only in the mucosal environment [506]? It would appear, from the
results discussed in this section, that the immunological milieu induced by the
instillation of FITC prevents the DCs from maturing, irreversibly differentiates them,
or perhaps induces a permanent, or long-term, tolerogenic effect. At the very least,
the FITC DCs are being altered in this fibrotic milieu in such a way as to be
unresponsive to GM-CSF.
A variety of experimental systems have provided evidence for the supposition that
immunological homeostasis in the lung and airways is maintained primarily by
endogenous immunosuppressive mechanisms that regulate local induction of T cell
responses [507], NO secretion by the AMs is thought to be a major contributing
factor in this phenomenon [194]. AMs can also downmodulate the antigen-
presenting capacities of DCs in the bronchial and alveolar environment [196], In
mice, NO production by AMs is the major source of the downmodulation of both T
cells and DCs [508]. Interestingly, production of NO by AMs has been shown to
inhibit the ability of lung DCs to respond to maturation factors such as GM-CSF,
thus essentially holding them in an immature state in terms of T cell stimulating
activity [182,195], NO-mediated suppression of DC function may also contribute to
the Th2-promoting activity of lung epithelial DCs, a notion consistent with the
proposed Th2-promoting activity of this mediator [163,509]. Thus, in the FITC-
treated mice, the production of NO by the AMs could be either terminally
differentiating them to a DC2 phenotype, or otherwise maintaining them in this state,
thereby decreasing their T cell stimulating abilities and contributing to the
pathogenic Th2 response in the lungs, and thus rendering them unable to respond to
the GM-CSF in vitro.
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Interestingly, although there are many similarities between the Th2-driven asthma
response and CFA, and indeed, NO has also been implicated in the pathogenesis of
asthma [510,511], the hypothesis presented above is in direct contrast to a proposed
scenario for the aetiology of asthma which suggests that unregulated in situ
maturation of respiratory tract DC functional activity may lead to excessive T cell
activation within the airway mucosa, and to damaging local pathology [163,164],
Another possibility is the idea proposed by Stein et al. [512] of alternative activation,
in which APCs can participate in anti-inflammatory processes, tolerance and healing.
Although this was originally applied to macrophages, it has been suggested that DCs
may also be alternatively activated and may be induced to exert suppressive effects
[513], IL-10-treated immature DCs induce tolerance in naive T cells, and IL-10
induces tolerance in vivo [514], Although IL-10 was not detected in the
supernatants, it may well be present in the tissues.
Finally, CD80 and CD86 have been shown to play a role in allogeneic T cell
proliferation by murine lung DCs, with CD80 being the more crucial costimulatory
molecule, as anti-CD80 antibody was more suppressive of T cell proliferation in a
mixed lymphocyte reaction than anti-CD86 antibody [154], Also, CD80 and CD86
appear, in some models, to have different roles in skewing T cells towards a Thl or
Th2 response. For example, Kuchroo et al. [515] and Freeman et al. [516] showed
that CD86 more effectively directed the differentiation of T cells toward a Th2-like
phenotype, where CD80 favoured Thl development. Masten et al. [154] suggest that
by using CD80 as a dominant costimulatory ligand, lung DCs normally favour the
development of a Thl response over a Th2 response in the lung after injury.
Therefore, in a pathogenic state like pulmonary fibrosis, if CD80 expression were
being suppressed a Th2 response would predominate, and in vitro T cell proliferation
would be decreased. Phenotyping the FITC and PBS lung DCs would be necessary
to explore this possibility.
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6.4.1.2 FITC DCs May Polarise T Cells Towards a Th2-type Response /n
Vitro
Cytokine measurements of supematants taken from the T cell proliferation assays
revealed that FITC DCs induced T cells to produce more IL-13 protein, a Th2
cytokine, than PBS DCs (Figure 6.13). This trend was seen at all time points, with
the exception of week six, and was significant at seven days after the first dose, and
seven days and six weeks after the second dose. It is possible that FITC does induce
DCs to polarise T cells to produce increased amounts of IL-13, but that while one
dose was not sufficient to sustain this effect, the second dose induced a longer-lasting
effect. This may be due to the complexity of the in vivo cytokine microenvironment
in which APCs, lymphocytes, lung epithelial cells and fibroblasts all contribute.
As discussed in Chapter 1, IL-13 has been implicated in the pathogenesis of asthma,
which is a Th2-mediated disease, causing subepithelial airway fibrosis [79,333,517].
IL-13 is also a potent stimulator of fibroblast proliferation and collagen production in
vitro [332,335], and its potential as a mediator of CFA progression is being
recognised.
Lee et al. [91], using a transgenic CC10-IL-13 mouse in which the overexpression of
IL-13 causes airway and parenchymal fibrosis, demonstrated that the fibrotic effects
of IL-13 are mediated to a great extent by its ability to selectively induce and activate
TGF-(31 in the lung. Although macrophages were the major site of production and
deposition in the tissue, TGF-pi mRNA and protein were also found in bronchiolar
epithelial cells, alveolar type II cells, and eosinophils.
Further studies by this group [494] assessed the roles of MCP and its major receptor,
CCR2, in the effector pathways of IL-13. They demonstrated that IL-13 is a potent
inducer of MCPs in vivo, although this stimulation is not MCP-specific. They
showed that many of the features of IL-13 overexpression in the lung, including
inflammation, hyaluronic acid accumulation, pulmonary fibrosis and respiratory
failure and death are mediated by mechanisms that are, at least partially, CCR2-
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dependent, indicating that MCP-mediated signaling via CCR2 plays a key role in the
pathogenesis of IL-13-induced inflammatory, fibrotic and proteolytic effector
responses in vivo. Additionally, they reported that the diminished fibrogenic and
hyaluronic acid stimulating effects of IL-13 in the absence of CCR2 are associated
with the diminished production and activation of TGF-(31, thus demonstrating that
CCR2 signaling is a critical event in cytokine induction and activation of TGF-pi in
vivo.
Interestingly, specific CCR2 signaling has been shown to promote a profibrotic
cytokine cascade in the original single dose surgical model of FITC-induced
pulmonary fibrosis [62], and the authors speculate that alterations in TGF-P may
contribute to the protection conferred to mice in the absence of CCR2 signaling.
Finally, both IL-13 and C-10, a novel C-C chemokine that is chemotactic for
mononuclear phagocytes, are increased in the pathogenesis of bleomycin-induced
pulmonary fibrosis [102], IL-13 is a potent inducer of C-10 in vivo, and
neutralisation of C-10 attenuated bleomycin-induced pulmonary fibrosis and
intrapulmonary macrophage numbers. Belperio et al. [102] suggest, therefore, that
IL-13 has a profibrotic role in the development of pulmonary fibrosis that is
independent of its known direct effects on fibroblasts, and is evidence for a
cooperative interaction between Th2 cytokines and specific C-C chemokines.
IL-10 and IL-12 were not detected in the supernatants from the T cell proliferation
assays, but interestingly production of IFN-y, a Thl cytokine, was increased in the
wells containing FITC DCs (Figure 6.14). As IFN-y was not detected in the BAL
fluid, it demonstrates that these two environments are not reflective of each other.
The increase was significant at one week and six weeks after the second FITC dose,
and the trend present at seven days after the first dose and 14 weeks after the second
dose. As with IL-13, the trend was not seen at six weeks after the first dose of FITC,
confirming the requirement for a second dose of FITC in this model. Although this
result may seem contradictory to the IL-13 production, possibly increased IFN-y
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production in vivo may be a secondary response in an attempt to balance the
increased Th2-type response to FITC.
Another possibility could be drawn from Rissoan et al. [168] who have described a
negative feedback mechanism to maintain the balance between Thl and Th2
responses. They demonstrated that IFN-y seemed to promote the survival and
maturation of DC2 cells. If, however, the FITC DCs are being held in a constant
immature state by NO production that overrides that aspect of IFN-y regulation,
perhaps the IFN-y acts solely to promote the survival of the DC2s, thus contributing
to the ongoing Th2-like response.
Finally, the production of IFN-y could be a feature unique to the FITC model. Sime
and O'Reilly [6] observe that although Th2 cytokines are important in the
development of fibrosis in CFA, and models of the disease suggest a shift in the
cytokine response towards a Type 2 response, this response clearly does not occur in
isolation, and is certainly more complex than initially appreciated. Therefore, it is
not surprising that Type 1 cytokines have been identified in fibrotic conditions.
Indeed, increased IFN-y production by lymphocytes has been noted in a mouse
model of silicosis [205], Additionally, IFN-y production has been found in
bleomycin-induced pulmonary fibrosis in C57BL/6J and A/J mice, but not in
bleomycin-resistant BALB/c mice, and that the potential for IFN-y to enhance
proinflammatory processes was noted [258]. BALB/c mice are susceptible to FITC-
induced pulmonary fibrosis, however, and perhaps accordingly, IFN-y production is
increased.
IFN-y production in the absence of IL-12 is curious, as IL-12 is essential for
stimulating IFN-y production [518]. Culturing lung DCs in GM-CSF, as was done in
the experiments discussed here, has been shown to shut down IL-10 mRNA
production and markedly upregulate IL-12p35 [165], However if, as suggested
previously, the DCs are resistant to maturation by GM-CSF, perhaps IL-10
production is reduced, certainly below the levels of detection for the assay used in
these experiments, but not enough to allow the upregulation of IL-12, thus explaining
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the lack of either cytokine in the cultures. Certainly, mRNA analysis of both the
DCs and T cells would provide much more information.
6.4.2 BAL AMs in T Cell Proliferation Assays
AMs are the prominent cell population obtained from the alveoli of CFA patients
[75], and it is well established that resting AMs help to create an immunosuppressive
environment in the lung that serves to limit immune response initiation, and
activation of antigen-specific T cells [126,194], Although their role in CFA
pathogenesis has been examined extensively, the focus has mainly been on cytokine
secretion by these cells.
As with DCs, although these results are preliminary, there are no available studies
examining the in vitro antigen presenting abilities ofAMs from fibrotic lungs, and so
the results of these experiments could have implications for the study ofCFA.
6.4.2.1 FITC BAL AMs May Be More Efficient In Vitro T Cell Stimulators
than PBS BAL AMs
The [3FI]thymidine incorporation, which reflects T cell proliferation, for all
experiments involving BAL AMs were considerably lower than those involving DCs.
This correlates well with published data showing that DCs are far superior at
stimulating T cell proliferation than BAL AMs [181,486], however as mentioned
previously, the lack of GM-CSF in the overnight AM cultures may have contributed
to this effect.
Although the data sets were not complete due to insufficient numbers of cells, the
results from the single experiments performed at each time point suggested a trend
for BAL AMs from FITC-treated mice to be more efficient T cell stimulators than
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PBS BAL AMs (Figures 6.7-11). This trend, reciprocal to that of the DCs, was
confirmed when the data were analysed as described above, in order to compare
between groups, although there were no significant differences (Figure 6.12). The
first and last time points, however, would need to be repeated in order to make
conclusive remarks regarding the results.
Despite their apparent end-stage differentiation state, AMs can express markers
thought to be rather specific for DCs [131]; indeed, in the interstitial lung disease
sarcoidosis, AMs express high levels of CD86 and CD40 [192], just as do mature
DCs. Similar changes have been found in mice when AMs were exposed to
bleomycin [193], GM-CSF is produced by several cell types in the lung (activated T
cells, epithelial cells, fibroblasts) and modulates the cytokine production ofAMs and
enhances their antigen-presenting capacity [75], although as discussed in Chapter 1,
its role in the pathogenesis of pulmonary fibrosis is controversial [300-303,305].
Therefore, if GM-CSF expression is upregulated in the lungs of FITC-treated mice, it
could be inducing high levels of costimulatory molecules on the AMs, resulting in
higher levels of T cell proliferation than induced by PBS control AMs, while the DCs
appeared to be resistant to the effects of this cytokine.
Another possibility to explain the increased T cell stimulatory abilities of FITC BAL
AMs could be related to the increased levels of IFN-y detected in the FITC-treated
mice. IFN-y is produced by lymphocytes and is able to activate macrophages
[519,520]. If this were the case, then the enhanced T cell-stimulating abilities of the
FITC BAL AMs would be a feature limited to the FITC model.
Finally, as described for the DCs, the concept of alternative activation of BAL AMs
could provide an explanation for the results described in this section. Stein et al.
[512] found that alternatively activated macrophages express a special set of
molecules that enables them to actively participate in anti-inflammatory processes,
tolerance induction, and healing. As such, they found that IL-4 enhanced the
capacity of macrophages for endocytosis and antigen presentation. Measurement of
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levels of this cytokine in the supernatants from these T cell proliferation assays may
be revealing, as would testing the hypothesis with the closely-related IL-13.
6.4.2.2 FITC BAL AMs May Polarise T Cells Towards a Th2-type
Response In Vitro
Although the results from the measurement of IL-13 in the supernatants from T cell
proliferation assays with BAL AMs do not form a complete data set, and are
preliminary due to insufficient cell numbers, they suggest that BAL AMs do
contribute to polarising the T cells towards a Th2 response by inducing IL-13
production in the T cells, but that this contribution may be transitory (Figure 6.15).
This would need to be confirmed by measuring IL-13 production at seven days after
the first FITC dose, and at 14 weeks after the second dose.
As with the DCs, no IL-10 or IL-12p70 production was detected in the supernatants.
IFN-y production however, was detected, although only the time points at six weeks
after the first FITC dose, and at six and 14 weeks after the second dose were
evaluated (Figure 6.16). No difference between the FITC- and PBS-treated groups
was detected at the first two time points evaluated, but at 14 weeks after the second
dose, BAL AMs from FITC-treated mice stimulated significantly less IFN-y
production than those from PBS-treated mice. Although the time points for seven
days after the first dose and seven days after the second dose need to be evaluated,
this result correlates with the lack of IL-12 production, and suggests that the Th2
polarisation in FITC-induced pulmonary fibrosis is still important even in the late
stages of the disease.
6.4.3 Future Directions for DC and BAL AM Work
The results of the experiments reported in this chapter show that while FITC DCs
stimulated less T cell proliferation than PBS DCs, FITC BAL AMs were better
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stimulators. As discussed above, the increased stimulating abilities of the FITC BAL
AMs could be explained by the cytokine milieu, possibly by the presence of IFN-y or
GM-CSF [75,86,287,519,520]. The FITC DCs however, have been altered by the
FITC environment in a fashion not reversible, or only partially reversible, by in vitro
culture with GM-CSF. This may be a terminally differentiated state, or related to
tolerance. Thus, the cytokine milieu affecting the BAL AMs in vivo would have
little or no effect on the FITC DCs. Perhaps the most important next step is to
phenotype both freshly isolated and cultured FITC- and PBS-treated DCs and BAL
AMs to establish the pattern of upregulation of MHC class II and costimulatory
molecules.
The cytokine analyses of the supernatants from the T cell proliferation assays with
both DCs and BAL AMs indicated that the APCs were stimulating IL-13 production
by the T cells. As discussed, IL-13 is a profibrotic cytokine, that has potential as a
mediator of pulmonary fibrosis [85,91,102,336]. Neither IL-10 or IL-12 were
detected in the supernatants, but IFN-y appeared to be upregulated in the FITC DC
supernatants.
Cytokine expression analysis at the mRNA level would be extremely beneficial, as
the ELISAs used for the experiments in this section may not have been sensitive
enough to detect low levels of cytokines. This would depend, however, on being
able to obtain larger numbers of cells on which to work. It would also be interesting
to examine the T cells for the presence of IL-4, the prototypic Th2 cytokine.
In summary, the key scientific questions that remain to be answered are: are the
FITC APCs skewing the response in the FITC-induced fibrotic lungs towards a Th2
phenotype? If so, is this response dominated by either IL-13 or IL-4, or do they act
in concert? Is IFN-y upregulated in the FITC lungs, and if so, is this specific to the
FITC model? Is the poor stimulating ability of the FITC DCs a protective or a
pathogenic mechanism? And finally, if the cytokine milieu induced by FITC acts to
alter the antigen presenting capacity of DCs, what is the mechanism? These
questions could form the basis for continuing the work detailed in this chapter.
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CHAPTER 7




As discussed in Chapter 1, there are two proposed routes for the development of
CFA following injury to the alveolar epithelium: the more traditional
"inflammatory" route, or the "epithelial-fibroblastic" route, a new hypothesis
suggesting that fibrosis results from primarily epithelial injury and abnormal wound
healing with minimal contribution from inflammation [48,266]. Regardless of the
route, it is becoming increasingly apparent that injured and activated AECs both
synthesise and respond to a variety of enzymes, cytokines and growth factors,
thereby contributing to the outcome of the profibrogenic processes [266].
The alveolar epithelium consists of type I and type II epithelial cells in an almost
balanced numerical proportion. While type I cells cover approximately 90% of the
alveolar surface, type II cells represent the stem cell population [2], Following injury
and damage to, or loss of, the highly vulnerable type I epithelial cells, proliferation of
type II cells results in alveolar re-epithelialisation. The lungs of CFA patients,
however, exhibit several significant changes in the alveolar epithelium. These
include the presence of hyperplastic type II pneumocytes, microscopical areas of
epithelial denudation, and areas of honeycomb lesions lined by bronchiolar
epithelium [64], Thus, it would appear that in CFA the ability of type II alveolar
epithelial cells to restore damaged type 1 cells is seriously affected [2,64],
This chapter will present the results from a preliminary examination of the in vitro
response of two murine lung epithelial cell lines to FITC treatment. The cell line
CMT64/61 is a mouse lung carcinoma alveolar epithelial type Il-like cell line, while
mtCCl-2 cells are a murine Clara cell-like line, generated from the lungs of a
transgenic mouse expressing the SV40 large T antigen under the control of a Clara
cell-specific promoter [420], Cultured cells exposed to FITC were examined for
signs of damage, such as peeling or shape change, assessed for viability/cell death,
and the cytokine profiles were evaluated by assaying supernatants.
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7.1.1 Aims of Chapter
The principal aims of this chapter are:
• To describe the morphological in vitro effects FITC treatment had on the two
epithelial cell lines
• To examine the effects ofFITC treatment on the viability of the two cell lines
• To examine the effects of FITC treatment on the epithelial cell lines in terms
of cytokine production
• To discuss the relevance of these in vitro findings in the context of CFA
pathogenesis, and suggest directions for future in vitro study
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7.2 Confluence of Plated Cell Lines
Epithelial cells in damaged lungs are often found at varying levels of confluence, due
to denudation of the alveolar surface following injury, and the subsequent re-
epithelialisation by the type II cells [2]. Therefore, in order to gauge the response of
the epithelial cells to FITC at different levels of confluence, cells from the two cell
lines were plated at three densities each, to achieve low, moderate, and complete
confluence after overnight culture. This procedure involved trypsinising the cells, as
described in sections 2.1.4 and 2.1.5, and plating them onto 24 well tissue culture
plates containing 1 ml complete medium. CMT64/61 cells were plated at densities
of 5xl04, 105, and 5x10s cells/well, while slower-growing mtCCl-2 cells were plated
at densities of 105, 5xl05, and 105 cells/well. Plates were incubated at 37°C in 5%
CO2 overnight. Table 7.1 shows the plating densities and estimated level of
confluence achieved after overnight culture for both cell lines. Figures 7.1 and 7.2
demonstrate the level of confluence in the wells for each cell line at different plating
densities.
Cell Line Plating Density Confluence Corresponding
Figure
mtCC1-2 10s LOW: 40-50% 7.1 A
5x10a MID: 70-80% 7.1 B
10° COMPLETE: 90-100% 7.1C
CMT64/61 5x104 LOW: 30-35% 7.2A
1(f MID: 50-60% 7.2B
5x10° COMPLETE: 90-100% 7.2C
Table 7.1 Plating densities and resulting confluence of epithelial cell
lines. Cells from each cell line were trypsinsed and plated onto 24 well plates at the
densities indicated in the table. After overnight incubation at 37°C and 5% C02, confluence




Figure 7.1 Confluence of mtCC1-2 cells after overnight incubation.
Cells from the mtCC1-2 cell line were trypsinised and plated at 105 (A), 5x105 (B), or 106
cells/well (C) of a 24 well plate, and cultured overnight at 37°C in 5% C02. Confluence was
estimated visually. Original magnification x200.
B
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Figure 7.2 Confluence of CMT64/61 cells after overnight incubation.
Cells from the CMT64/61 cell line were trypsinised and plated at 5x104 (A), 105 (B), or 5x105
cells/well (C) of a 24 well plate, and cultured overnight at 37°C in 5% C02. Confluence was
estimated visually. Original magnification x200.
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7.3 FITC Damage Assays
7.3.1 Method of Damaging Cells
After overnight incubation, medium was removed from all wells, and the cells were
washed by pipetting 500 pi of warmed, serum-free medium onto the cells, swirling
the plate, and removing the medium. Next, 500 pi of serum-free medium with the
necessary additives was added to each well. Serum-free medium was used to avoid
the possibility of FITC binding to the serum proteins. These additives were: no
additives (serum-free medium alone), 1:80 dilution of DMSO, 2 pg/ml BSA as a
negative control, 0.0003% H2O2 as a positive control, and FITC, dissolved in a 1:80
dilution of DMSO, at 0.05 mg/ml, 0.1 mg/ml, and 0.5 mg/ml. This was determined
to be the optimal concentration ofDMSO as it dissolved the FITC, but did not appear
to alter the cells in any fashion. The high dose of FITC was chosen after preliminary
experiments as it caused the most visible damage without excessive cell death. The
plates were then incubated at 37°C and 5% CO2 for 30 minutes, which was sufficient
time to cause damage to the cells with the least amount of cell death, and the
solutions then removed. Cells were washed once in complete medium, and 1 ml
fresh, warmed complete medium was added to each well. The plates were then
returned to the incubator for one, 12, or 24 hours.
7.3.2 FITC Damage Assay Results
Initial FITC damage assays were performed with FITC prepared as a colloidal
suspension in PBS, as described in Appendix 1, and as used for in vivo
administration. In the cell lines, however, the FITC particulates adhered to the cells
and could not be washed off (Figure 7.3). Thus, for subsequent in vitro studies,
FITC was dissolved in DMSO before being diluted 1:80 with medium. Appropriate




Figure 7.3 FITC in colloidal suspension (0.05 mg/ml) administered to
CMT64/61 cells, after washing in an attempt to remove the FITC. fitc
was suspended in PBS and administered to the cell line as described. After 30 minutes in
culture, cells were washed to remove residual fitc. In colloidal suspension, fitc could not
be removed from the wells, and caused extensive cell death to occur (cells rounded and
lifting from wells). Original magnification x200.
7.3.3 MTS Assays for Cell Death
The CellTiter 96x AQue0us One Solution Cell Proliferation Assay (Promega
Corporation, Madison, Wisconsin, USA) is a colorimetric method for determining
the number of viable cells in proliferation or cytotoxicity assays. The MTS
tetrazolium compound is bioreduced by cells into a formazan product that is soluble
in tissue culture medium. The quantity of formazan product as measured by the
amount of 490 nm absorbance is directly proportional to the number of living cells in
culture.
After damaging the cells as described in the section above, 200 pi MTS tetrazolium
compound was added to each well after one hour, 12 hours, and 24 hours. Plates
were then incubated for a further two to three hours (manufacturer's instructions, one
to four hours). From each well, 100 pi supernatant was added and pipetted into a
single well of a 96 well plate. This was repeated a further two times for each well.
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The absorbance of each well was then read at 490 nm on a Revelation 3.04
microplate reader (Dynex Tecnologies, Billinghurst, West Sussex, UK).
7.3.3.1 FITC Reduces Viability of CMT64/61 Cells
Figure 7.4 shows that CMT64/61 cells had increased viability over time, at all
degrees of confluence. This viability was not affected by BSA, the DMSO solution
in which FITC was dissolved, or FITC solution at 0.05 or 0.1 mg/ml, at any degree
of confluence. Microscopically, there were also no visible changes apparent.
Cells at low confluence (Fig. 7.4A) showed greatly decreased viability when treated
with H2O2, and this was also seen with FITC treatment at 0.5 mg/ml. The viability of
the FITC-treated cells did not improve over time. This same pattern was seen for
cells at mid confluence (Fig. 7.4B). Microscopically, most of the cells appeared
rounded, and many had become detached from the plates (Figure 7.5).
When CMT64/61 cells had achieved complete confluence before treatment, H2O2 did
reduce viability, but only to the same extent at one hour (Fig. 7.4C). This was seen
as peeling around the edges of some of the cells, although most appeared normal.
There was reduced viability at 12 and 24 hours after treatment, but it appears that the
cells were able to recover and continue proliferating to some degree.
Microscopically, however, the cells appeared normal. FITC treatment at 0.5 mg/ml
caused slightly decreased viability at one hour, with many cells looking very rounded













































Figure 7.4 MTS assay for cellular respiration on treated CMT64/61
cells at low, mid and complete confluence. Cells were seeded into 24 well
plates at 5x104 cells/well (A), 10 cells/well (B), and 5x105 cells/well (C) and cultured
overnight at 37°C and 5% C02. Cells were treated as described, then given MTS 1 hour, 12
hours or 24 hours after treatment. Absorbance of the supernatants was then read at 490nm.
Data are representative of three separate experiments, and are presented as mean ± SEM
of triplicate wells. Med = serum-free medium alone, BSA = 2 pg/ml BSA (neg. control), H202
= 0.0003% H202 (positive control), DMSO = 1:80 dilution of DMSO in serum-free medium,
0.05F = 0.05 mg/ml FITC in DMSO/serum-free medium, 0.1F = 0.1 mg/ml FITC in
DMSO/serum-free medium, 0.5F = 0.5 mg/ml FITC in DMSO/serum-free medium.
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Figure 7.5 CMT64/61 cells at mid confluence, 12 hours after exposure
to 0.5 mg/ml FITC. Many cells appear rounded, and are no longer adherent (arrows).
CMT64/61 cells were plated at 105 cells/well in a 24 well plate and cultured overnight to
achieve a mid level of confluence as described. After washing cells in serum-free medium,
FITC solution (0.5 mg/ml in a 1:80 dilution of DMSO in serum-free medium) was applied for
30 minutes. Cells were washed again and incubated for 12 hours in medium containing
serum.
Figure 7.6 CMT64/61 cells at complete confluence, one hour after
exposure to 0.5 mg/ml FITC. Many cells appear rounded, and are no longer
adherent. CMT64/61 cells were plated at 5x105 cells/well in a 24 well plate and cultured
overnight to achieve a mid level of confluence as described. After washing cells in serum-
free medium, FITC solution (0.5 mg/ml in a 1:80 dilution of DMSO in serum-free medium)
was applied for 30 minutes. Cells were washed again and incubated for one hour in medium
containing serum.
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At 12 and 24 hours after treatment however, cell viability was again slightly reduced,
but higher than at one hour, in contrast to the low and mid levels of confluence.
Microscopically at these time points, there was still some rounding and detachment
the FITC-treated cells.
7.3.3.2 FITC Does Not Affect Viability ofmtCC1-2 Cells
The viability of mtCCl-2 cells treated at low and mid confluence levels was only
affected by H2O2 (Figure 7.7AJB). Even 24 hours after treatment, cell viability was
still low. Microscopically, most of these cells were rounded, with many to most
having detached from the wells. Treatment of these cells with FITC, however, did
not affect cell viability. At complete confluence, the addition of H2O2 had no effect
on cell viability one hour after treatment, and only slightly decreased viability at 12
and 24 hours, although no visible changes could be seen in any of the cells (Figure








































Figure 7.7 MTS assay for cellular respiration on treated mtCC1-2 cells
at low, mid and complete confluence. Cells were seeded into 24 well plates at
105 cells/well (A), 5x105 cells/well (B), and 106 cells/well (C) and cultured overnight at 37°C
and 5% C02. Cells were treated as described, then given MTS 1 hour, 12 hours or 24 hours
after treatment. Absorbance of the supernatants was then read at 490nm. Data are
representative of three separate experiments, and are presented as mean ± SEM of triplicate
wells. Med = serum-free medium alone, BSA = 2 pg/ml BSA (neg. control), H202 = 0.0003%
H202 (positive control), DMSO = 1:80 dilution of DMSO in serum-free medium, 0.05F = 0.05
mg/ml FITC in DMSO/serum-free medium, 0.1 F = 0.1 mg/ml FITC in DMSO/serum-free
medium, 0.5F = 0.5 mg/ml FITC in DMSO/serum-free medium.
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7.3.4 In Vitro FITC-treated Epithelial Cell Cytokine Production
Supernatants were collected at each time point (lh, 12h and 24h) after the damage
experiments and were assayed for the presence of GM-CSF, TNF-a, IFN-y, TGF-p,
IL-1 (3, andMlP-la as described in section 2.4.
7.3.4.1 FITC Does Not induce GM-CSF Production In Vitro
GM-CSF plays a complex role in the processes of both tissue repair and fibrosis at
epithelial surfaces [305]. Transgenic overexpression of GM-CSF in the lung results
in enhanced lung growth and alveolar type II epithelial cell hyperplasia [303],
Administration of GM-CSF-neutralising antisera to mice with bleomycin-induced
pulmonary fibrosis increases hydroxyproline deposition in the lung, while in
contrast, overexpression of GM-CSF using a recombinant replication-defective
adenoviral vector results in fibrogenesis [301]. Following bleomycin-induced lung
injury in mice, GM-CSF has a protective effect on repair processes [300,305], GM-
CSF also affects the maturation of dendritic cells and thus may affect their function
[521].
No GM-CSF protein was detected in the supernatants from the CMT64/61 cell line.
The addition of H2O2 did induce GM-CSF production in the mtCCl-2 cell line
(Figure 7.8), however treatment with FITC did not induce cytokine production at any
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Figure 7.8 GM-CSF production by mtCC1-2 cells 24 hours after
various treatments. Cells from the mtCC1-2 cell line were trypsinised and plated in 24
well plates at required densities to achieve low (105 cells/well), mid (5x10s), or complete (10b)
confluence after overnight culture, as described previously. Cells were then subjected to
various treatments and supernatants were collected after 1h, 12h or 24h and assayed for
GM-CSF protein. The figure is representative of three individual experiments. Data are
presented as mean ± SEM of triplicate wells. Med = serum-free medium alone, BSA = 2
pg/ml BSA (neg. control), Fl202 = 0.0003% H202 (positive control), DMSO = 1:80 dilution of
DMSO in serum-free medium, 0.05F = 0.05 mg/ml FITC in DMSO/serum-free medium, 0.1F
= 0.1 mg/ml FITC in DMSO/serum-free medium, 0.5F = 0.5 mg/ml FITC in DMSO/serum-free
medium.
7.3.4.2 FITC Does Not Induce TNF-a Production In Vitro
Several studies have shown that hyperplastic type II AECs in fibrotic lungs constitute
the main site of synthesis of TNF-a and TGF-p [276,277,393]. In human CFA,
compared with cells from normal lungs, TNF-a immunoreactivity is increased in
hyperplastic type II AECs lining the thickened septae, compared with cells from
normal lungs [296]. In mice, TNF-a can stimulate fibroblast replication and
collagen synthesis in vitro, and pulmonary TNF-a gene expression increases after
administration of bleomycin [220], Transgenic mice overexpressing TNF-a in
alveolar epithelium have also been shown to develop pulmonary fibrosis [292],
However, it has also been demonstrated that overexpression of TNF-a alone in
mouse lungs was unable to produce significant pulmonary fibrosis [288], In the
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context of the abnormal wound-healing model of CFA therefore, TNF-a release from
damaged AECs could have considerable profibrotic effects and be a major
contributor to the pathogenesis ofCFA [266].
No TNF-a production was detected in the supernatants from either cell line, at any
time point, with any treatment.
7.3.4.3 FITC Does Not Induce IFN-y Production In Vitro
As discussed in Chapter 1, IFN-y is a Thl-type cytokine that can be produced by type
II AECs, and may have antifibrotic effects [255,258], It inhibits fibroblast collagen
synthesis in vitro, and attenuates bleomycin-induced lung fibrosis when administered
to mice [256]. IFN-y mRNA has been shown by in situ hybridisation to be present in
human lung biopsies of patients with CFA, but the protein is not translated, as shown
by immunohistochemistry [100], Diminished IFN-y reported in patients with CFA
therefore could enhance collagen accumulation [250], This supports the suggestion
that a balance of positively and negatively regulating cytokines might modulate the
fibrotic response to injury [83].
No IFN-y protein was detected in the supematants from either cell line, at any time
point, with any treatment.
7.3.4.4 FITC Does Not Induce IL-1J3 Production In Vitro
IL-1 is an important cytokine in both acute and chronic inflammation. The IL-1 gene
family has three known constituents, of which IL-1 [3 is the most prominent in the
propagation of inflammation [306],
254
There are several human and animal studies which have demonstrated the presence
of IL-ip in chronic inflamed tissues and in tissues undergoing fibrogenesis [230,307-
309]. Adenoviral IL-ip gene transfer causing transient overexpression of IL-lp in
the epithelial cells of rodent lung induces acute inflammation with alveolar tissue
destruction resulting in progressive interstitial fibrosis, which coincides with
sustained induction of the TGF-P [306]. Together, these data could indicate a critical
role for IL-ip in the induction of acute and chronic inflammation, and potentially, in
CFA.
No IL-ip protein was detected in the supematants from either cell line, at any time
point, with any treatment.
7.3.4.5 FITC Does Not Induce MIP-1 a Production In Vitro
As discussed in Chapter 1, MIP-1a is a member of the C-C chemokine supergene
family, and has been found to be associated with interstitial lung disease [337].
There are several roles MIP-1 a could play in CFA, including recruiting and
activating macrophages which subsequently secrete profibrotic factors or it may be
directly stimulating fibroblasts to proliferate and deposit ECM [222],
No MIP-1 a protein was detected in the supematants from either cell line, at any time
point, with any treatment.
7.3.4.6 FITC Does Not Affect TGF-J31 Production In Vitro
TGF-P 1 is well known to be important in the pathogenesis of animal models of
pulmonary fibrosis and in human fibrotic lung diseases [262], In vitro, conversion of
latent to active TGF-P 1 during epithelial wound repair occurs quickly, and TGF-p 1
255
speeds epithelial repair in 16HBE 14o" bronchial epithelial-derived cells after
damage bymultiple scoring [261].
TGF-pi is a directly fibrogenic cytokine, based on studies demonstrating that TGF-
pi protein, when overexpressed locally within the lung, can lead directly to
fibrogenesis with induction of myofibroblasts, which is histologically very
reminiscent of CFA [67,272], In a study of several different interstitial lung
disorders, TGF-pi was shown to be expressed mainly in AMs in early fibrotic lungs,
characterised by inflammation and minimal fibrosis, but in advanced fibrotic
honeycomb lesions primarily seen in CFA, it was mainly present in epithelial cells
[278]. Selman et al. [48] therefore speculate that fibrosis occurs where there is
epithelial expression ofTGF-pi.
FITC treatment had no effect on the production of total (latent + active) or active
TGF-pl protein, in the supernatants from either cell line, at any time point.
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7.4 Conclusions and Discussion
The body of work presented in this chapter was a preliminary investigation into the
in vitro effects ofFITC on lung epithelial cells.
7.4.1 MTS Assays for Cell Death
The MTS assays for cell death and viability showed that for the CMT64/61 cell line,
an alveolar epithelial type II-like cell line, FITC caused the most cell death when the
cells were at low and mid confluence (Figure 7.4A, B), and this did not change over
time. At complete confluence, however, while cell viability was slightly reduced at
one hour, at 12 and 24 hours there was relatively increased viability, and
microscopically fewer cells had rounded and lifted from the plates. These results
suggest that while FITC appears able to damage and/or kill type II-like mouse lung
epithelial cells, when they are at a high level of confluence, as would be expected in
normal mouse lung, either the damaged cells are able to recover and proliferate, or
surrounding, undamaged cells proliferate in their place.
As discussed in Chapter 4, a single intratracheal dose of FITC was not sufficient to
induce pulmonary fibrosis in mice. It would therefore be interesting to administer a
second dose of FITC to the treated CMT64/61 epithelial cells to determine if they are
able to recover as efficiently as after the first dose of FITC. It would also be
beneficial to continue these studies beyond the 24 hour time point.
Interestingly, FITC treatment did not affect the cell viability or microscopic
appearance of the Clara cell-like mtCCl-2 cell line (Figure 7.7). Clara cells are the
nonciliated secretory cells lining the bronchiolar epithelium and are involved in the
repair of damaged airways [420]. It may be that Clara cells, being found higher up in
the airways, are more resistant to damage than the fragile AECs.
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The mtCCl-2 cell line appeared to be more resistant to the effects of FITC than the
type II-like cell line, suggesting that this may also be the case in vivo. While Clara
cells may contribute to the repair processes after FITC administration in vivo, these
results suggest that FITC may not affect the bronchiolar epithelium at the dose used,
but instead causes critical damage deeper in the airways at the level of the alveolar
epithelium. Future in vitro work could involve administering higher doses of FITC
to the mtCCl-2 cells and, as with the CMT64/61 cells, examining later time points
after damage.
The particulate nature of the in vivo FITC solution appeared to contribute to the
patchy nature of the disease, making it particularly relevant to the study of human
CFA. However, it was not possible to use the particulate solution of FITC on these
cells lines, as was used in the in vivo experiments, and thus it is difficult to draw
parallels between the two systems.
It is also important to note that these cell lines may not completely accurately
represent the behaviour of normal lung epithelial cells, perhaps being more
protective than in vivo cells, and these experiments would ideally be repeated on
primary cell cultures in the future.
7.4.2 Cytokine Production
Although FITC treatment did not induce the production of any of the cytokines for
which the supernatants were examined in either cell line, this avenue of investigation
is still worth pursuing. The cells were not completely unresponsive, as shown by the
production of GM-CSF from the H202-treated mtCCl-2 cell line, although further
controls, such as TNF administration, or assaying for lactate dehydrogenase, may
prove useful.
Although the cytokine assays were negative, this does not mean cytokines were not
being produced. It may be that the cytokines were simply too diluted to be detected
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by the assays used, and these experiments could be repeated while culturing the cell
lines in a lower volume of medium. Examining the supernatants at later time points
may also provide different results. Finally, mRNA analysis of the cell lines would
perhaps also be even more useful, as protein production may not necessarily reflect
expression of cytokine mRNA [101,522]. Ideally however, as mentioned above,




Final Summary and Discussion
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"If our knowledge of medicine were sufficient, the diagnostic process,
starting with assessment of the clinical symptoms and signs, should
progress through elucidation of the underlying structural abnormalities and
disturbances offunction to knowledge of the cause or causes of all these
phenomena. Unfortunately, it is only in a few contexts that knowledge is
sufficient to permit this process to be carried to completion.... "
John Guyett Scadding, 1970 [523]
This final chapter will briefly summarise the results, discuss possible implications in
terms of application to CFA, and suggest directions for future work.
8.1 Summary of Results
The following results have arisen from the work detailed in this thesis:
• A single FITC dose administered nonsurgically into the trachea was not
sufficient to induce fibrosis in BALB/c mice, but a second dose administered
six weeks after the first induced fibrosis in the majority of mice (Chapters 3
and 4).
• A single intratracheal FITC dose induced a pattern consistent with acute lung
injury that persisted for up to five days. This was characterised by acute
inflammation in the lungs that resolved by seven days after FITC
administration. Cellular infiltrate in the tissues was initially granulocytic,
becoming monocytic by Day 5 when T lymphocytes became prominent,
particularly in areas of alveolar wall oedema. Few B cells were apparent,
although at Day 7 they appeared to localise to areas with dense collections of
cells. FITC deposition had become patchy by Day 5, and was localised
around bronchi and blood vessels and in AMs (Chapter 3).
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• The method devised to score the inflammatory response confirmed that the
FITC-induced inflammation was mild initially, becoming moderate by Day 7,
as compared to the control mice (Chapter 3).
• PMNs were significantly increased in the BAL fluid from FITC-treated mice
one day after the initial FITC dose, and gradually returned to normal levels
by Day 7. TGF-P protein was expressed throughout the lung on structural
and immune cells, particularly AMs, peaking at Day 5. MHC class II+ cells
with dendritic-like processes were present and were often localised to areas of
alveolar wall oedema and cell aggregation (Chapter 3).
• Increased levels of the proinflammatory cytokine TNF-a were found in the
BAL fluid of acute phase FITC-treated mice, peaking at Day 1 and gradually
decreasing over the seven days, but were consistently higher than those of
control mice. No significant changes in EFN-y or TGF-p levels were seen in
the BAL fluid (Chapter 3).
• The long-term response to FITC, gauged from six weeks after the first dose
up to 14 weeks after the second dose, was characterised by a predominantly
mononuclear cell infiltrate after the second dose, which was present at all
subsequent time points. Fewer lymphocytes were present, although the
infiltrate still consisted mostly of T cells, with some B cells. A small number
of strongly staining MHC class if cells were evident in the tissues, and in the
B cell aggregates present from six weeks after the second dose of FITC. At
14 weeks after the second dose of FITC there were areas of severe fibrosis
with obliteration of alveolar wall architecture and large fibrous deposits next
to areas of normal tissue. Patchy FITC distribution was evident at all time
points, and was often found in conjunction with alveolar wall thickening,
fibrous tissue deposition, and B cell aggregates (Chapter 4).
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The severity of fibrosis in FITC-positive fields increased with time, as
determined by the modified Ashcroft scoring method for quantifying fibrosis
(Chapter 4).
TGF-P staining was present in the lung tissue at all long-term time points,
although at a lower intensity than at acute time points (Chapter 4).
TGF-P, fFN-y and TNF-a levels were not detected in the BAL fluid of mice
at long-term time points (Chapter 4).
Cell isolates obtained from murine lung tissue by adapting several methods
from other groups were phenotypically consistent with DCs (Chapter 5).
Although they were in a mixed population, contaminating cells did not
interfere with proliferation assay results. BAL isolates were phenotypically
consistent with AMs.
FITC DCs appeared to be less efficient at stimulating T cell proliferation in
vitro than PBS DCs at later time points, and induced the production of IL-13,
suggesting they may polarise towards a Th2-type cytokine response in FITC-
treated lungs (Chapter 6). IFN-y was also detected in the supernatants, which
may enhance the inflammatory response, or be an attempt to redress the Th2
cytokine imbalance.
FITC BAL AMs appeared to be more efficient at stimulating T cell
proliferation in vitro than PBS BAL AMs, and preliminary results showed
they also induced IL-13 production (Chapter 6). IFN-y production was
decreased at 14 weeks after the second dose, possibly supporting a role for
BAL AMs to contribute to the Th2 response.
The addition of FITC to epithelial cell lines in vitro decreased viability of the
type II AEC-like line, but had no effect on viability of the Clara cell-type
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line, possibly because cells higher up in the airways are less susceptible to
injury (Chapter 7).
8.2 General Discussion and Suggestions for Future Work
Because CFA is, by definition, of unknown aetiology, induced animal models have
an intrinsic fault. However, each animal model has its own unique features that
allow for multiple avenues of investigation, and help to partly establish pathways of
lung injury leading to fibrosis.
The two-dose, nonsurgical model of FITC-induced pulmonary fibrosis characterised
in this thesis has proved to be a useful model for examining the role of chronic
inflammation in the mechanisms that lead to pulmonary fibrosis. The initial lung
injury with accompanying acute inflammation appeared to shift to a more chronic
pattern, but was prevented from resolving by the second dose of FITC. This second
dose eventually led to a chronic, progressive disease state with a moderate, persistent
inflammation and increasing severity of fibrotic changes in areas of FITC deposition.
As well, the presence of B cell aggregates suggests a humoral response may also be
present and indeed likely, as anti-FITC antibodies have been demonstrated in the
original single-dose surgical model [243,244],
As discussed, this model requires optimisation in terms of physical accuracy of
dosing, and in terms of accuracy in amount of FITC delivered, to ensure consistency
between animals. Ideally, it should also be extended to later time points in order to
better determine the nature of the long-term response. Further immunohistochemical
staining for CD4 and CD8 T cells would also be beneficial to establish the nature of
the lymphocytic infiltration.
Although the presence of chronic inflammation is subject to debate when considering
the pathogenesis of CFA [5], an unremitting profibrotic inflammatory response is a
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cause of dysregulated fibrogenesis, and an animal model of pulmonary fibrosis that
also has localised injury, is progressive in nature and may be immunologically
mediated has great potential and application to the human disease.
Although TGF-p was not detected in the BAL fluid, it seems highly unlikely that this
profibrotic cytokine would not be involved in the fibrotic process, and indeed, the
presence of TGF-p in the tissues, demonstrated by immunohistochemistry, suggests
otherwise. As discussed, BAL protein levels are not necessarily reflective of tissue
processes, and ideally, mRNA analysis of BAL AMs and lung tissue should be
performed for all cytokines mentioned to develop an accurate cytokine profile. The
use of specific antibodies to cytokines and transgenic mouse strains deficient in
certain cytokines would also provide clues to the pattern of cytokine involvement in
FITC-induced pulmonary fibrosis.
The finding that lung DCs and AMs from FITC-treated mice may polarise T cells
towards a Th2-type response by the induction of IL-13 production is particularly
exciting, given the "Th2 cytokine hypothesis" of lung fibrosis [6,83], and the
growing interest in the role of IL-13 in pulmonary fibrosis [79,85,102,327,332]. An
interesting avenue of investigation in this respect would be the MCP-mediated
CCR2-dependent proinflammatory and profibrotic functions of IL-13 and TGF-P
[494], particularly as the importance of CCR2 in the profibrotic cytokine cascade of
FITC-induced pulmonary fibrosis has been demonstrated [62],
The reciprocal T cell-stimulating abilities of lung DCs vs. AMs are intriguing.
Certainly, the preliminary results obtained for the FITC AMs should be repeated to
establish if they are indeed more efficient stimulators, and most importantly, both
cell types from FITC- and PBS-treated mice should be phenotyped. The lack of IL-
10 or IL-12 in the supernatants from DC experiments seems unlikely, and mRNA
analysis would be the logical next step.
It is likely that the cytokine milieu in the FITC-treated lungs is altering the antigen-
presenting capacities of both APC types, and for the DCs, in a GM-CSF-independent
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fashion. The apparent immature state of the DCs fits well with the Th2 cytokine
hypothesis, as immature DCs, or DC2s, are known to skew T cells towards Th2-type
responses [171]. It has been suggested that DCs could be responsible for
maintaining a chronic localised immune response in asthmatic airways [372], and
this may also hold true for FITC-induced fibrotic lungs. Chronic inflammation and
structural changes in the airways could lead to local DC maturation and antigen
presentation occurring in the asthmatic airways [372], but equally, perhaps chronic
inflammation could participate in maintaining the DCs in an immature state,
particularly in fibrotic lungs, suggesting a point of divergence for these two disease
states.
DCs, but not AMs, were seen in B cell aggregates, and it may be that this local
microenvironment could contribute to the behaviour of the DCs. It has been shown
that chronic antigen presentation by DCs leads to neoformation of organized
lymphoid structures within peripheral tissues, such as the pancreas [524], and
Lambrecht [372] speculates that repetitive presentation of antigen to Th2 cells by
DCs in asthmatic airways could also lead to formation of these aggregates; perhaps
again, this could apply to the fibrotic lung as well. Additionally, DCs might directly
interact with B cells in the airways to enhance immunoglobulin production [372],
However, if TGF-P and/or IL-10 levels are revealed to be increased in the tissue of
FITC-treated mice, the concept of "tolerogenic" DCs could also be explored, as both
these cytokines have been shown to induce tolerance in DCs [492,525].
Although the cell line experiments were largely unrevealing, the decreased viability
of the type II AEC-like line is interesting, and should be repeated on primary type II
cell cultures. If Clara cells are more resistant to the injurious effects of FITC, this
could be another avenue for investigation. Certainly, all the experiments described
for the cell lines would bear repeating on primary cell cultures.
In conclusion, the key question in CFA is why do some lungs heal with fibrosis,
whereas others are restored to a virtually normal state? Appropriate therapy relies on
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the correct understanding of the nature of the lung's response to injury, and although
the mechanisms remain elusive, some facts are becoming clearer. Pulmonary
inflammation and fibrosis in the FITC-induced model and indeed, in CFA, most
likely occur via more than one pathway. These processes are undoubtedly very
complex and involve multiple interactions among inflammatory cells, lung
parenchymal cells, and their products. Animal models of this disease play an
essential role in directing research towards the understanding of the mechanisms of
pulmonary fibrosis in humans, and with advances such as the recent cloning of the
entire mouse genome [526], will hopefully lend significant insight into these
processes with the aim of improving therapeutic strategies and halting the downward




Appendix 1: Reagent Recipes
A1.1 Avertin (tribromoethanol anaesthetic)
For 200 ml:
• 2.5g 2,2,2-tribromoethanol (Aldrich)
• 5 ml 2 methy-2-butanol (tertiary amyl alcohol))
• 200 ml dH20
Tribromoethanol and tertiary amyl alcohol were mixed on a heated stirrer until all
crystals dissolved, then distilled H20 was added until totally dispersed. This solution
is stored at 4°C protected from light, and warmed to 37°C before use. Dose: 0.2 ml
up tolOg body weight given intraperitoneally.
A1.2 Flow Cytometry
A 1.2.1 Flow buffer
• PBS
• l%(w/v)BSA
• 0.05% (w/v) NaN3
• Stored at 4°C.
A1.2.2 Flow fix
• PBS
• 2% (w/v) formaldehyde
• Stored at room temperature.
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A1.3 MACS Buffer
• 0.5% BSA in PBS
• Filter sterilised and stored at 4°C.
A1.4 Particulate FITC Solution
• 2 mg/ml FITC in sterile PBS
FITC powder was weighed out, then diluted with sterile PBS, and pipetted
vigorously until no remaining particles were visible. The solution was always
prepared fresh.
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Appendix 2: Unpublished Data from Original FITC Model
The following images are unpublished data from the work of Roberts et al. [243] on
the original one-dose surgical FITC-induced model of pulmonary fibrosis.
Figure A2.1 FITC-treated SCID mice (A) show severe inflammation
three days after instillation similar to that seen in immunocompetent
FITC-treated mice (B). Original magnification x100.
Figure A2.2 Three months after FITC instillation, fluorescent FITC was
visible in the lungs of both SCID (A) and immunocompetent (B) mice.
Original magnification x100.
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Figure A2.3 Despite the presence of FITC, three months after FITC
instillation, no scarring or infiltrate was seen in the lungs of SCID mice
(A), in direct contrast to the scarring and infiltrate found in the lungs of
the immunocompetent mice (B) at the same time point. Original
magnification x100.
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